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Abstract 
The role of Lemur tyrosine kinase 3 (LMTK3) and its association with cell proliferation 
and endocrine resistance in breast cancer due to its ability of regulating estrogen receptor 
α (ERα) has been previously addressed in our laboratory. However, the ER-independent 
function of LMTK3 has not been studied yet.  
We found that LMTK3 promotes the development of a metastatic phenotype by 
inducing the expression of genes encoding integrin subunits. Invasive behaviour such as 
actin cytoskeleton remodelling and focal adhesion were positively correlated with the 
abundance of LMTK3 formation in various breast cancer cell lines. Using SILAC (stable 
isotope labelling by amino acids in cell culture) proteomic analysis, we found that 
LMTK3 increases the protein levels of integrin subunits α5 and β1 through activating the 
CDC42 GTPase, which promotes integrin α5 and β1 expression via the transcription 
factor serum response factor (SRF). Furthermore, abundance of LMTK3 was positively 
correlated with that of integrin β1 in breast cancer patients’ tumours.  
As LMTK3 is also localised in the nucleus, we then investigated its nuclear function. 
We mapped LMTK3 binding across the genome using ChIP-seq and found that LMTK3 
binding events are correlated with repressive chromatin markers. We further identified 
KRAB-associated protein 1 (KAP1) as a binding partner of LMTK3. The LMTK3/KAP1 
interaction is stabilized by PP1α, which suppresses KAP1 phosphorylation specifically at 
LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in 
transcriptional repression of LMTK3-bound tumour suppressor-like genes. Furthermore, 
LMTK3 functions at distal regions in tethering the chromatin to the nuclear periphery, 
resulting in H3K9me3 modification and gene silencing. In summary, we propose a model 
where a scaffolding function of nuclear LMTK3 promotes cancer progression through 
chromatin remodelling in an ERα-independent and kinase-independent manner. 
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1.1%Cancer% %
1.1.1 Cancer is the major cause of death worldwide 
Cancer is a major type of disease and the leading cause of death in the world. From the 
Globocan report, there were approximately 14.1 million new cancer cases and 8.2 million 
cancer deaths, making up 14.6% of all human deaths, in 2012 worldwide (Figure 1). In 
addition, about 32.6 million people were living with cancer in 2012 (within 5 years of 
diagnosis) (1). It is also predicted that the number of annual cancer cases will increase 
from 14 to 22 million in the next two decades (1). 
The most common types of cancer in males include lung, prostate, colorectal and 
stomach; while breast, colorectal, lung and cervical cancers are the most common types 
in females. The overall cancer incidence rate is about 25% higher in men (205 out of 
100,000) than in women (165 per 100,000). Male incidence rates are highly variable 
between regions, with a highest incidence in Australia/New Zealand. This is due to the 
high probability of developing prostate cancer in this region. Relatively, there is less 
variation in female incidence rates, which peaks in Northern America mainly due to the 
development of breast cancer (1).  
In the United Kingdom (UK), more than 331,000 people were diagnosed with cancer 
in 2011, with an incident rate of 524 cases out of 100,000 people (2). The European 
Age-Standardised (AS) incidence rates for all cancers (excluding non-melanoma skin 
cancer) in the UK has increased by 23% in males and by 43% in females during the 
period 1975-1977 to 2009-2011. The rate of the rise of the incidence rates peaked at the 
late 1990s, while reduced to only 3% increase in males and 7% increase in females over 
the last decade (between 2000-2002 and 2009-2011). Approximately 159,000 people died 
from cancer in the UK in 2011 (2). On the positive view, despite the increase in cancer 
incidence, cancer mortality has been decreasing in the UK. Between 1990-1992 and 
2009-2011, the European AS mortality rates decreased by 26% in males and 20% in 
females. A further 17% decrease of cancer deaths is expected between 2011 and 2030 in 
the UK (3). There are more than 200 different types of cancer diagnosed in the UK, 
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among which, breast, lung, prostate and bowel cancers account for over half (53%) of all 
new cases. Breast cancer is the most common cancer in the UK, despite the fact that it is 
rare in men. 
!
Figure 1 Cancer incidence and mortality. The!incidence!and!mortality!of!all!cancers!(excluding!nonMmelanoma!skin!cancer)!in!the!world.!Modified!form!Globocan!2012:!Estimated!Cancer!Incidence,!Mortality!and!Prevalence!Worldwide!in!2012(1).!
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1.1.2 Hallmarks of cancer 
It is already known that cancer can develop from one single cell. The oncogenic 
transformation from a normal cell into a malignant cell in humans is a multistep process, 
which is manifested in genetic changes that contribute to the progressive conversion of 
normal human cells into malignant derivatives (4, 5). Thanks to the progress in cancer 
research over the past decades, the understanding of the biological behaviour of cancer 
has greatly improved. Researchers realised that a single tumour could have over a 
hundred different mutations. In addition, when different cancer specimens are compared, 
the groups of mutations are hardly identical, suggesting that every tumour is unique. 
Hanahan and Weinberg thus simplified and suggested that the hallmarks of cancer 
comprise six biological capabilities acquired during the multistep development of human 
tumours (4, 5). The hallmarks constitute an organising principle for rationalising the 
complexities of neoplastic disease. Scientists have now realised that tumours are more 
than a mass of sustaining proliferative cancer cells that comprise a collection of distinct 
cell types, including normal cells forming tumour-related stroma, which function actively 
to contribute to the initiation, development and metastasis of tumour cells. The 
conceptual progress has allowed Hanahan and Weinberg to revisit their original 
elaboration of hallmarks of cancer. Together with the initial six, they have recently 
summarised in total ten biological capabilities and enabling characteristics attained 
during the multistep development from normal cells to human tumours 5. These 
hallmarks are (Figure 2):  
• Self-sufficiency in growth signals leading to sustaining proliferation  
• Resistance to cell death signals 
• Avoidance of anti-growth signals 
• Uncontrolled replicative immortality 
• Sustained angiogenesis replicative immortality 
• Activation of invasion and metastasis 
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• Instability and mutation of genome 
• Deregulation of cellular energy metabolism 
• Tumour-promoted inflammation 
• Escaping from immune destruction 
!
Figure 2 Hallmarks of cancer.  
Biological capabilities that were proposed by Hanahan and Weinberg as hallmarks of 
cancer are shared in common by all human cancers. Modified from Hanahan and 
Weinberg, 2011   
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1.1.3 Breast cancer   
1.1.3.1%Introduction%
As mentioned above, breast cancer is one of the most common cancers in the world, 
second only to lung cancer, making up 25% of all cancer cases. It is also the most 
frequent malignancy in females worldwide with an estimated 1.67 million people newly 
diagnosed globally in 2012 (1). The incidence of breast cancer in western countries is 
about 5 times higher than that in other parts of the world, although incidence has been 
rising worldwide in recent years. According to the latest figures from Cancer Research 
UK, around one in eight women in the UK and the United States will develop breast 
cancer during their lifetime (2). More than 49,500 women and 400 men in the UK were 
diagnosed with breast cancer in 2010. Since 1970s, breast cancer incidence rates in 
women have increased by almost 70% in the UK, causing more than 11,000 deaths 
(around 11,700 females and 80 males) per year. Female breast cancer death rates have 
decreased by 40% in the UK since the mid-1980s, despite the increases in incidence rates. 
The causes of better survival rates of breast cancer patients include improved and earlier 
diagnosis, advances in surgery practice and the introductions of various therapies, such as 
radiation-therapy, systemic chemotherapy, endocrine therapy and other targeted therapies. 
However, breast cancer still remains the main cause of death worldwide. Therefore, a 
better understanding of the mechanisms underlying carcinogenesis, tumour progression 
and metastasis as well as resistance to therapies could help us develop more effective 
therapies and continue to improve patients’ prognosis. 
1.1.3.2%Risks%
The increasing breast cancer incidence also gave rise to the awareness of the importance 
of understanding the risk factors of breast cancer, which include aging, family history, 
key driver gene mutations, sex hormone levels and hormone replacement therapy, obesity, 
alcohol intake and smoking, etc. Aging, similar to other type of cancers, is one of the 
most significant risk factors. Interestingly, most breast cancers occur in women over 50, 
while it is rare in women under 40. In addition, surveys have shown that a number of 
people with cancer family history have a higher risk of developing breast cancer. Indeed, 
about 5–10% of cases of breast cancer are because of genes inherited from the person's 
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parents, including the germline mutations of BRCA1 and BRCA2 genes, as well as TP53 
and PTEN genes (relatively rarer). The remaining majority of breast cancer cases are 
so-called sporadic cases (6). There is a great deal of epidemiological evidence linking 
breast cancer incidence to environmental factors such as diet, while the life-time 
exposure to ovarian estrogens is also a critical factor in breast cancer development (7).  
1.1.3.3%Classification%
Like other cancers, breast cancer can be classified by several grading systems including 
histopathology, grade, stage, etc., however, the classification according to the receptor 
status of breast cancer has provided stirring insights to therapies and has improved the 
patient survival significantly. In generally, breast cancers are classified by the receptor 
status using immunohistochemistry (IHC), which stains the cells based on the presence of 
estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor 
receptor 2 (HER2). According to the status of the three markers, breast cancer has been 
classified into the following 4 groups:  
• Luminal A: ER+ and/or PR+, HER2-, with low Ki67. It makes up approximately 40% 
of all breast cancers.  
• Luminal B: ER+ and/or PR-, HER2+ (or HER2- with high Ki67). It makes up 
approximately 20% of all breast cancers. 
• Triple negative/basal-like: ER-, PR- and HER2-. It makes up approximately 15-20% 
of all breast cancers. 
• HER2 amplified: ER-, PR- and HER2+. It makes up approximately 10-15% of all 
breast cancers. 
Among the three markers, ER has been addressed and benefited the therapy 
strategies for a long period. The importance of ovarian function in breast cancer 
progression was demonstrated in the 1880s, with estrogen being identified in the 1930s as 
the ovarian hormone responsible. ERα was identified in the 1960s and the gene was 
cloned in 1985. Early in the 1970s, breast cancer was divided into two disease subsets on 
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the basis of the presence of ERα, namely ERα negative and ERα positive breast cancer. 
In the early stage of breast cancer, most of the tumours are ERα positive, while in 
advanced breast cancer, the proportion of ERα negative cancer increases (8). A second 
estrogen receptor gene, encoding ERβ was identified in 1996. ERα is required for 
mammary development and is expressed in about 70-80% of breast tumours. A clear role 
for ERβ has, as yet, not been established, although many groups have described its 
expression in breast cancer (9-11).  
The ERα signalling pathway is a complex biological pathway that controls various 
cancer cell functions, such as cell proliferation, anti-apoptosis, invasion and angiogenesis. 
The classic function of ERα is its nuclear activity, which requires it to bind and modulate 
the expression of hundreds of genes, usually after its activation through binding to 
estrogen (12, 13).  
ERα and ERβ are members of the nuclear receptor superfamily of small molecule 
activated transcription factors. The human ERα protein is 595 amino acids in length and 
comprises three functional domains. A near central DNA binding domain (DBD) 
mediates binding to promoters of estrogen responsive genes. Estrogen binds to the 
C-terminal ligand-binding domain (LBD), estrogen-binding resulting in receptor 
activation, allowing ERα recruitment to gene promoters and subsequent regulation of 
gene expression. Transcriptional regulation by ERα upon estrogen binding involves the 
recruitment of transcriptional co-regulator proteins to the LBD and a region N-terminal to 
the DBD, AF-1, which can be activated through phosphorylation by a number of protein 
kinases, including ERK1/2 MAP kinase (MAPK) and AKT, thus lead to 
estrogen-independent activation of ERα (14) (Figure 3). 
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!
Figure 3 Mechanisms of estrogen receptor (ER) action in breast cancer. Modified!figure!from!(15).!
 
1.1.3.4%Therapies%
ERα has not only become a breast cancer classification marker, but is also a key 
therapeutic target in breast cancer (16). ER positive cancer cells depend on estrogen for 
their growth, so in therapies, ERα is targeted using anti-estrogens, primarily tamoxifen, 
which compete with estrogen for binding to ERα, and prevents its activation. The use of 
tamoxifen as an adjuvant agent after primary surgery in early stage ERα positive breast 
cancer for as little as 1 year reduces recurrence, with maximal benefit being observed 
with 5 years of tamoxifen treatment (17). Other strategies for inhibiting ERα action in 
post-menopausal women include suppression of the amount of circulating estrogen using 
aromatase inhibitors. The aromatase enzyme carries out a key step in the synthesis of 
estrogens from testosterone and androstenedione. Alternating tamoxifen and aromatase 
inhibitors, for example by switching to an aromatase inhibitor following 2-3 years of 
tamoxifen therapy yields better responses than tamoxifen alone (18, 19). Indeed, the 
current generation of aromatase inhibitors, such as anastrazole and letrozole provide an 
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improved disease-free survival (DFS) and OS compared to tamoxifen alone. Furthermore, 
Falsodex was developed as a novel type of ER antagonist that binds to the receptor and 
promotes its degradation, which leads to loss of cellular ER (20) and is used as a second 
line agent following recurrence after tamoxifen treatment (21). In general, ER+ breast 
cancers have a better prognosis.  
Similar to ERα, HER2 is not only a classification marker but also a key therapy 
target, especially in HER2 amplified breast cancers. HER2 is a receptor tyrosine kinase 
(RTK), which responds to growth signals and guides normal breast cell growth. In HER2 
amplified breast cancers, the increased copy number of HER2 results in uncontrolled cell 
growth and tumour progression. Therefore prior to modern treatments, HER2 positive 
cases had worse prognoses (8). However, HER2 positive breast cancer cells respond to 
drugs such as trastuzumab, a monoclonal antibody targeting HER2, which suppresses 
HER2 signalling activation and therefore improves the prognosis significantly (22). In 
comparison, triple negative cancers, which lack positive receptors and thus therapy 
targets, are short of potential targeted treatments and have comparatively poorer 
prognoses (23).  
Chemotherapy is predominantly used to treat breast cancer, especially for 
triple-negative breast cancer. Chemotherapy drugs such as doxorubicin, docetaxel, 
inhibits cell division and proliferation through inducing DNA damage during cell 
replication process. Radiotherapy is widely used after surgery to remove the potential 
remaining or escaped microscopic tumour cells from surgery (24). It is usually given to 
the regions of tumour bed and the lymph nodes, and is able to reduce the risk of 
recurrence by more than 50% if treated properly. 
1.1.3.5%Metastatic%breast%cancer%
As is mentioned in the previous section, activation of invasion and metastasis is one of 
the hallmarks of cancer in tumour progression. Metastasis, or metastatic disease, is the 
spread of a certain amount of cancer cells from one organ (or part) to another 
non-adjacent organ (or part). Cancer occurs after a single cell is genetically damaged to 
produce cells with an uncontrolled proliferation pattern, which produces a primary 
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tumour. These malignant primary tumour cells are allowed to disseminate. To do so, 
cancer cells have to acquire the capabilities to break down the basement membrane, 
invade into the stroma (local invasion), and break into the blood circulation. Furthermore, 
they need to manage to survive in the circulation before they can arrest at a distant organ, 
break out of the blood vessels and grow into metastases. In addition to cell-autonomous 
mechanisms, cancer cells recruit various stromal cell types to help in each step during 
this invasion-dissemination cascade. 
Among the 490,000 deaths per year, it is not the primary tumour, but its metastases 
at distant sites that are the main cause of death. Recently, the rates of metastasis and 
mortality in breast cancer patients have decreased as a result of early diagnosis by better 
screening systems and the introduction of the adjuvant therapy. Adjuvant therapy 
includes radiotherapy, hormone therapy and chemotherapy. These therapies can help 
destroy breast cancer cells that might have already spread to distant sites by the time of 
diagnosis. In women with breast cancer who are younger than 50 years of age, 
chemotherapy increases their 15-year survival rate by 10%; in older women the increase 
is 3%. However, despite the benefit on survival, chemotherapy causes a wide range of 
acute and long-term side effects, which may substantially affect the patient’s quality of 
life. Unfortunately, as it is impossible to predict the risk of metastasis development in 
individual patients accurately, nowadays more than 80% of the patients are receiving 
adjuvant chemotherapy, although only approximately 40% of the patients relapse and 
ultimately die of metastatic breast cancer. Therefore, many patients who would be cured 
without chemotherapy, with only surgery and radiotherapy, are being ‘over-treated’ and 
suffer the toxic side effects of chemotherapy. 
In order to reduce the amount of patients over-treated with needless therapies, new 
prognostic markers are urgently needed to identify patients who are at the highest risk for 
developing metastases. This might enable oncologists to begin introducing treatment 
strategies to individual patients. Gene-expression signatures of primary breast tumours 
might be one way to identify the patients with high risk of developing metastatic cancer, 
and who would therefore benefit from adjuvant therapy.  
! 34!
1.1.3.6%Endocrine%resistance%
Although endocrine therapies lead to a significant improvement in outcomes, one-third of 
women treated with tamoxifen for 5 years will relapse within 15 years, and one in four 
breast cancer patients treated with other endocrine therapies will also relapse (25). A 
great deal of effort has been made on understanding the molecular mechanisms of 
endocrine therapy resistance in ER-positive breast cancers. The clinical clues and 
molecular features of the endocrine resistant breast cancer are summarized below (15, 
26). 
• Decrease or loss of ER: approximately 20% of patients treated with endocrine 
therapy encounter ER loss. The growth of these tumours are no longer driven by 
estrogen, thus anti-estrogen treatments are no longer effective (27, 28). 
• Upregulation of HER2 in a few patients after endocrine therapy: the increased HER2 
abundance may subsequently take over the role of ER in tumour progression (28, 
29) 
• Loss of PR: when compared to ER, PR is more frequently lost after endocrine 
therapy, which results in a more aggressive disease (30, 31). 
• Expression of mutant or truncated isoforms of ER. For example, expression of 
ERα36, ERβ2/cx and ERβ5 might aid tamoxifen resistance in breast cancer (32, 33).  
• Modifications of ERα: A series of modifications of ERα are considered as a main 
cause of tamoxifen resistance, for instance, ER phosphorylation and methylation is 
highly related to clinical outcome (34).   
• Enhanced AP1 and NF-κB transcriptional activities are associated with endocrine 
resistance (35), indicative of ERα independent transcriptional pathways emerging as 
important players in endocrine resistance. 
• ER co-regulators: The transcriptional activity of ER requires the recruitment by ER 
and function of transcriptional co-regulator proteins. Expression of a number of key 
co-regulators, particularly the related p160 coactivators SRC1 and AIB1 has been 
! 35!
linked to non-response to tamoxifen. For example, Amplified in Breast Cancer 1 
(AIB1) is frequently over-expressed in breast cancer and high-levels of AIB1 
expression in HER2 over-expressing ERα-positive breast cancer are associated with 
poor patient outcome (36). Hence altered expression and/or activities of 
co-regulators may allow estrogen-independent regulation of gene expression by ERα 
and consequently escape from the ERα inhibitory effects of endocrine agents.  
• Deregulation of the cell cycle: Endocrine therapy leads to reduced proliferation via 
G1 arrest and not surprisingly, aberrant expression of molecules that are important 
for cell cycle progression may result in resistance, i.e., overexpression of Myc, 
cyclin D1 and E1, and reduction of CDK inhibitors. Many regulators of the cell 
cycle are themselves regulated by ERα, and their escape from ERα control may 
promote breast cancer cell proliferation (37). 
• Increased RTK signalling leading to the activation of the ERK and PI3K pathways: 
PI3K is discovered to activate several molecules in survival pathways and may 
promote ER transcriptional activity even independent of estrogen (38), while 
ERK1/2 activation may decrease ER expression (39).  
As a result, many clinical strategies have focus on co-targeting these features 
together with ER to overcome endocrine resistance, among which co-targeting kinase 
pathways are the mostly investigated ones. 
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1.2%Protein%Kinase%
1.2.1 Introduction 
Protein kinases are a type of kinase enzyme that regulates protein modifications by 
transferring phosphate groups to them, which is called phosphorylation. In general, they 
transfer a phosphate group from γ phosphate of adenosine-5'-triphosphate (ATP), or 
another nucleoside triphosphate, to specific amino acids with a free hydroxyl group on 
the other protein. As most protein kinases have more than one substrate, protein kinases 
are thus classified based on the receiver amino acid specificity rather than protein 
substrate specificity. Kinases can act on either serine/threonine (Ser/Thr) or tyrosine 
(Tyr), as well as on all three (40). There are approximately more than 500 protein kinase 
genes throughout the human genome, making up 2% of all human genes (41). 
Importantly, up to 30% of all human proteins can be phosphorylated by kinases. 
Phosphorylation plays an important role in cellular signalling transduction, leading to 
activation or inhibition of biological activity, increase or decrease of molecule movement 
and facilitation or disruption of protein-protein interaction.  
Due to the fact that phosphorylation has profound impact on cellular signalling, the 
activity of protein kinases is highly regulated. The activity of a kinase can be turned on 
by phosphorylation, which can be mediated by the kinase itself (autophosphrylation), or 
by other kinases. On the other hand, the phosphorylation status can also be regulated by 
other proteins such as phosphatases (dephosphoryaltion) or small molecules (inhibitors, 
activators).     
1.2.2 Kinase domain structure 
The protein kinase domain is a structurally conserved domain responsible for the catalytic 
function of protein kinases. The similarity in their catalytic domains were first discovered 
by Barker and Dayhoff revealing that about 300 amino acids (aa) of the catalytic domain 
of the cAMP-dependent protein kinase are highly related to viral src gene products (42). 
They showed that the src genes originated in the host genomes, where they are members 
of a superfamily of protein kinases, suggesting that at least some of the eukaryotic protein 
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kinases arose from the single archetypal gene. The first crystal structure of the 
cAMP-dependent protein kinase was observed (43), followed with a large amount of 
subsequent discoveries of other crystal structure of the protein kinases (44-46). These 
studies uncovered that classical protein kinases usually share a conserved catalytic 
domain composed of β-sheet and α-helix structure, with a length of approximately 250 aa 
(47). 
1.2.3 Classification of human kinome 
As previously mentioned, considering their profound importance in signal transduction, it 
is not surprising that protein kinases make up approximately 2% of the genome (so called 
kinome), as well as that about 30% of cellular proteins are phosphorylated on at least one 
site by kinases (47). Recently, there is an increased awareness about the fact that 
dysregulation of protein kinases can result in abnormal cellular function and may 
subsequently lead to diseases, including cancer. Therefore, better understanding the 
behaviour of kinases (kinome) could eventually benefit the therapies against cancer. 
 The human kinome has now been classified into 9 groups, 90 families and 145 
subfamilies based on the work by Manning and colleagues (41, 48). The 7 main groups 
are as follows (Figure 4):  
• AGC kinases (49): this group of 60 Ser/Thr protein kinases consists of PKA, PKG, 
PKC families and other kinases such as AKT, S6K etc. As this is one of the most 
studied kinase groups, the mutation and dysregulation of AGC family are implicated 
in various human diseases, such as cancer and diabetes.  
• Calcium (Ca2+)/calmodulin (CaM)-dependent protein kinases (CAMK): this group 
of kinases includes CaMKs, check point kinases (CHKs), AMP-activated protein 
kinases (AMPKs) and microtubule affinity-regulating kinases (MARKs).  
• Casein kinase 1 (CK1): this group of kinases comprises CK1s, vaccinia related 
kinases (VRKs), and tau-tubulin kinases (TTBKs)  
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• Homologs of the yeast Sterile 7, Sterile 11 and Sterile 20 kinases (STE): this group 
contains kinases that belong to the MAPK cascades- Ste7/MAP2K, Ste11/MAP3K, 
Ste20/MAP4K. Particularly, the well-studied MEK and RAFs are the main 
component of MAP2K and MAP3K, respectively. As it is implicated in the MAPK 
cascades, this group is highly implicated in human diseases like cancer (50).  
• Tyrosine kinase-like (TKL): this group contains 43 members that resemble both Tyr 
and Ser/Thr kinases, which are mainly implicated in cell proliferation, survival and 
differentiation processes (51).   
• CMGC kinases, which contain cyclin-dependent kinases (CDKs), mitogen-activated 
protein kinases (MAPKs), glycogen synthase kinase 3 (GSK3) and Cdc2-like kinase 
(CLK) families. This group of kinases are widely involved in processes like cell 
cycle regulation, cell survival, stress response and metabolism control. 
• Tyrosine kinases (TKs): this group represents the largest group in the human kinome 
that contains 90 members, which mainly phosphorylate tyrosine residues. TKs are 
further separated into two subgroups: Receptor tyrosine kinases (RTKs) and 
cytoplasmic tyrosine kinases (CTKs). RTKs have transmembrane domains, ligand 
binding extracellular domains and catalytic intracellular kinase domains. As several 
RTKs are growth receptors responding to growth factors, we will further discuss a 
few group members in Section 1.4. CTKs are non-receptor tyrosine kinases that lack 
transmembrane domains, however they are not only locate in the cytosol, but also in 
the nucleus and the inner surface of the plasma membrane. SRC, JAKs and c-ABL 
are the most investigated CTKs, which are highly associated with oncogenesis and 
cancer progression. 
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Figure 4 The phylogenetic tree of the complete superfamily of human protein 
kinases. 
A total of 518 human protein kinases are classified based on similarity between the 
protein sequences of these catalytic domains. Each kinase is at the tip of a branch, and the 
similarity between various kinases is inversely related to the distance between their 
positions on the tree diagram (41).  
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1.3%Lemur%tyrosine%kinase%3%(LMTK3)%
1.3.1 The LMTK family 
LMTK (LMR or AATYK) family belongs to the RTKs. It consists of three members: 
LMTK1 (also named LMR1 or AATK), LMTK2 (also named LMR2, BREK, KPI2 or 
AATYK2) and LMTK3 (also named LMR3, AATYK3). LMTK1 and LMTK2 genes are 
relatively evolutional conserved (52), while LMTK3 has been positively selected from 
chimpanzees to human, except its catalytic core domain (53). LMTK1 has an alternative 
splicing variant (LMTK1B) that does not contain a transmembrane domain (TM), while 
the rest of the LMTK families including LMTK1B, LMTK2 and LMTK3 contain the 
N-terminal transmembrane domains (TMs) (Figure 5). All three LMTK members are 
highly sequence conserved in their N-terminal kinase domains (KD)!as well as in short 
fragmentary homologous stretches in the N-terminal region, kinase domain-flanking 
regions, and C-terminal region (Figure 6). It is noteworthy that the LMTK family has 
several amino-acid substitutions in their conserved kinase domain compared with other 
members of the protein tyrosine kinase (PTK) family. In addition, the C-terminal 
PP1C-interacting motif of LMTK2 (54) is conserved in all three members. Lastly, these 
proteins contain several binding motifs such as src homology 2 and 3 (SH2 and SH3) 
domains, suggesting that it could interact with a variety of adapter proteins that can 
modulate intracellular signalling (55, 56).  
!
Figure 5 The structure of LMTK family. The! family! members! of! LMTK! (LMTK1A,! LMTK2! and! LMTK3)! contain! relatively!conserved!transmembrane!domains!(TM)!and!catalytic/kinase!domains!(KD).! !
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Figure 6 Sequence alignment of human LMTK1A, LMTK2 and LMTK3. 
The sequence similarity alignment was carried using uniprot align tool 
(http://www.uniprot.org/align/). Grey boxes represent similarity scores. 
 
Interestingly, not only the LMTK family members that contains TM domains, but 
also the one without a TM domain (LMTK1a) are highly expressed in the membrane 
fractions of mice brains, which is possibly through its N-terminal palmitoylation, 
concluding that all members of the LMTK family are membrane-associated proteins (57). 
A set of studies have shown that the LMTK family is predominantly expressed in the 
nervous system and is involved in apoptosis and neurite growth, while others have shown 
that LMTK family is also involved in other diseases such as cancer, diabetes, cystic 
fibrosis and azoospermia. These will be further discussed in the next section.   
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1.3.2 LMTK1 
Mouse LMTK1 (AATYK) gene was first isolated from 32Dcl3 cell line derived form the 
normal mouse bone marrow (58), and the human LMTK1 gene addressed a year later 
(59). By using fluorescence in situ hybridization (FISH), Seki and colleagues determined 
that the chromosomal location of human LMTK1 gene is on 17q25.3 (60). Both mouse 
and human LMTK1 have two isoforms: one with TM domains that is composed of 1374 
aa; the other without TM domains that encompasses 1271 and 1317 aa in mouse and 
human species, respectively. Mouse and human LMTK1 (with TM domains) amino acids 
sequences are 87% identical, with a tyrosine kinase domain, N-terminal region and a 
C-terminal proline-rich domain individually.  
 As mentioned above, LMTK1 is predominantly located in most regions of the brain 
(61), thus a majority of studies on LMTK1 have been focused on its function in the 
neural system. As a kinase associated with apoptosis, which plays an important role in the 
normal neural system development, LMTK1 promotes neuronal differentiation (62), 
promoting the neurite outgrowth in developing neurons (63). Noteworthy, the functions 
listed above are all dependent on the kinase activity of LMTK1. For example, Tomomura 
and Furuichi discovered that LMTK1 is upregulated and hyper-phosphorylated upon low 
potassium-induced apoptosis in cerebellar granule cells, which is significantly abolished 
when LMTK1 is mutated on its kinase domain (64). More specifically, after nerve growth 
factor stimulation, LMTK1 is phosphorylated by p35/CDK5 at Ser34, which suppresses 
the tyrosine phosphorylation of LMTK1 by Src family kinases, resulting in enhanced 
neurite outgrowth (65).  However, in mature neurons, LMTK1 behave oppositely: it 
induces the apoptosis of mature neuron cells (66), negatively regulates dendritic 
formation and axonal outgrowth via CDK5-Rab11A-induced endosomal trafficking (67, 
68).  
 In addition to its regulation of neural growth, LMTK1 is also widely involved in 
cancer progression, generally behaves as a tumour suppressor. For instance, LMTK1 
expression was found to be downregulated in colon cancer (69); LMTK1 could inhibit 
cell growth and migration and promote cell apoptosis of melanoma (70). Another 
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evidence is that hyper-methylation, which is the mechanism of repression of tumour 
suppressor genes, and downregulation of LMTK1 was detected in human cancer cell 
lines and lung and breast cancer tissues (71).  
 There is also a very recent study showing that LMTK1 might be implicated in 
protecting the insulin resistance of diabetes. Jacovetti and colleagues discovered that 
together with miR-338-3p (a microRNA generated from the intron of LMTK1), LMTK1 
is downregulated in the islets of insulin resistant animal models, and silencing LMTK1 
could promote β-cell proliferation (72). 
1.3.3 LMTK2 
The second group member of the LMTK family, LMTK2 is located at 7q21.3 of 
chromosome 7. This human gene encodes a 1503 aa protein. It is also known as 
brain-enriched kinase (BREK), apoptosis-associated tyrosine kinase (AATYK2), 
kinase/phosphatase inhibitor 2 (KPI-2) and Cprk. Homology analyses proposed that 
LMTK2 was a tyrosine kinase, however, several studies have now shown that LMTK2 
selectively phosphorylates serine and threonine residues (73, 74). As it is conserved, the 
LMTK2 protein kinase domain and the C-terminal PP1C-binding motives are highly 
identical to the other two group members. However, it has been shown that LMTK2 has 
two hydrophobic TM helices between 11-31 and 43-63 linked with a membrane anchor 
and short hydrophilic loop on the opposite side of the membrane(75) (54) (Figure 5). 
Interestingly, although the theoretical molecular mass of LMTK2 is 165 kDa, LMTK2 on 
SDS-PAGE showed an aberrantly high apparent molecular weight at approximately 200 
kDa. The possible explanation is that LMTK2 may undergo some post-translational 
modifications such as phosphorylation and/or glycosylation, or alternatively this is due to 
its low electrophoretic mobility, because of the presence of its COOH-terminal 
proline-rich domains, since proline-rich proteins often migrate slower on SDS-PAGE.  
 Considering the structure similarity with LMTK1, LMTK2 is also able to interact 
with CDK5 and PP1C. Manser and colleagues showed that LMTK2 is phosphorylated by 
CDK5 at Ser1418, which would enhance its activity to phosphorylate and inhibit PP1C 
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on Thr320. This cascade may play an important role in neuronal function regulation (54, 
76). 
 As it is associated with the membrane, LMTK2 is also associated with intracellular 
transport and trafficking as well as endosomal recycling. Studies have shown that 
LMTK2 is an interacting protein of myosin VI, a known protein involved in multiple 
endocytic and exocytic membrane trafficking pathways. LMTK2 interacts with myosin 
VI at the WWY site in the C-terminal tail of the latter (77). Interestingly, although 
LMTK2 is located at the cytoplasmic membrane vesicles and perinuclear recycling 
endosomes, it is only responsible for the transportation of transferrin molecules from the 
early endosomes to the perinuclear recycling endosomes (78). This function on 
endocytosis is implicated in diseases such as cystic fibrosis. It has been shown that 
LMTK2 is able to phosphorylate cystic fibrosis transmembrane conductance regulator 
(CFTR) on Ser737, which enhances the endocytosis of CFTR. As pharmacologically 
rescue of CFTR could result in better outcome of cystic fibrosis patients, targeting 
LMTK2 may be a potential therapy (79, 80). 
Surprisingly, there are not as many studies on LMTK2 and neural function as that on 
LMTK1, regardless of the fact that they are both predominantly expressed in the brain, as 
well as their structure similarity. The only study that also gave LMTK2 its alternative 
name (brain enriched kinase -BREK), has shown that BREK is widely expressed in 
different components of the mouse brain, such as the olfactory bulb, olfactory tubercle, 
hippocampus, striatum, cerebellum, and cerebral cortex. High expression and 
phosphorylation of BREK detected at 0-2 weeks after birth suggests that BREK might 
play a role in neural development and function during the early postnatal period. BREK 
is phosphorylated upon the stimulation of NGF in a PKC-dependent manner, resulting in 
the suppression of NGF-induced neuronal differentiation (73).  
Interestingly, Lmtk2 knockout mice are viable; nevertheless, they are strongly 
associated with male infertility due to defects in spermatogenesis. Kawa and colleagues 
generated Lmtk2 knockout (Lmtk2(-/-)) mice to further study the function of LMTK2. 
They discovered that Lmtk2(-/-) mice are infertile with azoospermia, which is due to the 
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fact that the germ cells failed to carry out the normal change in morphology to become 
elongated spermatids, regardless that they are able to differentiated normally until the 
round-spermatid stage. Their study concluded that Lmtk2 is essential for late stage of 
spermatogenesis (81). 
The majority of the work on LMTK2 is mainly on its function in cancer. In 2008, a 
study identified common alleles associated with prostate cancer risk by conducting 
genome-wide association using blood samples from near 200 prostate cancer patients. 
Within the newly identified common loci, they identified a few susceptibility genes, 
among which LMTK2 was highlighted (82). In another two studies using larger cohorts 
LMTK2 was also picked up as one of the potential genes associated with prostate cancer 
risk (83, 84). Since then, a number of follow-up studies have confirmed the role of 
LMTK2 in prostate cancer. Firstly, Harries and colleagues discovered that there is a 68% 
reduction of LMTK2 expression in prostate cancer tissues, confirming its protective 
function (85). Secondly, as a potential mechanism of this protective role of LMTK2, it 
has been shown that LMTK2 phosphorylates PP1C on Thr320, which inhibits the 
function of PP1C, resulting in an increase in the phosphorylation of GSK3β at Ser9. This 
inhibitory phosphorylation of GSK3β subsequently inhibits KLC2 phosphorylation and 
increases the binding of Smad2 cargo to KLC2, resulting in the activation of the 
TGFβ-Smad2 signalling. Therefore, LMTK2 is able to promote the anti-oncogenic CDK 
inhibitory proteins p15 and p21 expression, which is mediated by the TGFβ-Smad2 
signalling, and inhibits tumour growth (86). Lastly, LMTK2 may suppress prostate 
cancer progression through its association with myosin VI (87). Moreover, there is also a 
study showing that in lung adenocarcinoma, LMTK2 somatic mutation is frequently 
detected and might be potential driver mutations of lung cancer (88).  
1.3.4 LMTK3 
The last member of the LMTK family, LMTK3 is located at 19q13.33 on chromosome 19. 
This human gene encodes a 1489 aa protein. Similar to the other two members, LMTK3 
is also classified as a tyrosine kinase, but found to be able to phosphorylate Ser/Thr 
residues. As LMTK3 is also composed of a N-terminal TM domain, a relatively 
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conserved kinase domain, and a proline-rich C-terminal domain, it is not a surprise that it 
has also showed an aberrantly high molecular weight on SDS-PAGE (89), which might 
be due to some post-translational modifications or alternatively due to its low 
electrophoretic mobility because of the proline-rich domains, as in the case of LMTK2. 
Interestingly, mass spectrometry analysis revealed that both bands of LMTK3 on 
SDS-PAGE were full-length LMTK3 (89), suggesting that some post-translational 
modifications are more likely to be the cause.  
1.3.4.1%Structure%of%LMTK3%
One of the main obstacles for the investigation of LMTK isoforms is that there are no 
crystal structures yet for these kinases, which is partly due to the fact that all these 
kinases comprise of large disordered regions (Figure 7A), whose structures are unlikely 
to be determined. These polypeptide protein segments are referred to as intrinsically 
disordered regions (IDRs), which are devoid of stable secondary and/or tertiary structures 
under physiological conditions and therefore cannot be assigned in x-ray datasets. 
However, a majority of the intrinsically disordered proteins (IDPs) have some transient 
secondary structures that are required for their function. Hence, most proteins are neither 
fully ordered nor fully disordered but contain ordered and disordered regions at different 
ratios (The example of LMTK3 can be seen in Figure 7A). Previously, the concept of a 
well-folded structure was thought to be indispensable for protein function. This idea was 
based on the lock-and-key theory explaining the specificity of enzymes. The well-defined 
binding pocket for the formation of kinase-substrate complex ensures a tight and fit 
binding between the kinase and substrate. Therefore, it is of great interest to find out that 
the IDRs are actually functional. Traditionally, IDRs were thought to be the domains 
linking the structured domains; nevertheless, it is now well established that IDRs actively 
participate in diverse functions. More precisely, disordered regions: 1) are frequently 
subjected to posttranslational modifications, which is of great importance for cellular 
signalling transduction; 2) function in scaffolding and the recruitment of binding partners; 
3) are responsible for conformational variability and adaptability (90). Moreover, there is 
a strong correlation between intrinsic disorder and various diseases, such as cancer 
(mostly found), diabetes, neurodegenerative and cardiovascular diseases. There are high 
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abundances of intrinsic disorders in many disease-associated proteins. One of the 
suggested mechanisms is that the existence of IDRs enables the disease-associated IDPs 
to undergo misfolding (transient secondary structure) or conformational changes that 
result in diverse interaction networks, leading to the loss of normal protein function and 
gain of the toxic one (i.e. oncogenic).  
As expected, the amino acids frequency in disordered proteins significantly differs 
from that of ordered proteins, while the amino acids sequences encode the absence of 
compact structure. IDPs are often enriched in Proline, Glysine and Alanine, which are 
called “disordered promoting amino acids”, while lacking “order promoting amino 
acids”- Asparagine and Cysteine. It is also known that repetitiveness and low amino acids 
complexity can result in protein disorder, such as the Proline-rich repeats. This rule is 
widely used to predict IDRs of proteins and there are several online software programs 
available using this approach. We were able to confirm that LMTK3 is composed of a 
large IDR (Figure 7A). The existence of IDRs suggests that LMTK3 may have profound 
functions in addition to its kinase activity, which will be addressed later in the result 
chapter.  
Regardless of that, as the kinase domain of LMTK3 is relatively conserved, the 
predicted LMTK3 kinase domain 3-dimensional (3D) structure has been reported (91). 
Using I-TASSER server, Anbarasu and Jayanthi generated a model of LMTK3 kinase 
domain with combination of one α helix, few anti-parallel β sheets and larger carboxy 
terminal with more α helices (Figure 7B). As protein kinases transfer a phosphate group 
from ATP to the amino acids residues of another protein, their kinase domains need to 
bind with ATP. In order to investigate the binding cavity and critical residues involved in 
LMTK3, the authors performed molecular docking of LMTK3 kinase domain with ATP 
and selected the model with the least binding energy (Figure 7C). In this model, the 
Tyr185 and Asp284 of LMTK3 kinase domain formed several hydrogen bonds and the 
Lys177, His264, Asp266, Gly286, His289 and Phe322 residues formed hydrophobic 
bonds with the ATP. Little conformational change was observed with LMTK3 upon ATP 
binding (Figure 7C).  
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Figure 7 The structure of LMTK3. 
(A) Structural overview of LMTK3. LMTK3 is composed of ordered domains, whose 
structure is known, and variable intrinsically disordered domains. The ratio of order and 
disorder score is shown. Data acquired using DICHOT 
(http://spock.genes.nig.ac.jp/~genome/DICHOT/). (B) Structure of the human LMTK3 
domain generated by I-TASSER server. (C) Molecular docking results of LMTK3 with 
ATP. The ATP binding cavity visualized in PyMol.  
 !
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1.3.4.2%The%physiological%function%of%LMTK3%
As mentioned above, LMTK kinases are widely expressed in brain tissue while LMTK1 
and LMTK2 are highly associated with neuronal development. Researchers thus 
questioned whether LMTK3 is also important in brain function. Inoue and colleagues 
generated a LMTK3-null mouse line using LacZ-neor cassette by replacing the end of 
exon 1 and the entire sequences of exon 2 and 3 that encodes its kinase domain (92). 
Lmtk3(-/-) mice were born from crossing Lmtk3(+/-) heterozygotes. Lmtk3(-/-) mice were 
viable and appeared normal, indicating that Lmtk3 is not essential during embryonic and 
early postnatal development. Unlike Lmtk2, Lmtk3(-/-) male and female mice were both 
fertile, without notable histological alterations in male testes. Interestingly, the pregnant 
rate of female Lmtk3(-/-) mice after dating with male Lmtk3(-/-) mice was notably low, 
which could be due to their social and sexual behaviour abnormalities.  
As a result, Lmtk3(-/-) mice weighed less and consumed more food when compared 
with the WT ones, which is due to the fact that Lmtk3(-/-) mice are hyperactive in their 
locomotor activity in both novel and familiar environments. They also exhibited reduced 
anxiety and depression-like behaviour when compared to the control ones. Furthermore, 
they had relatively higher level of dopamine metabolism, another parameter for 
determine their hyperactivity and less anxiety. 
Mechanism wise, Lmtk3 positively regulated the trafficking of N-methyl-D-aspartate 
(NMDA) receptor, a glutamate receptor and ion channel protein in neurons. They found 
that Lmtk3 deletion induced a significant increase in the intracellular level of GluN1 and 
GluN2B subunits of NMDA receptor through endocytic trafficking, a typical function of 
the membrane LMTK family kinases. They also pointed out another mechanism, 
considering the structural similarities of all family members and suggested that LMTK3 
may also be a substrate of CDK5/p35, whose deletion also results in the hyperactivity of 
mice.  
 
 
! 50!
1.3.4.3%The%involvement%of%LMTK3%in%cancers%(except%breast%cancer)%
Unlike the two other LMTKs, the functional studies of LMTK3 are predominantly 
focused on cancer to date. The involvement of LMTK3 in cancer started from two 
different screening experiments: Jeffrey and colleagues performed an RNAi screen 
targeting the entire tyrosine kinases in acute myeloid leukemia (AML) cell lines and 
examined the cell viability. They have shown that LMTK3 is associated with leukemic 
cell survival (93). Another study, using RNAi targeting 691 human kinases in 
Wnt3a-stimulated human cells has suggested a putative role of LMTK3 in the 
Wnt/β-catenin pathway (94). Two years later, our group performed a kinome screening 
and identified LMTK3 as an ERα regulator and prognostic marker of breast cancer (53), 
which will be addressed in detail in Section 1.3.4.4.  
 Gastric cancer is the 4th most common malignancy worldwide, with approximately 
940,000 new cases annually and is the second highest cause of cancer-related deaths. 
Interestingly, although it is not hormone-dominant, the incidence of gastric cancer in 
males is more than 2-fold higher than females, and treatment with anti-estrogens used in 
breast cancer such as tamoxifen increased the second primary colorectal and gastric 
cancers. These suggest that estrogen may play a protective role in gastric cancer. As 
LMTK3 is a regulator of ERα (Section 1.3.4.4), Wakatsuki and colleagues investigated 
the potential implication of LMTK3 in gastric cancer. Using the genomic DNA from 169 
Japanese and 137 U.S. gastric cancer patients, they found that the SNP rs9989661 T/T of 
LMTK3, which predicts improved outcomes in breast cancer, is associated with poorer 
overall survival (OS) rates in gastric cancer. Another SNP of LMTK3, rs8108419 G/G, 
was also predictive for poor OS in Japanese female and U.S. male patients. They 
concluded that LMTK3 polymorphisms might serve as a prognostic factor candidate in 
gastric cancer, and that LMTK3 might be protective due to its role in promoting estrogen 
signalling (95). 
However, a later study questioned this notion. Although the SNPs of LMTK3 are 
associated with gastric patient outcome, the role of LMTK3 protein abundance in gastric 
cancer, on the other hand, is not well elucidated. Li and colleagues detected that LMTK3 
is present predominantly in the nucleus, but also appears in the cytoplasm of gastric 
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cancer cells. Surprisingly, although LMTK3 staining was also found at the adjacent 
non-cancerous gastric mucosa, the abundance of LMTK3 in the adjacent regions was 
notably lower than that in the cancerous regions. They also addressed, using the samples 
from 83 gastric patients (55 male and 28 female), that LMTK3 abundance is significantly 
associated with invasion depth and the stage of gastric cancer, as well as poor prognosis. 
Their work suggests that instead of being protective, LMTK3 could be a negative 
prognostic marker and a potential therapeutic target in gastric cancer (96). Although 
LMTK3 is an estrogen signalling regulator, it’s function in gastric cancer can be 
divergent, or at least not only a modulator of ER, but also be a positive regulator of 
cancer progression via other mechanisms. 
 According to the studies above, LMTK3 appears not to be a breast cancer-specific 
associated protein. Therefore, another study was carried out to investigate the association 
of serum LMTK3 abundance with colorectal cancer (CRC) patients’ survival. The 
authors obtained the blood specimens from 60 (34 male and 26 female) primary CRC 
patients without any source of chemotherapy or radiation therapy, using the peripheral 
blood from 53 (31 male and 22 female) healthy volunteers as controls. By performing 
ELISA tests, they were able to detect a significantly higher serum LMTK3 abundance in 
CRC patients against the control group. Furthermore, they found that patients with higher 
serum LMTK3 (n=30) have a notably poorer OS compared to the lower serum LMTK3 
group. They also addressed that LMTK3 could be a biomarker for predicting tumour 
progression in patients with CRC based on the fact that the serum LMTK3 abundance 
correlates with the histological differentiation, the depth of tumour invasion, and the 
tumour-node-metastasis (TNM) stage (97). 
 In addition to its role in gastric and colorectal cancer, LMTK3 is also implicated in 
lung cancer. Lung cancer is divided into two major subtypes: non-small cell lung 
carcinoma (NSCLC) and small cell lung carcinoma (SCLC) based on pathological 
features. 80% of all lung cancer cases belong to NSCLC. Xu and colleagues collected 
serum from 524 patients suffering from NSCLC prior to surgery, 280 patients with 
benign lung disease as well as 100 healthy volunteers. Through ELISA, they detected that 
LMTK3 serum abundance was significantly elevated in NSCLC patients compared to the 
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benign and healthy controls. They further addressed that LMTK3 is appropriate 
diagnostic and differential marker to discriminate NSCLC from benign lung disease. 
Considering that high serum LMTK3 abundance (6.85 ng/ml) could predict poorer 
prognosis, LMTK3 can not only be a diagnostic but also an independent prognostic 
biomarker (98). Similarly, another study was performed using relative small samples (67 
NSCLC patients, 28 benign lung disease and 53 healthy volunteers) (99). In accordance 
to the previous study, in the NSCLC group, they detected a significantly higher serum 
LMTK3 concentration, which was notably correlated with age, TNM stage and lymph 
node metastasis. They further found that LMTK3 abundance in normal lung tissues is less 
than the NSCLC tissues, suggesting the potential of using LMTK3 as a poor prognosis 
biomarker in NSCLC cancer.  
However, a recent screen suggested that LMTK3 might behave as a malignant 
transformation suppressor in lung cancer. The group performed an shRNA screen 
targeting the human transcriptome in order to identify malignant transformation 
suppressors of lung epithelial cells.!They!monitored!the!anchorage independent growth, 
a hallmark of cellular malignant transformation in vitro, of an immortalized human lung 
epithelial cell line (BEAS-2B) after being infected with the indicated shRNA library, 
which consists of 87,283 shRNAs targeting 32,216 human transcripts. As a result, they 
identified 6 candidate transformation suppressors including LMTK3 (100). Although they 
did not pick LMTK3 for further investigation in this work, this might suggest that 
LMTK3 might have an unexpected function in lung cancer, which obviously needs 
further investigation. 
In summary, the majority of the work on the function of LMTK3 in cancer is linked 
to clinical studies. Although several groups have addressed the role of LMTK3 as an 
oncogenic regulator in the indicated types of cancer, based on its association with 
prognosis, contradictory conclusions also exist. It is noteworthy that divergent functions 
of several proteins in cancer have been shown, such as the suppressive function of 
oncogene myc in cancer metastasis (101) and the distinct behaviour of TGFβ in the 
cancer progression (102); nevertheless, detailed mechanistic studies are needed before we 
can conclude the existence of complex roles of LMTK3 in cancer.    
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1.3.4.4%LMTK3%and%breast%cancer%
As discussed in 1.1.3, ERα is an estrogen-stimulated nuclear transcription factor that 
is expressed in the majority of breast tumours. The binding of estrogen to ERα results in 
ERα dimerization and its recruitment to the estrogen-responsive elements (EREs) on the 
promoters of ERα target genes. Endocrine therapy antagonising ERα using tamoxifen, 
which inhibits breast cancer growth through competitive binding of ERα with estrogen, 
has been the main treatment for breast cancer for the past 30 years (103). However, 
intrinsic or acquired resistance has always been the main obstacle in treating the disease. 
One of the possible mechanisms could be the activation of tyrosine kinase receptors and 
their downstream kinase pathways, which could phosphorylate and lead to 
estrogen-independent activation of ERα, as well as altered ERα stability. In order to 
identify previously uncharacterised kinases that could regulate ERα activity, our group 
carried out a kinome siRNA screening using the TFF1 gene, also known as pS2, as a 
read-out for ERα transcriptional activity (53). From those kinases whose silencing 
reduced TFF1 gene expression by >50%, we selected LMTK3 for further research, not 
only because LMTK3 knockdown also repressed the expression of two additional 
ERα-regulated genes: progesterone receptor (PGR) and growth regulation by estrogen in 
breast cancer 1 (GREB1) genes, but also due to that it is the only kinase that is subjected 
to Darwinian positive selection compared with its chimpanzee ortholog. Several studies 
have addressed that humans and the great apes (especially chimpanzees) differ in their 
susceptibilities to epithelial neoplasms, including breast cancer (104-108), possibly 
resulting from recent evolutionary events reflected in the adaptive profile of genes that 
have a regulatory role in estrogenic signalling. Therefore, it was of enormous interest to 
select this kinase for further investigation.  
Interestingly, inhibition of LMTK3 resulted in a decrease of ERα mRNA and protein, 
suggesting a dual regulation at the transcriptional and translational level. An in vitro 
kinase assay showed that LMTK3 was able to phosphorylate ERα, protecting it from 
ubiquitin-mediated proteasomal degradation. Moreover, inhibition of PKC by LMTK3 
could also be a possible explanation for the reduced ERα degradation, since PKC 
inhibition partially prevented the downregulation of ERα protein induced by LMTK3 
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silencing, while activation of PKC combined with LMTK3 siRNA treatment led to 
further ERα degradation. On the other hand, LMTK3 affected ERα transcription by 
positively regulating FOXO3, a known transcriptional activator of ESR1, possibly via 
inhibition of PKC-mediated AKT phosphorylation, which leads to FOXO3 degradation 
(109) (Figure 8). 
As expected, LMTK3 knockdown significantly inhibited ERα positive breast cancer 
cell growth. Meanwhile, LMTK3 silencing also led to suppressed tumour size in nude 
orthotopic mice models. To determine whether there is a correlation between LMTK3 
abundance and poor prognosis in human breast cancers, we carried out 
immunohistochemistry of 613 breast cancer samples. Notably, higher nuclear LMTK3 
expression was associated with shorter DFS and OS. Finally, inhibition of LMTK3 in 
tamoxifen-resistant cell lines (BT-474, MLET5 and LCC9) re-sensitised cells to 
tamoxifen treatment as demonstrated by cell proliferation inhibition. In summary, this 
work demonstrated that LMTK3 is able to regulate ERα transcriptional activity, protein 
phosphorylation and stability, and plays a role in tamoxifen re-sensitisation, suggesting 
that LMTK3 could be a new potential target in breast cancer. 
! 55!
!
Figure 8 LMTK3 positively regulates ESR1 gene transcription, protein levels and 
phosphorylation, promoting resistance to endocrine therapies. 
LMTK3 enhances transcriptional activation of ESR1 by inhibiting PKC, whose activity 
results in phosphorylation of AKT, which in turn phosphorylates FOXO3, resulting it to 
degrade. LMTK3 also directly phosphorylates ERα protein, which protects ERα from 
ubiquitin (Ub)-mediated proteasomal degradation. 
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Tumour pathology provides useful insights into the relevance of potential new 
biomarkers and associations reveal insights into the role of novel markers in breast cancer 
biology. Based on our findings above, we then wished to establish the tumour 
characteristics associated with LMTK3 overexpression, and validate our clinical 
outcomes in another published cohort of Asian patients from Singapore (110). Our group 
noticed that LMTK3 immunohistochemistry staining using the Santa Cruz antibody is 
predominantly in the nucleus and in the cytoplasm with variable levels. Thus we decided 
to investigate the function of nuclear and cytoplasmic LMTK3 individually. We detected 
that high nuclear LMTK3 abundance directly correlated with invasive ductal carcinomas, 
high tumour grade and the Nottingham Prognostic Index (NPI). With regards to breast 
cancer biomarkers, LMTK3 positively correlated with HER2 and the tumour proliferation 
marker Ki67. We also discovered that LMTK3 negatively correlated with BRCA1 and 
surprisingly the hormone receptors ERα and PgR. As to the cytoplasmic LMTK3, high 
LMTK3 was also associated with high tumour grade and high CK5/6 basal-like tumours. 
Similar to the nuclear LMTK3, cytoplasmic LMTK3 was also negatively correlated with 
ERα and PgR. As this is identical to the cohort used in the previous study, high baseline 
LMTK3 abundance is associated with a decreased OS and DFS (111). 
As mentioned above, abolishing LMTK3 expression re-sensitize tamoxifen-resistant 
cells to tamoxifen treatment. Our group tested whether this is the case in vivo using the 
resistant BT474 cell line, which expresses high endogenous LMTK3 mRNA and protein 
levels compared to MCF7. BT474 were injected into SCID mice, which were then 
separated into 4 groups when the tumours reached the area of approximately 100-200 
mm3 and treated with: 1) 10mg of control siRNA (in PBS), 2) 10mg of LMTK3 siRNA, 3) 
0.5mg/kg of tamoxifen + 10mg of control siRNA and, 4) 0.5 mg/kg of tamoxifen + 10 
mg of LMTK3 siRNA. As expected, tamoxifen alone did not suppress tumour growth; 
however, with the presence of LMTK3 siRNA, tumour was significantly reduced, 
suggesting that LMTK3 could re-sensitise the response of the resistant tumours to 
tamoxifen. To identify potential pathways other than ERα that LMTK3 might be involved 
in tamoxifen-resistance, we performed a microarray-based genome-wide gene expression 
analysis using BT474 cells transfected with siControl or siLMTK3 in the presence or 
absence of tamoxifen treatment. We identified a few genes that could be involved in the 
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resistance mechanism, such as c-MYC, HSPB8 and SIAH2. Furthermore, we found that 
LMTK3 could increase HSPB8 transcription and protein abundance resulting in reduced 
autophagy, which protected cells from tamoxifen-induced growth inhibition (112).  
 Other groups have also addressed the involvement of LMTK3 in breast cancer. 
Asano and colleagues investigated the correlation of LMTK3 mRNA level with patient 
outcome in 219 breast cancers. They found that LMTK3 levels were not associated with 
prognosis, however, they are highly correlated with shorter OS and DFS in ERα positive 
patients receiving adjuvant endocrine therapy. Their results suggested that high 
expression of LMTK3 is an independent prognostic factor in ERα positive breast cancer 
patients receiving adjuvant endocrine therapy (113). Another group identified 
microRNA-34a (miR-34a) as an upstream repressor of LMTK3. They first detected a 
remarkably reduction of miR-34a upon estrogen treatment. They also found that 
overexpression of miR-34a could suppress cancer cell proliferation and tumour formation. 
They then discovered that overexpression of miR-34a suppresses LMTK3 transcription 
and subsequent protein expression. Finally, as a confirmation of our previous study, they 
addressed that miR-34a could suppress ERα phosphorylation, most probably through the 
regulation of LMTK3 (114). 
In summary, although different groups including us have elucidated a detailed role of 
LMTK3 in breast cancer progression as an ERα regulator, there are still several issues 
that need to be further investigated. First of all, little is known about the upstream 
regulators of LMTK3. As previously mentioned, unlike other RTK family kinases, 
LMTK family kinases have relatively small extracellular domains. This raises the point 
that LMTK3 might not have a specific growth factor as its ligand, like other RTKs. Then, 
how is LMTK3 activated? Are there any LMTK3 kinases and phosphatases that can 
regulate the activity of LMTK3? Secondly, can LMTK3 activate the known RTK 
downstream pathways such as GRB2-RAS-MAPK pathway (this will be described in 
Section 1.4)? Thirdly, as it has already been addressed in our clinical study using the 
Asian patients’ cohort, LMTK3 seems to be associated with invasive ductal breast cancer. 
Therefore, is it possible that LMTK3 might also be involved in the invasion and 
metastasis processes of breast cancer? Lastly, immunohistochemistry staining of LMTK3 
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indicated that a great portion of LMTK3 is localised in the nucleus of breast cancer cells. 
What is the potential function of the nuclear LMTK3? Is it involved in the transcriptional 
regulation process (this question will be described in Section 1.5)? Among these, the last 
three aspects comprise the result chapter of my PhD thesis. 
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1.4%Growth%receptor%signalling%
Cancer is a disease with uncontrolled cell growth, which is organised distinct from that of 
normal, healthy cells. To understand the distinct ways that cancer cells ‘invent’ to 
program their growth, we need to first be aware of how normal cells regulate their growth 
and division. Normal cells receive growth signals, especially via growth factor ligands 
from outside of the cells. These growth factors then interact with a complex of cell 
surface growth receptors, which subsequently transduce the signals across the plasma 
membrane into the cytoplasm. There, a complex network of proteins respond to these 
signals, control and regulate in a well-organized way and finally transduce these signals 
into the nucleus, where the decision of whether to stimulate or inhibit a variety of 
biological responses is made. This process is a result of communication between 
neighbours of an individual cell, who cannot decide on their own whether they should 
proliferate or remain quiescent. These neighbour cells may be stimulated with growth 
factors or inhibitors, which would efficiently regulate these processes.  
1.4.1 Growth factors and their receptors 
The discovery of growth factors starts from EGF, which was first discovered to be 
involved in provoking premature eyes opening in newborn mice, while its mitogenic 
effects were detected later. EGF binds to the cell surface protein, EGF receptor (EGFR), 
which particularly recognises extracellular EGF and transduces the growth signal into the 
cell. Prior to ligand binding, EGFR presents as a monomer. When bound by EGF, EGFR 
forms homodimer or heterodimer, and the kinase domain of EGFR in the cytoplasm 
becomes activated, leading to autophosphorylation on multiple tyrosine residues at the 
C-terminal end, which results in a tyrosine kinase phosphorylation on certain cytoplasmic 
proteins that trigger cell proliferation. Since the discovery of the EGFR, other receptors 
have been characterised. Each of these receptors has its own growth factor ligand(s), 
which is able to promote a variety of biological responses. These growth factors and their 
receptors previously shown to be implicated in tumour pathogenesis include: 
platelet-derived growth factor (PDGF), including PDGF-A, PDGF-B, PDGF-C and 
PDGF-D, and their receptors PDGFRs; Nerve growth factor (NGF) and its receptor Trk; 
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fibroblast growth factors (FGFs) and their receptors FGFRs; hepatocyte growth receptor 
(HGF/SF) and its receptor Met; vascular endothelial growth factors (VEGFs) and their 
receptor VEGFRs; insulin-like growth factors (IGFs) and their receptor IGFR1; glial cell 
line-derived neurotrophic factor (GDNF) and its receptor Ret; and stem cell factor (SCF) 
and its receptor Kit. 
1.4.2 RAS-regulated signalling pathways 
The dependence of individual cells on their surrounding neighbours is nicely illustrated 
during homeostasis. However, cancer cells supported by oncoproteins, which take-over 
the natural growth-stimulating machinery, tackle this program. Among these 
oncoproteins, RAS is one of the most studied ones.   
1.4.2.1%RAS%oncoprotein%
The RAS protein family comprises a group of structurally and functionally conserved 
small GTP-binding proteins. There are three RAS genes encoding four homologous RAS 
proteins: HRAS, NRAS, KRAS4A and KRAS4B. They serve as transducers that respond 
to the cell surface receptors and transduce signals to the intracellular effector pathways. 
Their activity is controlled by the binding status of GTP and GDP, which represent the 
“active” and “inactive” forms, respectively. An “inactive”, GDP-bound RAS is 
stimulated by guanine nucleotide exchange factors (GEFs) to release its GDP and acquire 
a GTP instead. On the other hand, an “active”, GTP-bound RAS is regulated by 
GTPase-activating proteins (GAPs), which promote GTP to GDP exchange. Strikingly, 
oncogenic point mutations are widely present on RAS, which would thus block the 
inhibition of RAS activity by GAP. The known RAS mutants are Q61, G12 and G13. 
Oncogenic Q61 mutations impairs the GTP hydrolysis through blocking the nucleophilic 
attack on the γ-phosphate; G12 and G13, on the other hand, inhibit the interaction affinity 
of RAS and GAP.  
A few studies reported the amplification of RAS proteins (115-117); nevertheless, 
mutations in any of the three RAS (H-, N- and K-) genes are the main most common 
events in human tumourigenesis. Approximately up to 30% of all human malignancies 
carry RAS mutations. According to the database generated by the Sanger Centre 
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(catalogue of somatic mutations in cancer: http://sanger.ac.uk/cosmic), the frequency of 
the three RAS gene mutations varies between cancers. K-RAS is one of the most 
frequently mutated one. For instance, from 57% of patients suffering pancreatic cancer, 
31% of patients with biliary tract cancer carry K-RAS mutations. N-RAS mutations are 
highly detected in patients with skin cancer (18%), while H-RAS mutations are widely 
seen in bladder cancer (11%). By comparison, N- and H-RAS mutations are much less 
frequent (8% and 3%, respectively). G12 and G13 mutations comprise 99% of all the 
mutations detected on K-RAS, and Q61 mutation takes up the remaining 1%. However, 
in the case of N-RAS and H-RAS, Q61 mutations take up 60% and 34.5%, respectively 
(118). As a consequence, these mutations result in sustained RAS activation and 
subsequently uncontrolled downstream growth signalling transduction. 
1.4.2.2%RASWregulated%downstream%signalling%pathways%
When activated, RAS binds to and activates downstream effector enzymes, through 
which it promotes cell proliferation and survival.  
The first discovered effector is RAF protein Ser/Thr kinase, which is composed of 
c-RAF1, BRAF and ARAF. RAF activation is followed by its relocation to the plasma 
membrane, where RAS proteins are anchored. Once RAS is bound to GTP, the affinity of 
RAS and RAF interaction increases significantly, together with other scaffold proteins 
that further tighten the binding while proteins trigger phosphorylation on RAF, resulting 
in the activation of RAF kinase. Activated RAF subsequently phosphorylates a second 
kinase called mitogen-activated protein kinase 1 and 2 (MEK1/2), which in turn 
phosphorylates extracellular signal-regulated kinases 1 and 2 (ERK1/2). The processes 
above take place in the cytosol of the cell, while ERK1/2 not only phosphorylates the 
cytoplasmic substrates, but also translocates to the nucleus and induces the 
phosphorylation of transcription factors. For example, in the cytosol, ERK 
phosphorylates MNK1, which then phosphorylates eIF4E, a translation initiation factor 
that responsible for protein synthesis; in the nucleus, ERK phosphorylates the ETS family 
factors ELK1, which forms complex with serum response factor (SRF) and activates the 
transcription of growth-related genes such as c-FOS (119). ERK also phosphorylates 
c-JUN, which forms a heterodimer called AP1 with FOS. As a consequence of activating 
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the expression of these transcription factors, a variety of cell cycle regulatory proteins 
such as Cyclin Ds are expressed, resulting in cell cycle progression through the G1 phase 
(120). 
In addition to the activation of RAF-MEK-ERK cascade, RAS also interacts and 
stimulates type I phosphatidylinositol 3-kinases (PI3Ks) (121, 122). PI3K activation leads 
to AKT activation and subsequent stimulation of the downstream mTOR cell growth 
pathway and FOXO transcription factors that regulate cell cycle and apoptosis.  
The third effector is the exchange factors of the RAS-related RAL proteins 
(RAL-GEFs), through which RAS activates RAL and CDC42/RAC, resulting in the 
regulation of actin cytoskeleton and cell motility.  
1.4.2.3%The%SH2%and%SH3%group%proteins%linking%receptors%and%RAS%
Oncogenic mutation may lead to sustained activation of RAS and its downstream 
pathways, which is abnormal to the natural growth-stimulating machinery. However, 
RAS is also a downstream effector that responds to the amplification or hyper-activation 
of growth receptors. Interestingly, RAS is not directly linked to the receptors; instead, it 
stands in the middle of the cascade and requires adaptor proteins such as growth factor 
receptor-bound protein 2 (GRB2) to communicate with the receptors. 
 The Src’s homology domains (SH1, 2 and 3) give rise to the model of RTK 
signalling cascade. Researchers discovered that upon ligand activation, the cytoplasmic 
tails of RTKs interact directly with a specific SH2 domain-containing protein. GRB2 is 
composed of two SH3 domains and a SH2 domain. Its SH3 domain recognises the 
proline-rich regions in SOS, which comes close to the RAS proteins, recognising 
specifically the RAS-GDPs and stimulating the switch from GDPs to GTPs. 
1.4.3 Integrin receptors 
Unlike the growth receptors mentioned above that respond to growth factors, the integrin 
receptors are a set of receptors that are responsible for the attachment of cells to the 
extracellular matrix (ECM) that is usually found in the space between cells. The most 
common ECMs are collagens, fibronectin, vitronectin and laminins. Like other growth 
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factors, ECM controls cell behaviour, such as proliferation, growth arrest, migration etc. 
The effects of ECM on cells are mediated by integrins. Integrins are heterodimeric 
transmembrane receptors that comprise two subunits, α and β. There are at least 18 α and 
8 β subunits forming 24 distinct heterodimers, which bind to specific ECM components. 
For example, one of the most studied α5β1 integrin favours fibronectin, while αVβ3 
binds to a wide range of ECM molecules. 
 When bound to ECM ligands, α and β integrins form focal adhesions and affect the 
organisation of the cytoskeleton, which results in evoking a number of cellular responses, 
such as cell migration and invasion. The promotion of cell migration and invasion is not 
only due to their direct adhesion to the ECM, but also because they regulate the 
intracellular signalling that controls cytoskeleton formation and force generation. For 
example, upon stimulation by ECM ligands, integrins activates focal adhesion kinase 
(FAK), which subsequently activates RAS-RAF-ERK and CDC42-PAK signalling that 
leads to cytoskeleton alterations, contraction and gene transcriptions. Importantly, 
considering the similarity in the downstream pathways with other growth receptors, 
increased evidence supports a central role of the crosstalk between integrin and growth 
factor receptors. 
1.4.4 RTK functions in the nucleus 
The internalisation of RTKs has been discovered in the 1990s. Upon internalisation, 
receptor complexes remain active, however, they are eventually degraded by the 
lysosome or recycle back to the plasma membrane. Interestingly, increasing evidence has 
shown that RTKs are found in the nucleus. Usually the nuclear forms of RTKs are their 
cleaved cytoplasmic domain fragments, however, the presence of full length RTKs has 
also been reported (123, 124).  
 Nuclear EGFR is one of the most studied nuclear RTKs. EGFR was found to 
translocate to the nucleus after internalisation instead of being degraded. In this case, 
EGFR requires the nuclear localisation sequence (NLS) (645RRRHIVRKRTLRR657), 
which interacts with importin complex that helps nuclear import.!High level of EGFR 
was found in the nuclei of various tumours, such as skin, breast, bladder, cervix and 
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others (125-130). Nuclear EGFR is highly associated with increased tumour grade and 
size, lymph node involvement and poorer OS (126, 129, 131, 132). It is also associated 
with high Ki67 and cyclin D1 levels 130. The increased cyclin D1 expression was 
surprisingly found to be a direct effect of the nuclear EGFR acting as a transcriptional 
co-activator. Although no comprehensive sequencing was carried, a few EGFR-targeted 
pro-tumourigenic genes have been identified: cyclin D1 (124), iNOS (128), COX2 (133), 
c-Myc (134) and BCRP (135).  
 In addition to EGFR, a few studies have also addressed the involvement of other 
nuclear RTKs in the transcriptional regulation, such as nuclear ERBB2 regulating COX2; 
FGFR-I functioning as a transcription factor of FGF-2, etc. Although none of these 
studies addressed the behaviour of RTKs in a genome-wide scale, they provide strong 
rationale for clinically targeting the transcriptional co-factor activity of RTKs in the 
future. 
1.5%Transcriptional%regulation%
In general, gene expression is well controlled: the status of cells decides which groups of 
genes should be expressed, while the rest should be repressed. This process is controlled 
by a group of proteins called transcription factors (TFs), which bind to specific DNA 
sequenced in the control regions of genes (Figure 9). In most case, the transcription of a 
gene is not dependent only on a single TF; instead, it requires several distinct TFs (or 
co-factors) to function together. Some of these proteins do not bind at the promoter 
regions, but are attached to the distal control element called enhancer or silencer, which 
can be up to 1 Mbp away (either upstream or downstream) from the transcription start 
site (136). The way the distal regulatory element controls gene transcription from 
hundred thousand base pairs away is dependent on the DNA-bending proteins that 
mediate DNA bending and subsequently bring the distal regulatory element closer to the 
transcription mediator complex. This provides access to the RNA polymerase II (Pol II) 
that initiates the RNA synthesis (Figure 9). Usually, after extending the RNA transcripts 
for ~80 nucleotides, transcriptional pausing occurs, during when other polymerase 
complexes step in and resume the elongation and fully transcribe the pre-mRNA. 
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Interestingly, cancer cells can take advantage of this process: Myc oncoprotein functions 
as an anti-pausing protein, which permits various genes to be fully transcribed.  
!
Figure 9 Gene expression regulation. 
Transcription factors and co-factors bind to the promoters as well as to the distal control 
element (enhancers) of genes. Thereafter, RNA polymerase II will bind together to the 
promoter regions and initiate the gene transcription. The figure is obtained from the 
biology of cancer (second edition).  
 
1.5.1 Chromatin structure and epigenetic gene regulation 
1.5.1.1%Chromatin%structure%
The core of chromatin is formed by DNA wraps around nucleosomes, which presents the 
“beads on a string” organisation of nucleosomes and linker DNA forms the primary 
structure, while the interactions between nucleosomes give rise to the secondary structure 
of chromatin. As the nucleosomes are highly identical, composed of four histone species: 
H2A, H2B, H3 and H4, the secondary structure of chromatin is highly ordered. Some of 
the nucleosomes are further folded with the help of linker histone H1 and non-histone 
proteins into an ordered, compact nucleoprotein complex (137). Chromatin can be 
divided into euchromatin and heterochromatin according to the states of compaction and 
the transcription potential. In general, euchromatin is a nucleosome-relaxed and open 
region where DNA is accessible and often (not always) transcriptionally active, while 
heterochromatin is mostly associated with transcriptional repression. Heterochromatin 
tends to be located at the nuclear periphery, and is always compact and associated with 
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repetitive and gene-poor DNA sequences; however, it can undergo transitions to more 
decondensed and transcriptional active form in certain circumstances. This event is 
usually accompanied by profound changes in the epigenetic modifications on histones 
and DNA. 
1.5.1.2%Epigenetic%regulation%
Epigenetics refers to changes in gene activity and expression without alterations in DNA 
sequence. This post-translational modification is composed of the modifications on DNA 
and histone proteins.  
DNA methylation is the first recognized epigenetic modification that is associated 
with transcriptional silencing. It is predominantly found in the CpG islands of genes. In 
human, more than 50% of all CpGs are methylated, predominantly in heterochromatic 
regions. The regulation of this modification is crucial for gene expressions and 
chromosomal stability: hyper-methylation can result in chromatin condensation to a 
heterochromatin state, while less methylated regions are usually opened and accessible to 
TFs. 
Histone modifications including acetylation, methylation, phosphorylation, etc, are 
critical for the regulation of chromatin structure and gene transcription status. Among 
those, acetylation and methylation of lysines of the histone tails are mostly studied. 
Acetylation status is balanced by the histone acetyltransferases and deacetylases. When 
acetylated, originally condensed chromatin can be opened and give rise to transcriptional 
activation. When compared to the acetylation, which is simply associated with 
transcriptional activation, histone methylation can lead to either transcriptional activation 
or suppression, depending on the lysine residues where this modification occurs and the 
degree of methyl groups (mono-, di- or tri-). In general, in active gene regions, H3K4me, 
H3K4me3, H3K9me, H3K27me, H3K36me, H3K36me3, H3K79me and H3K79me3 are 
enriched, while in inactive regions, H3K9me2, H3K9me3, H3K27me2 and H3K27me3 
are enriched. 
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1.5.1.3%Aberrant%epigenetic%regulation%in%cancer%
Based on the studies over few decades, it is evident that deregulation of chromatin 
structure and epigenetic regulations are present in all stages of cancer progression. Back 
to 1983, DNA hypo-methylation was identified in cancer cells (138). This demethylation 
is associated with chromosomal instability, resulting in genetic mutations that account for 
the inactivation of tumour-suppressors and the activation of oncogenes. However, 
hypo-methylation is not the only type of DNA methylation alterations detected in cancers. 
Hyper-methylation of CpG islands of tumour-suppressor genes, which could result in 
silencing, was proposed later on (139). The abnormal histone modifications are also 
widely detected in various cancers. For example, loss of H4K16ac and H4K20me3 were 
suggested as a hallmark of human cancers (140). Aberrant levels of histone modifications 
were also addressed to be associated with various cancer progression and prognosis 
(141-144).  
Currently, aberrant modification, especially the hyper-methylation on 
tumour-suppressor genes is considered to be the major epigenetic alteration in cancer, 
which plays a key role in the malignant transformation. Therefore, reagents targeting 
enzymes responsible for DNA methylation is widely used in the treatment of different 
cancers. 
1.5.2 Chromatin remodelling and repositioning 
As previously mentioned, for routine cellular process, genes that reside in euchromatin 
are continually undergoing regulated structural changes to allow for gene activation or 
repression, which require dynamic packaging and unpacking of transcriptional regulatory 
elements, such as promoters and enhancers. Therefore, the expression of genes is not only 
dependent on the transcriptional regulatory elements, but also rely on proteins that 
mediate the regulation of chromatin architecture. Modulation of chromatin is critical for 
cell proliferation; therefore, it is not surprising that alteration of chromatin structure is 
often observed in cancer cells. A large number of genomic regions that are repressed in 
the normal state could be activated (or repressed, if they were originally activated) by an 
aberrant involvement of remodelling proteins in cancerous cells in response to 
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deregulated oncogenic signals. Thus, it is crucial to understand the underline mechanisms 
of this process. 
1.5.2.1%Chromatin%remodelling%
Chromatin remodelling is a dynamic regulation of chromatin architecture to allow the 
access of transcriptional regulatory machinery proteins to condensed genomic DNA, and 
thereby control the active states of chromatin and subsequently gene expression. Studies 
suggest that the active and inactive chromatin can be distinguished by measuring the 
sensitivity of chromatin to nucleases. Active chromatin was easily accessible to nucleases 
like DNase1 and was described as hyper-sensitive sites, which is the outcome of 
conformational change within the condensed chromatin. In general, two major 
mechanisms exist which regulate this conformational change: 1) as mentioned earlier, 
histones are able to undergo post-translational modifications, enabling the recruitment of 
various effector proteins to chromatin, thereby changing the active state of chromatin. 2) 
Specific chromatin remodelling complexes displace or translocate the histone octamers 
from DNA, which exposes indicated DNA sequences to sequence specific regulatory 
factors.  
1.5.2.2%Chromatin%repositioning%
In addition to the broad involvement of chromatin re-modelers in the regulation of 
chromatin active and inactive status, the sub-nuclear localisation of chromatin is also 
important. As mentioned earlier, heterochromatin is ubiquitously localised at the nuclear 
periphery, suggesting that there could be distinct localisation styles of active and inactive 
chromatin, and therefore, the positioning of chromatin could also result in changes in 
gene expression. It is already known that chromatin domains with high transcriptional 
activity are usually located at the nuclear centre, with very few cases positioned at the 
nuclear pores, whereas the transcriptionally silent regions are almost associated with 
nuclear periphery or the nucleolus (145). This is visible by light microscopy, as the 
heterochromatin is darkly stained and electron-dense. Furthermore, different 
experimental approaches including chromosome conformation capture (i.e. Hi-C), ChIP, 
DNA adenosine methyltransferase Identification (DamID) and fluorescence in situ 
hybridization (FISH) provided solid evidence for this (146). Interestingly, several specific 
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DNA-dense foci located at the nuclear periphery when silent, are able to relocate away 
from these peripheral heterochromatic compartments upon activation (147-149). This is 
not the case for several housekeeping genes, which are highly expressed while being at 
the periphery; nevertheless, the tethering of genes to the nuclear periphery has significant 
impact on the transcription. This would be discussed later.  
 The idea of molecular tethering of genetic loci is suggested by the observation that 
silent genes associated with the nuclear periphery are more constrained in their 
movement compared to the active ones at the centre of the nucleus (150). This scaffold 
function is mediated by the nuclear lamina, which is one of the main components of the 
nuclear membrane that provides a large surface area for chromosomes to anchor. Lamin 
proteins comprise the nuclear lamina. They are contacted by a number of proteins such as 
barrier-to-autointegration factor (BAF), lamina-associated polypeptide 2β (LAP2β), 
lamin B receptor (LBR), heterochromatin protein 1 (HP1), etc., which are able to bind 
chromatin directly or indirectly. Moreover, recent researches showed that lamins 
themselves are able to interact directly with histones and DNA!(151).! !
!
Figure 10 Components of the nuclear lamina. 
Lamins form a meshwork of intermediate filament proteins underlying the inner nuclear 
membrane (INM), where they interact with several distinct classes of transmembrane 
proteins. Figure is adapted from (145) 
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The importance of lamins as scaffolds is confirmed by the fact that deleting or 
mutating lamins results in the failure of correctly positioning genes at the nuclear 
periphery (152-155). ChIP-seq experiments of lamins were also performed to further 
study lamin-associated genes, which were shown to express low or absent active histone 
markers. Thereafter, a comprehensive genome-wide map of lamin gave rise to the term 
lamin-associated domains (LADs), which refers to the large chromatin domains up to 10 
megabases that lamins are associated with (156). DamID technique provides evidence 
that mammalian genomes contain approximately 1,100 to 1,400 LADs. LADs are found 
on more than 35% of the genome, suggesting that the interaction between LADs and the 
nuclear lamina is important for the positioning of chromatin. Although lamin (or LADs) 
is indispensable for accurate positioning genes at the periphery, it is not necessary for the 
maintenance of periphery heterochromatin, as absence of either A- or B-type lamins does 
not result in the release of heterochromatin from the nuclear envelope (157-159). A 
recent study show that LBR is sufficient for the periphery positioning of heterochromatin, 
and the retention of LBR upon lamin A or B depletion could be the reason for the 
maintenance of periphery heterochromatin (155). One hypothesis that lamin-association 
could repress gene expression is that lamin interaction may physically suppress the 
interaction of a promoter with its distal regulator element (enhancer), which needs further 
investigation.  
As mentioned above re-localisation of genes to the nuclear lamina can strongly affect 
transcription. However, to experimentally validate this, manually interfering with the 
nuclear positioning of chromatin is needed. Several studies succeeded in artificially 
relocate chromatin locus to the periphery in an inducible manner (160-162). Kumaran 
and Spector developed a nuclear lamina-targeting system in a cumate-inducible U2OS 
cells stably expressing lacl-mCherry-lamin B1. They found that when inducing 
lacl-mCherry-lamin B1 expression, the marked chromatin locus was detected at the 
nuclear lamina (160). Similarly, Reddy et al (161) and Finlan et al (162) also developed 
inducible systems in culture cells to visualize the repositioning of loci to the nuclear 
lamina. These studies indicate that artificially repositioning genes to the nuclear lamina 
favour transcription repression, although not all the activity of promoters was affected by 
this sub-nuclear repositioning.  
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The subsequent question is: what is the mechanism of endogenous genes 
repositioning to the nuclear lamina? The idea that all three H3K9 methylations (me1, me2 
and me3) and H3K27me3 modifications are associated with LADs (163, 164), and the 
accumulation of these repressive histone markers seem to correlate with the subnuclear 
distribution suggested that histone modification could be the cause of chromatin 
repositioning. As evidence, an RNAi screening found that silencing of S-adenosyl 
methionine (SAM) synthetase genes caused global methylation loss, which resulted in 
transcriptional activation and release of chromatin from the nuclear lamina (165). In 
depth, by regulating the methylation status through inhibiting MET-2 (mediates mono- 
and di-methylation of H3K9) and SET-25 (mediates H3K9me3) respectively, they 
discovered that H3K9me1 and me2 is necessary for the perinuclear anchoring, while 
H3K9me3 is not required for the positioning, but necessary for the transcriptional 
repression after the anchoring. 
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1.6%Aims%
Although we have already elucidated a role of LMTK3 in breast cancer progression as an 
ERα regulator, there are still several issues that need to be addressed, which became the 
aims of my PhD project. As the previous work was mainly focused on the role of 
LMTK3 on ERα regulation, I was interested in investigating whether LMTK3 can 
contribute in breast cancer progression in an ERα-independent manner, and investigate 
the role of LMTK3 in invasion and metastasis in ERα-negative breast cancer. 
Therefore, my work focused on: 
• Examining the expression pattern of LMTK3 in different categories of breast 
cancer cells.  
• Characterising the functional portrait of LMTK3 through identifying 
LMTK3-regulated proteins using SILAC-based approach and Gene Ontology 
analysis. 
• Investigating whether LMTK3 is involved in invasion and metastasis processes in 
breast cancer. 
• Studying the potential mechanism of LMTK3 that contribute to the regulation of 
invasion and migration. 
• Gaining insights into the clinical correlation of LMTK3 with 
metastasis-associated proteins. 
In addition, as we have previously discovered that a great portion of LMTK3 protein 
localises in the nucleus of breast cancer cells, we were also interested in examining the 
function of the nuclear LMTK3.  
For this part of my thesis, my work involved: 
• Gaining a globally picture of LMTK3-chromatin association through 
genome-wide ChIP-sequencing. 
• Investigating the function and the underlying mechanism(s) of LMTK3 in gene 
transcription through chromatin binding. 
• Identifying the binding partner(s) of LMTK3 on the chromatin. 
• Studying the in vivo and clinical impact of LMTK3 DNA binding events. 
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2.1%Materials%
2.1.1 Buffer and solutions 
Table 1 List of buffers and solutions 
Reagent Recipe Storage 
1M Tris-HCl 60.5 g Tris in total of 500ml ddH20 and adjusted to desired pH 
with pure HCl  
RT 
RIPA Tris-HCl: 50 mM, pH 7.4; NP-40: 1%; Na-deoxycholate: 
0.25%; NaCl: 150 mM; EDTA: 1 mM; PMSF: 1 mM; 
Aprotinin, leupeptin, pepstatin: 1 µg/ml each; Na3VO4: 1 mM; 
NaF: 1 mM  
4°C  
Laemmli buffer  50mM Tris-HCl pH 6.8; 15% glycerol; 0.1% (w/v) 
bromophenol blue; 4% SDS  
-20°C 
5x Loading buffer  0.25M Tris-HCl, pH 6.8; 15% SDS; 50% glycerol; 25% beta- 
mercaptoethanol; 0.01% bromophenol blue  
4°C 
10x SDS-PAGE 
Running buffer  
10g SDS; 30.3g Tris, 144.1g glycine dissolved in 1 l of ddH20  RT 
10x Semi Dry 
Transfer buffer  
Tris Base 5.8g; Glycine 2.9g; Methanol 200ml and make up to 
1L with ddH20  
RT 
10x TBS  24.23g Trizma HCl; 80.06 g NaCl dissolved in 1l of ddH20 and 
adjusted pH to 7.6 with pure HCl  
RT 
TBS-Tween  100ml of TBS 10x; 900ml ddH20; 1ml Tween® 20 (BDH)  RT 
Blocking buffer  TBS containing 0.1% (v/v) Tween20 and 5% (w/v) non-fat milk  4°C 
0.4% 0.4% w/v SRB powder dissolved in 1% acetic acid  RT 
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Sulforhodamine B 
(SRB)  
40% 
Trichloroacetic 
Acid (TCA)  
40 w/v TCA dissolved in ddH20  4°C 
IF fixation buffer  4% w/v paraformaldehyde  4°C 
IF blocking buffer  10% AB-serum in PBS  -20°C 
ChIP Solution A 0.1M NaCl, 1.0mM EDTA, 0.5mM EGTA, 50mM HEPES with 
1% formaldehyde 
RT 
ChIP LB1 50mM Hepes-KOH, pH 7.5, 140mM NaCl, 1mM EDTA, 10% 
glycerol, 0.5% NP-40 or Igepal CA-630, 0.25% Triton-X 100 
4°C 
ChIP LB2 10mM Tris-HCL, pH8.0, 200mM NaCl, 1mM EDTA, 0.5M 
EGTA 
4°C 
ChIP LB3 10mM Tris-HCL, pH 8, 100mM NaCl, 1mM EDTA, 0.5mM 
EGTA, 0.1% Na-Deoxycholate, 0.5% N-lauroylsarcosine 
4°C 
ChIP RIPA 50mM HEPES pH 7.6, 1mM EDTA, 0.7% Na deoxycholate, 
1% NP-40, 0.5M LiCl 
4°C 
TE buffer 10mM Tris-HCl (pH8.0), 1mM EDTA  RT 
De-crosslinking 
buffer 
1% SDS, 0.1M NaHCO3 RT 
RIME trypsin 10µg/ml trypsin in 100mM NH4HCO3 4°C 
FISH 
post-fixation 
washing buffer 
10% PBS (10x), 10% MgCl2 0.5M in H2O  4°C 
FISH fixation 
buffer 
10% PBS (10x), 10% MgCl2 0.5M, 30% H2O and 50% of 8% 
PFA  
4°C 
FISH 
hybridization mix  
4.5 µl of pure formamide, 3.6 µl 25% Dextran Solfate and 0.9 
µl of 20x SSC solution  
4°C 
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2.1.2 Mammalian cell lines 
Table 2 List of mammalian cell lines 
Cell Type Tissue Morphology Tumourigenicity 
MCF7 Breast Epithelial Human cell line derived from a pleural 
effusion of adenocarcinoma 
MCF7-LMTK3 Breast Epithelial MCF7 cell line stably overexpressing 
pCMV6- LMTK3 (full length) plasmid 
MDA-MB- 231 Breast Mesenchymal Human Metastatic and high invasive cell 
line derived from pleural effusions of 
ductal carcinoma 
T47D Breast Epithelial Human cell line derived from a pleural 
effusion of an infiltrating ductal 
carcinoma 
T47D-LMTK3 Breast Epithelial T47D cell line stably overexpressing 
pCMV6- LMTK3 (full length) plasmid 
 
Table 3 Media for culturing 
Cell Type Media Additives Storage 
MCF7, 
MDA231, 
BT549, T47D 
DMEM (Dulbecco’s 
Modified Eagle’s 
Medium) (Sigma-Aldrich, 
Dorset, UK)  
2mM Glutamine 50 
units/ml Penicillin 
50µg/ml Streptomycin 
10% FCS  
4°C, used 
within one 
month  
 
MCF7-LMTK3, 
T47D-LMTK3 
DMEM (Dulbecco’s 
Modified Eagle’s 
Medium) (Sigma-Aldrich, 
Dorset, UK) 
2mM Glutamine 50 
units/ml Penicillin 
50µg/ml Streptomycin 
10% FCS, 
1000-500µg/ml G-418 
(Roche Diagnostic Ltd, 
West Sussex, UK) 
4°C, used 
within one 
month 
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Table 4 SILAC media 
Name Media Additives Storage 
DMEM-14 
(R0K0) 
Control SILAC DMEM media 
containing unlabelled arginine 
and lysine amino acids 
10% SILAC 
dialysed foetal 
bovine serum 
 
4°C, used 
within one 
month 
DMEM-15 
(R10K8) 
SILAC DMEM media 
containing 13C and 15N labelled 
arginine, and13C and 15N 
labelled lysine 
10% SILAC 
dialysed foetal 
bovine serum 
4°C, used 
within one 
month 
DMEM-16 
(R6K4) 
SILAC DMEM media 
containing 13C labelled arginine 
and 2D labelled lysine amino 
acids 
10% SILAC 
dialysed foetal 
bovine serum 
4°C, used 
within one 
month 
 
Table 5 Transfection media and reagents 
Transfection media Transfection reagents Storage 
Normal growth media (NEAT) HiPerFect Transfection Reagent 
(Qiagen, West Sussex, UK) 
4°C 
Opti-MEM® I Reduced Serum 
Medium (Gibco®) 
Lipofectamine® LTX Reagent 
(Invitrogen, Life Technologies Ltd, 
Paisley, UK) 
4°C 
FuGENE HD (Promega) 
 
2.1.3 Plasmid constructs 
Table 6 Plamids and constructs 
Vector Insert Sequence (Amino acids) Source 
pCMV6 Empty vector Empty vector Origene 
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Myc/FLAG  
pCMV6 
Myc/FLAG 
LMTK3 Full length Origene 
pCB7 ITGA5 Full length Addgene 
pRK5 ITGB1 Full length Addgene 
pGL3 ITGA5 -908/+241bp promoter (luciferase. 
reporter)  
Semi Kim 
pGL3 ITGB1 -2kb promoter (luciferase. reporter) Robert 
Grosse 
pGL3 ITGB1 -3kb promoter (luciferase. reporter) Robert 
Grosse 
pGEX-2T GST-GRB2 Full length John 
Ladbury 
pGEX-2T GST-RAF1 RAS-binding domain (RBD) Addgene 
pGEX-6P-1 GST-LMTK3 GST-LMTK3 aa112-690 Genscript 
pGEX-6P-1 GST-LMTK3 GST-LMTK3 aa491-690 Genscript 
pET-49b GST-LMTK3 GST-LMTK3 aa111-490 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa133-411 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa691-1171 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa867-1098 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa867-1171 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa906-1183 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa906-1407 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa1184-1407 Vorgias 
pET-49b GST-LMTK3 GST-LMTK3 aa1184-1489 Vorgias 
pCR-Blunt 
II-TOPO 
Crispr-LMTK3 gRNA targeting LMTK3 exon 12-1 
GTGACCGTGAGCACATCGTCGGG 
N/A 
pCR-Blunt 
II-TOPO 
Crispr-LMTK3 gRNA targeting LMTK3 exon 12-3 
GGAAGGGACCGTCTCGGGGTGGG 
N/A 
 
! 79!
2.1.4 Antibodies 
Table 7 Primary antibodies 
Antibody Producer Antibody Producer 
LMTK3 (I-17) Santa cruz  LMTK3 (M02) Abnova 
β-actin (AC-15) Abcam Alexa Fluor® 488 
Phalloidin 
Life Technologies 
Vinculin EMD Millipore FAK Cell signalling 
Integrin β1 Cell signalling Integrin α5 Cell signalling 
Integrin β3 Cell signalling Integrin αV Cell signalling 
SRF Cell signalling GRB2 Cell signalling 
SOS1 Santa cruz CDC42 Cell signalling 
RAS Cell signalling KAP1 (TRIM28) Abcam 
H3K9me3 Abcam Lamin A Abcam 
Lamin A/C Santa cruz p-KAP1 (S824) Abcam 
p-KAP1 (S473) Abcam PP1α Santa cruz 
GST Abcam PP1β Santa cruz 
HDAC1 Santa cruz β-tubulin Abcam 
 
Table 8 Secondary antibodies 
Antibody Producer 
Polyclonal goat anti-rabbit IgG/HRP  Dako, Cambridge, UK 
Polyclonal goat anti-mouse IgG/HRP Dako, Cambridge, UK 
Alexa Fluor® 555 goat anti-mouse IgG  Invitrogen, Paisley, UK  
Alexa Fluor
® 
488 goat anti-mouse IgG Invitrogen, Paisley, UK 
Alexa Fluor
® 
555 goat anti-rabbit IgG Invitrogen, Paisley, UK 
Alexa Fluor
® 
488 goat anti-rabbit IgG Invitrogen, Paisley, UK 
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2.1.5 Primers 
Table 9 Primers 
 Gene names F’ R’ 
G
en
om
ic
 D
N
A
 
BAP1 CCTCAGTCCCACACACAGAC GGAAGACGAGCCCAGAGG 
GLOD4 CTGCGAGCAGCCATGATT CGCCATGTTCCCTGAGAC 
GPAM AGTTCGCACCCTAGCAGCTC CGCACACTCGAGTACACACA 
RBM42 CTCATAGGCCCAGGTTCTTG CCGCTGGTTCTGCTGTCTAC 
TRMT61B AGGCACAGCAAGACAGGAC GGATGGTCACTCAACCAGGA 
CWC25 GAAATAGTTCGGGGGCTACC AGCCCTGTACGTCATCGTTC 
C1D GACTCCAGTCTCCCGGAAAG TGAGATTTGCCTTTGGAGAAG 
Negative 
ctl-1 GAGCAGCATTTTAGGCTTGG TGCAGTGGCTTTTCTCAATG 
Negative 
ctl-2 AAACCTGCACGCTGGACTAC CATGGCTGGCAAGAAGGT 
cD
N
A
 
CWC25 ATTCCTCCCCTGTTTTGTCC GAAGACCCTGGTTACGGTCA 
GLOD4 AGATTCTGACTCCCCTGGTG GCTTCCCTCTGGATCCATCT 
GPAM CCAGCCTGTGCTACCTTCTC CTGTTTCATGGCAGACTTGG 
RBM42 CTGTGATCCGCCCAATTATC CCACCATGGGAGGAACTACT 
TRMT61B CCCAGGTGATACTGTTTTGGA GCCAGATCATGGTGGTCTTT 
TFPT CGGGAATTAAATCGCAGAAA CCGAGTTATCCTCTGCACCT 
BAP1 Purchased from Qiagen (QT00204701) 
C1D Purchased from Qiagen (QT00041475) 
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2.2%Methods% %
2.2.1 Mammalian cell culture  
2.2.1.1%Maintaining%and%passaging%cells% %
Cells were maintained in 75 cm
2 
or 150 cm
2 
flasks with DMEM medium supplied with 
10% FCS and 1% Penicillin/ Glutamine at 37 °C in a humidified 5% CO2 incubator. 
Cells were routinely passaged at a confluence of ~90%. To passage cells, medium was 
firstly removed with aspirators and washed with room temperature PBS. 2-3 ml of 1x 
trypsin in EDTA was added into each flask in order to let the cells detach. 7-8 ml of 
medium with FCS was added into flasks to neutralize the trypsin and cell clumps were 
resuspended gently through pipetting. Suspension of cells was taken out of flask, and 
transferred in 15 mL sterile centrifuge tube and centrifuged at 1000 rpm for 5 min. Once 
centrifugation was finished, the supernatant was aspirated and cell pellet was resuspended 
in a certain amount of medium depending on requirement. The proper dilution of cells 
was then reseeded into new flasks and fresh media was added. Cell passages used in all 
experiments were normally between passages 4 and 20 and mycoplasma was tested 
routinely.  
2.2.1.2%Cell%transfections% %
For siRNA transfection, cancer cell lines were seeded into different sizes of dishes (6 cm 
or 10 cm) or plates (6-well or 24-well) with appropriate amount of medium depending on 
experiment design. Cells were allowed to attach at 37°C with 5% CO2 for overnight 
before transfection. On the next day, the named siRNA was firstly added into neat 
medium and incubated at RT for 10 min before proceeding to the next step. 3 to 1 (v/w) 
ratio of Hiperfect Transfection Reagent (Qiagen) were then added into the previous 
solution and mixed gently. The master mix was incubated at RT for 15 minutes to enable 
the formation of transfection complexes. Subsequently, the complexes were added 
drop-wise onto the cells, and the plates were gently swirled to allow distribution of the 
transfection complexes evenly. The cells with the different transfection complexes were 
then incubated under normal growth conditions for indicated time. Each transfection was 
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performed at least three times and the following assays including protein and RNA 
extractions were implemented.  
For plasmid DNA transfection, cells were plated into the indicated dishes or plates 
for each experiment as aforementioned. On the transfection day, the indicated amount of 
plasmid DNA was added into Opti-MEM
®
. After 5 min incubation, certain volume of 
Lipofectamine® 2000 (ratio 1 µg: 2 µl) or FuGENE HD (ratio 1 µg: 3 µl) was added into 
same amount of Opti-MEM®. Each mix was incubated for 15 min at RT to allow 
complex formation. During the time, replace the medium from DMEM with 10% FCS 
and 1% Penicillin/ Glutamine to DMEM with 10% FCS and 1% Glutamine. After 
incubation, the mix was then added drop-wise onto the cells, and the plates were swirled 
to allow distribution of the transfection complexes evenly. The cells with the different 
transfection complexes were then incubated under normal growth conditions for indicated 
time. Each transfection was performed at least three times for the experiments described 
in this work. 
2.2.1.4%Generation%of%stable%cell%lines%
MCF7 and T47D cells were used to generate cell lines stably expressing human wild type 
LMTK3 (pCMV6-LMTK3). These plasmid constructs were purchased from Origene 
(Table 6) and sequences were confirmed before experiments. To start, a working 
concentration of G418 to guarantee selection and maintenance of the neomycin- resistant 
cells by eliminating non-transfected cells was determined as following. A titration 
experiment was designed by treating non-transfected MCF7/T47D cells seeded at 
different densities to different doses of G418 (0, 0.1, 0.3, 0.5, 0.8, 1 mg/ml) for 10 days, 
and 1 mg/ml showed to be the minimum amount of G418 that caused 99% cell death at 
all densities. Next, 1 × 106 cells were seeded in 100 mm dishes in medium in the absence 
of antibiotics and attached overnight. On the following day, plasmids pCMV6-LMTK3 
was transfected into cells using protocol described above. After 48 hours, stably 
transfected cells were treated with normal growth media in the presence of 1 mg/ml of 
G418. In 10 days from the addiction of the antibiotic, non-transfected cells died and 
removed. Stably transfected cells were plated at a lower density to allow each single cell 
form a monoclonal colony with G418. When clones were visualized by eyes, 20 clones 
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for each transfection condition were reseeded into 24-well plates: cloning discs were 
dipped in trypsin-EDTA for 2-3 min, then put on top of a single cell colony and 
incubated for 5 min at 37 °C to allow cells to detach. Each cloning disc carrying 
monoclonal cells was then transferred to each well of a 24-well plate in presence of 
G-418. Cells derived from monoclonal colonies were cultured by changing medium twice 
a week, and expanded when confluent. Finally, selected stable cells were acquired and 
success of transfection was confirmed by RT-qPCR and western blotting to check the 
mRNA and protein expression levels.  
2.2.1.5%Generation%of%CRISPR/Cas9%LMTK3%knockout%cell%lines%
MDA-MB-231 cells were transiently cotransfected with expression plasmids encoding 
the indicated CRISPR guide RNA pairs against LMTK3 exon 12, together with an 
expression plasmid encoding a CAS9-GFP fusion protein (Addgene), using lipofectamine 
LTX (Invitrogen, Carlsbad, CA) transfection reagent. 72 h following transfection, cells 
were FACS sorted for GFP expression and re-plated at clonal densities to obtain 
single-cell clones. Genomic DNA from individual clones was used in PCR analysis of 
LMTK exon 12 and products indicating CRIPSR mediated deletion within the exon 
further characterized by DNA sequencing. Cell lysates prepared from LMTK3 exon 12 
deletion positive clones were used in western blot analysis to confirm LMTK3 knockout. 
2.2.2 Protein extraction and western blotting  
2.2.2.1%Total%protein%extraction% %
RIPA buffer was used to extract whole cell lysates. Cells were washed with PBS 3 times 
scraped with RIPA buffer, and then incubated in ice for 25 min before centrifuging at 
13000 rpm for 10 min at 4 °C. Supernatants were transferred to new tubes and stored at 
-80 °C. 
2.2.2.2%Nuclear,%chromatinWbound%and%cytoplasmic%protein%extraction%
Nuclear, chromatin-bound and cytoplasmic extracts were performed using Subcellular 
Protein Fractionation Kit (Thermo Scientific). Briefly, cells were harvested by scraping 
with cold PBS and centrifuged at 800 g for 5 minutes to pellet. Next, cell pellet was 
washed twice in cold PBS and supernatant was removed. Certain amount of ice-cold CEB 
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buffer depending on the cell pellet volume was added to the cell pellet. Cell lysate in the 
tube was mixed gently through suspending with pipets. The mix was then incubated on 
rotator at 4 °C for 10 minutes, followed with centrifuging at 4 °C for 5 minutes at 500g. 
Supernatant is the cytoplasmic extraction. Subsequently, ice-cold MEB was added to the 
pellet and mixed vigorously and incubated on rotator at 4 °C for 10 minutes, followed 
with centrifuging at 4 °C for 5 minutes at 2000g. Supernatant is the membrane extraction. 
Ice-cold NEB was then added to the pellet and mixed through vortex at highest setting for 
15 sec and incubated on rotator at 4 °C for 30 minutes, followed with centrifuging at 4 °C 
for 10 minutes at 5000 g. Supernatant is the soluble nuclear extraction. To harvest the 
chromatin-bound extraction, NEB containing protease inhibitors, 5% CaCl2 and 3% 
Micrococcal Nuclease was added to the pellet, followed with 15 sec vortex and 15 min 
incubation at RT. After incubation, mix was vortex on the highest setting for 15 seconds 
and centrifuge the tube at 16,000 g for 5 minutes to harvest the chromatin-bound 
extraction. 
2.2.2.3%Protein%quantification%and%lysate%preparation%
Protein concentration was measured by Bradford Reagent Kit (Bio-Rad, Berkeley, CA, 
USA). 1 µl of each protein samples were normally added into 500 µl of Bradford buffer 
and incubated at room temperature for 2 min. Absorbance readings of the prepared 
samples were then were measured at 595 nm using a Beckman DU® 530 Life Science 
UV/Visible spectrophotometer (Harlow Scientific, Arlington, MA). After measurement, 
the concentration of the unknown samples was determined based on standard absorbance 
value. An equal amount of protein in all samples was processed and lysates were heated 
with 5x sodium dodecyl sulfates (SDS) sample buffer at 100 °C for 5 min before they 
were loaded to 10% SDS-PAGE. 
2.2.2.4%SDSWpolyacrylamide%gel%electrophoresis%and%western%blotting%
Different percentages of acrylamide resolving and stacking gels were prepared manually 
as required for indicated proteins. Samples (30 µg) and rainbow markers (Thermo 
Scientific, Leicestershire, UK) were loaded onto the gels. Subsequently, electrophoresis 
was run at 80V for 30 min and changed to 120V for 1-2 hours in 1x running buffer. 
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).  
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Samples were then transferred to Hybond ECL super nitrocellulose membranes (GE 
Healthcare). Subsequently the membranes were blocked in TBS containing 0.1% (v/v) 
Tween20 and 5% (w/v) non-fat milk for 1 h. The primary antibodies were probed with 
membranes overnight at 4 °C. The membranes were then washed three times in 
TBS/Tween for 15 min following incubation with HRP-conjugated secondary antibodies 
(1:3000 dilution) for 1 h. The membranes were then washed three times again and were 
detected with Enhanced chemiluminescence (ECL). Films were developed using a 
Konica SRX-1001A X- ray developer. Alternatively, membranes were incubated with 
anti-mouse or anti-rabbit secondary antibodies for 1 h and developed on the films. 
2.2.3 RNA extraction and PCR 
2.2.3.1%RNA%extraction%
RNA extraction was performed using RNeasy Kit from Qiagen (Crawley, UK). Briefly, 
cells seeded in 6-well plate were firstly washed twice with PBS. 350 µl of RLT buffer 
was added directly to the cells in the plate and scraped down with cell scrapers. Lysate in 
RLT was then transferred into a QIAshredder spin column placed in a 2 ml collection 
tube, which was centrifuged at full speed for 2 min to remove cell non-soluble debris. 
Subsequently, an equal volume of 70% ethanol was added to the lysate followed by pipet 
mixing. The mix from previous step was then transferred to an RNeasy spin column 
placed in a 2 ml collection tube, and centrifuged at 13,000 rpm for 15s. The flow-through 
was discarded. 700 µl RW1 buffer was added directly to the RNease spin column and 
centrifuged at 1000 rpm for 15s to wash the spin column membrane. 500 µl RPE buffer 
was then added to the RNease spin column and centrifuged at 13,000 rpm for 15s. 
Another 500 µl RPE buffer was added to the RNeasy spin column and centrifuged at 
13,000 rpm for 2 min. Lastly, the RNeasy spin column was placed in an RNase-free 
collection tube and 30 µl RNase-free water was added to the center of the membrane of 
the RNeasy spin column, followed by centrifuging at 13,000 rpm for 15s to elute RNA. 
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2.2.3.2%Reverse%transcription.%
The reverse transcription of total RNA to cDNA was performed using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies Ltd, Paisley, 
UK). Briefly, a master mix containing 2 µl 10x RT buffer, 1 µl dNTP Mix, 2 µl 10x RT 
random primers, 1 µl MultiScribeTM reverse transcriptase and 1 µl RNase inhibitor was 
prepared per sample. Next, 1 µg total RNA with water was added to the master mix up to 
20 µl per reaction. To perform reverse transcription, the reactions were incubated at 37°C 
for 2 h. Subsequently, the cDNA samples were collected and diluted 1 in 10 with water 
and stored at -20°C. 
2.2.3.3%Quantitative%realWtime%PCR%
RT-qPCR assays were performed to study the expression of genes of interest using 
TaqMan® Universal PCR Master Mix or SYBR® Green PCR Master Mix (Applied 
Biosystems, Life Technologies Ltd, Paisley, UK). For each reaction 5 µl of cDNA from 
the previous reverse transcription was used together with 10 µl TaqMan Master Mix, 1 µl 
of indicated TaqMan® probe and 4 µl of water, or 10 µl SYBR Green Master Mix, 2 µl 
of indicated SYBR Green primer mix and 3 µl of water. All the reactions were done in 
Fast Optical 96-well reaction plate (Applied Biosystems) in triplicate. Before putting on 
the machine, the plate was sealed with the Optical Adhesive Cover Starter Kit (Applied 
Biosystems) and centrifuged (2,000 × g) for 30 seconds at 4°C. RT-qPCR analysis was 
performed on a 7900HT Thermocycler (Applied Biosystems) on the program as follows: 
stage 1, 10 min at 95°C; stage 2, 20 s at 95°C and 20 s at 60°C for 40 cycles. Finally, the 
results were recorded and analysed accordingly. 
2.2.4 Luciferase reporter assay 
7.5×104/well MCF7 or MDA-MB-231 cells were seeded into 24-well plate and 
transfection was performed using FuGENE® HD transfection reagent according to 
manufacturer’s instructions (Roche, UK). Cells were transfected with different luciferase 
report constructs together with renilla luciferase reporter vector. Cell lysates were 
collected after 24 hours transfection and firefly and renilla luciferase activities were 
measured by the Dual-GloTM Luciferase Assay kit as manufacturer’s protocols described. 
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Briefly, cells were washed with PBS twice and 55 µl of passive buffer was added into 
each well and incubated at room temperature for 30 min on the plate shaker. After 
incubation, 50 µl of cell lysis was transferred into white 96-well plate. 50 µl of 
Dual-Glo® Luciferase Reagent was added into each well immediately. Once mixed, the 
plate was put on a reader to measure the firefly luminescence. Then, 50 µl of Stop & 
Glo® Reagent was added to each well, mixed and renilla luminescence was subsequently 
measured in the same plate. The transcriptional activity of constructs was determined by 
firefly luciferase activity normalized against renilla luciferase activity. 
2.2.5 Cell proliferation assay 
3000 cells per well of MCF7 and T47D cells stably expressing LMTK3 or empty vector 
were seeded in 96-well plates. Cells were fixed every 24 hours by gentle addition of 100 
µl of 40% trichloroacetic acid (TCA) (w/v) (final concentration of 10% TCA) per well. 
Plates were incubated for 1 hour at 4°C. After the incubation, plates were washed five 
times with distilled water, dried and subsequently stained with 100 µl of sulforho- damine 
B (SRB) solution 0.4% (w/v) in 1% acetic acid for 1 hour at room temperature. Unbound 
dye was removed by washing plates five times with 1% acetic acid. Plates were then left 
over night to dry completely. Bound stain was solubilized by the addition of 100 µl of 10 
mM Tris base with 10 min incubation on the plate shaker. Absorbance was determined on 
an automated plate reader (96-well microtiter) at 492 nm.  
2.2.6 3D-Matrigel assay 
Laminin-rich basement membrane matrix (Matrigel) (BD Biosciences) was used for 3D 
cell cultures. 1 × 104 cells were trypsinized and suspended in 2% (v/v) Matrigel in 
DMEM containing 10% FCS. The mix was then seeded over a layer of polymerized 100% 
Matrigel in eight-well chamber slides. Phase-contrast or confocal micrographs of 
representative fields were taken after 5 to 8 days using Axiovert 100 MetaMorph 
microscope. 
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2.2.7 Cell adhesion assay 
Each well of the 96-well plates was coated with 50 ml of the following ECM ligands (10 
mg/ml) diluted in PBS: collagen (C3867, Sigma); fibronectin (F1141,!Sigma); vitronectin 
(V8379, Sigma) and laminin (L6274, Sigma). Plates were incubated overnight at 4°C. On 
the second day, plates were washed with PBS and blocked with 1.5% bovine serum 
albumin in PBS for 2 hours at 37°C. During the time, cells were washed with PBS and 
detached with 20 mM EDTA in PBS. Cells were then washed with serum-free DMEM 
three times and resuspended in the same medium to a concentration of 2 × 105 cells/ml. 
After the incubation, plates were washed with PBS three times, and 100 µl of cell 
suspension was added to each well, incubated at 37°C for 10 to 30 min, and gently 
washed with PBS three times to remove the unattached cells. Attached cells were fixed 
with 10% TCA for 1 h at 4°C, washed with water and stained with 0.4% SRB solution. 
Absorbance was read at 492 nm. 
2.2.8 Collagen I hanging drop assay 
MCF7 and MCF7-LMTK3 cells or T47D and T47D-LMTK3 were detached by 0.05% 
trypsin and 1 mM EDTA. DMEM culture medium with FCS was added to neutralize the 
trypsin and resuspend the cells. Cells were counted and diluted to a concentration of 2.5 × 
106 cells/ml. 5ml of PBS was added to the bottom of 60-mm dishes. The lids were 
inverted and twenty 10 µl droplets of cell suspension were added onto the bottom of the 
lid of each dish. The lids were inverted onto the PBS-filled bottom chamber and 
incubated at 37°C. Once sheets were formed, aggregated cells were transferred to a 
coverslip coated with collagen I and incubated at 37°C and 5% CO2. For control panel, 
pictures were taken after 30 min; for experiment group, pictures were taken until 
spheroids formed. 
2.2.9 Invasion and migration assays 
2.2.9.1%Invasion%assay%
For invasion assay, matrigel was diluted 1:5 in serum-free DMEM and evenly coated in 8 
mm Transwell chambers, which were placed in 24-well plates. The plates were incubated 
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at 37°C for 1 h. During the incubation, cells were washed with serum-free DMEM for 
three times and counted. After the incubation, 1 × 105 of cells were added to upper 
chambers. Medium (500 µl) containing 10% FCS was added below the Transwell 
chamber. Cultures were maintained for 48 hours for MDA-MB-231 and BT549 cells, or 
72 hours for MCF7 and T47D cells. Then membranes were removed, stained with DAPI 
(4,6-diamidino-2-phenylindole), and pictures were taken using EVOS FL Cell Imaging 
System.  
2.2.9.2%Migration%assay%
For migration assay, cells were washed with serum-free DMEM for three times and 1 × 
105 of cells were added directly to the 8 mm Transwell chambers (without matrigel). 
Medium (500 µl) containing 10% FCS was added below the Transwell chamber. Cultures 
were maintained for 12 hours for MDA-MB-231 and BT549 cells, or 24 hours for MCF7 
and T47D cells. Then membranes were removed, washed and stained with DAPI 
(4,6-diamidino-2-phenylindole), and pictures were taken using EVOS FL Cell Imaging 
System. 
2.2.10 Wound healing assay 
Cells were treated and seeded in a 6-well plate, and cultured until completely confluent. 
A straight scratch was made each well. The plate was then placed under a real-time 
microscope. Pictures were taken of the scratches every 1 h (5 views each well) for 24 to 
72 h depending on the cell line used. Results were analysed using ImageJ. 
2.2.11 Immunofluorescence analysis 
Cells plated on coverslips to ~70% confluence. Then coverslips were washed with PBS 
and fixed with 4% PFA at room temperature for 10 min. After the fixation, coverslips 
were washed 5 min with PBS for 3 times and can be stored at 4 °C for up to 2 weeks. 
Coverslips were then incubated in 0.2% Triton X-100 for 10 min, followed with blocking 
step using blocking buffer (10% human AB serum in PBS) for 30 min. Subsequently, 
coverslips were incubated with primary antibody diluted in the blocking buffer for 2 h at 
RT. After the incubation, coverslips were washes 5 min with PBS for 3 times, followed 
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by staining with either FITC (fluorescein isothiocyanate) or Texas Red–conjugated 
secondary antibodies for 1 h each at room temperature. Coverslips were washed and 
DAPI was used to stain nuclei. Fluorescence was detected using a Leica SP5 Confocal 
Microscope at appropriate wavelengths. Results were analysed using LAS AF lite 
software and ImageJ. 
2.2.12 Fluorescence In Situ Hybridization (FISH) 
MCF7 and MCF7-LMTK3 cell pellets were resuspended and incubated with hypotonic 
solution for 15 min at 37°C, followed by 5 min centrifuging at 1300 rpm. Cells were 
fixed and a drop of the cells were placed on the slide, followed by 37°C incubation 
overnight. Slides were supplied with 150-200 µl of 0.005% Pepsin/0.001 M HCl and 
incubated for 15 min at 37°C. Slides were incubated in PBS for 5 min, post fixation 
washing buffer (10% PBS (10x), 10% MgCl2 0.5M in H2O) for 5 min, Paraformaldehyde 
(PFA) /PBS (10% PBS (10x), 10% MgCl2 0.5M, 30% H2O and 50% of 8% PFA) for 5 
min, PBS for 5min and 5 min each in ethanol series (70%, 90%, 100%). Slides were 
air-dried and supplied with the hybridization mix (1µl of indicated probes, 4.5 µl of pure 
formamide, 3.6 µl 25% Dextran Solfate and 0.9 µl of 20x SSC solution), followed by 5 
min incubation at 75°C and 37°C overnight in dark. Slides were washed three times with 
0.1x SSC for 5 min each at 57°C. Slides were supplied with DAPI and ready for analysis 
under the confocal microscope. 
2.2.13 Protein precipitation 
2.2.13.1%Immunoprecipitation%assay%
For immunoprecipitation, indicated antibodies (2 µg) were incubated with beads 
(ImmunoCruzTM IP/WB Optima Systems) for 2 h at 4°C. Cell lysates were harvested 
using RIPA buffer, and incubate with 50 µl of pre-clear beads for 30 min at 4°C.  After 
the antibody incubation, pellet matrix via centrifugation at maximum speed for 30 
seconds at 4° C. Supernatant were discarded and matrix was washed with PBS for 3 times. 
Matrix was then incubated with 1 mg of pre-cleared cell lysates at 4 °C overnight. 
Immunoprecipitates were washed three times with PBS before being resolved by SDS–
PAGE and immunoblotted with indicated antibodies.  
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2.2.13.2%GST%pullWdown%assay%
For GST-pull-down assay, 20 µg GST-tagged proteins were incubated with GST beads 2 
h at 4°C, followed by three times wash with PBS. 1mg cell lysates harvested by RIPA 
buffer were then incubated with matrix at 4°C overnight, followed by five times washing 
with PBS and then resolved by SDS–PAGE and immunoblotted with indicated 
antibodies. 
2.2.14 Chromatin Immunoprecipitation (ChIP) and coupled to deep 
sequencing (ChIP-seq) analysis 
2.2.14.1%ChIP%
2.2.14.1.1!Prepare!beads!
50-100µl of beads (protein A beads for rabbit ChIP antibody and protein G beads for 
mouse ChIP antibody) were added to an eppendorf and put on a magnetic stand. 
Supernatant was removed and beads were washed with 1ml of 5mg/ml BSA in PBS for 3 
times. Beads were then resuspended in 350µl of 5mg/ml BSA in PBS and the indicated 
antibody (4ug for ChIP; 10ug for ChIP-seq.) was added. The beads were mixed and 
incubated at 4°C on rotator for 4-6 h.  
2.2.14.1.2!Fixation!and!tissue!douncing!
Cells were fixed in ChIP Solution A (Table 1) for 10 min at 37°C, followed by 
neutralizing with 1:10 (v/v) 1M glycine for 5 min. Cells were then washed with PBS for 
3 times, scraped down with PBS and collected by centrifuging at 800g for 5 min. The 
pallet can be stored in -80°C.  
For tumour tissues, fresh frozen tissues were cut into small pieces in a pre-cold plate on 
dry ice (remove fat tissues and leave tumour tissues only). Tumour tissues pieces were 
transferred to a mortar on the dry ice. Liquid nitrogen was poured onto the tumour, which 
was pulverized immediately. Tumour powders were transferred to an eppendoff tube, 
fixed with Solution A for 20 min at 37°C and neutralized with 1:10 (v/v) 1M glycine for 
10 min. Pellet was harvested through centrifuging. 
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2.2.14.1.3!Sonication!and!chromatin!IP!
1ml of buffer LB1 (Table 1) supplied with fresh added protease inhibitor was added to 
the cell or tissue pellets, which were then incubated at 4°C on the rotator for 10 min. 
Pellets were collected through 2000g centrifuging at 4°C for 5 min. Then 1ml of buffer 
LB2 (Table 1) supplied with fresh added protease inhibitor was added to the pellets, 
which were then incubated at 4°C on the rotator for 5 min. Pellets were collected through 
2000g centrifuging at 4°C for 5 min. 300µl of LB3 (Table 1) supplied with fresh added 
protease inhibitor was added to the pellets, which were sonicated in 4°C water bath 
(Diagenode Bioruptor) (5 min x4 for cells, 15 min x2 for tumours. 30s on 30s off).  
After the sonication, 30µl of 10% Triton-100 in LB3 were added to each tube, which 
were centrifuged at full speed at 4°C for 10 min. During the time, beads incubated with 
antibodies were washed 3 times with 5mg/ml BSA in PBS, and resuspended in 100µl of 
5mg/ml BSA in PBS and 10µl of 10% Triton-100 in LB3. Sonicated lysates were then 
added to the beads and together were incubated on the rotator overnight at 4°C. 
2.2.14.1.4!Reverse!cross>link!and!harvesting!precipitated!genomic!DNA!
After the incubation, beads were washed with ChIP RIPA buffer (Table 1) for 6 times, 
followed with 2 times’ washing with TE buffer (Remove all the residual TE.). 100µl of 
de-crosslinking buffer was added to the beads. The tubes were incubated on the 65°C 
heat block shaker for 30 min and then incubated in the 65°C water bath overnight.  
After the incubation, 200µl of TE was added to the tube. RNAase was then added to the 
mix to make up to 20µg/ml concentration and incubated at 37°C for 1 h. Subsequently, 
200µg/ml of Proteinase K was added to the mix and incubated at 55°C for 2 h. After the 
incubation, 400µl of Phenol:! Chloroform:! Isoamyl! alcohol! was! added! to! the! tube.!After!mixing!well,! cloudy! supernatant!was! transferred! to! a! phase! lock! eppendorf!column,! followed! by! 5! min! centrifuging! at! top! speed.! The! upper! layer! was! then!transferred! into! a!new!eppendorf! containing!NaCl! (final! concentration!200mM).!3!volume!of!cold!100%!ethanol!and!2µl of glycoblue were added to the tube. The samples 
were then incubated at -80°C for at least 30 min after vortex. After the incubation, 
precipitated genomic DNA pellets were harvested through 45 min top speed centrifuging 
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at 4°C, followed with a washing with 70% ethanol. The pellets were resuspended with 
100µl of water. 
2.2.14.2%ChIPWseq%
For generating the ChIP-seq library, 5 ng of LMTK3 ChIP-enriched DNA was modified 
with the ChIP-seq DNA Sample Prep Kit (Illumina). The DNA end was ligated with 
adaptor (NEBNext® Multiplex Oligos for Illumina (Index Primers Set 1)), and PCR 
amplified for 15 rounds. Amplified DNA was gel purified through collecting the 
fragments around 300bp. The purified DNA was sent for sequencing (Illumina).  
2.2.14.3%Bioinformatic%and%statistical%analyses%
Peaks were then called using MACS under recommended settings: bandwidth=300, p 
value cut off = 1e-5, mfold range= 10, 30. False Discovery Rate (FDR) cut off was 0.001 
(0.1%) for all peaks. Peaks and raw signals were then uploaded to and analysed with 
Galaxy/Cistrome.  
2.2.15 Rapid immunoprecipitation mass spectrometry of endogenous 
proteins (RIME) 
MCF7 cells (1 × 108) were cross-linked with ChIP Solution A for 8 min and neutralized 
with 1:10 1M Glycine for 5 min. The cells were washed with ice-cold PBS, harvested in 
PBS. The nuclear fraction was extracted similar to ChIP using LB1, LB2 and LB3, and 
sonicated in a waterbath sonicator (Diagenode Bioruptor). A total of 30 µl of 10% Triton 
X-100 in LB3 was added, and lysate was centrifuged for 10 min at top speed to purify the 
debris. The supernatant was then incubated with 100µl of protein G beads pre-bound with 
20µg of LMTK3 or IgG antibody, and immunoprecipitation was conducted overnight at 
4°C on the rotator. The beads were washed 10 times with ChIP RIPA buffer and twice in 
100mM ammonium hydrogen carbonate (AMBIC) solution.  
Precipitated protein was trypsinized with 10µl of trypsin (10µg/ml in 100mM NH4HCO3) 
with a brief vortex to resuspend the beads, which were then incubated at 37°C overnight. 
After the incubation, the supernatant was collected and directly placed into formic acid to 
a final concentration of 5%. 
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Digested peptide mixtures were analysed on the LC-MS/MS following the instructions of 
previous published paper (166).  
2.2.16 Formaldehyde-assisted isolation of regulatory elements (FAIRE) 
1 × 107 MCF7 and MCF7-LMTK3 cells were cross-linked using ChIP Solution A for 10 
min. After the fixing, 1:10 1M Glycine was added for neutralizing with 5 min incubation. 
Cells were collected through scraping using PBS. The nuclear fraction was extracted 
similar to ChIP using LB1, LB2 and LB3, and sonicated in a waterbath sonicator 
(Diagenode Bioruptor). 10% Triton X-100 in LB3 was added to a final concentration of 
1%, and lysate was centrifuged for 10 min at top speed to purify the debris. The 
supernatant can be stored in -80°C. 
For harvesting and purifying FAIRE DNA, 1 volume of Phenol:! Chloroform:! Isoamyl!alcohol!was!added to each sample.!After!5!sec!vortex,!supernatant!was!transferred!to!a! phase! lock! eppendorf! column,! followed!by!5!min! centrifuging! at! top! speed.! The!upper!layer!was!then!transferred!into!a!new!eppendorf.!Repeat!this!step!twice.!NaCl!(to! a! final! concentration! of! 200mM),! 3! volume! of! cold! 100%! ethanol! and! 2µl of 
glycoblue were then added to the tubes. The samples were then incubated at -80°C for at 
least 30 min after vortex. DNA were precipitated through centrifuging at top speed at 4°C 
for 30 min, and washed once with 70% ethanol. DNA pellets were resolved in 50µl of 
water. RNAase was then added to the mix to make up to 20µg/ml concentration and 
incubated at 37°C for 1 h. Subsequently, 200µg/ml of Proteinase K was added to the mix 
and incubated at 55°C for 2 h. 10 volume of de-crosslinking buffer was then added to 
each sample, which was then incubated on the 65°C heat block shaker for 30 min and 
then incubated in the 65°C water bath overnight. After the de-crosslinking, FAIRE DNA 
was then purified using PCR purification kit (Qiagen), and eluted with 200µl of water. 
2.2.17 Clinical specimens, TMAs, immunohistochemistry, and scoring 
Tissue microarrays (TMAs) containing 858 primary operable breast cancer cases from 
the previously validated Nottingham Tenovus Primary Breast Carcinoma Series were 
used. The cohort comprised women aged up to 70 years, who presented between 1986 
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and 1999. Appropriate ethics committee approval was obtained. LMTK3 scoring was 
performed as previously described (1). ITGB1 rabbit monoclonal antibody (ab115146, 
Abcam) was optimized to a working concentration (4 mg/ml) on full-face excisional 
tissue sections. Subsequently, 858 breast cancer TMA cases comprising 4-mm-thick 
formalin- fixed paraffin-embedded tissue cores were immunostained with the optimized 
ITGB1 antibody on the Leica BOND-MAX automated system according to the 
manufacturer’s instructions. ITGB1 immunohistochemical staining and scoring were 
performed as previously described (8). TMA scoring was performed by two independent 
investigators (Y.X. and H.Z.). High-resolution digital imaging (NanoZoomer, 
Hamamatsu Photonics) at ×20 magnification with a Web-based interface (Distiller, 
SlidePath Ltd.) was used. All cases were scored without knowledge of the 
clinicopathological or outcome data. 
2.2.18 Xenograft mouse model 
Female 7-week-old, nu/nu-BALB/c athymic nude mice were acclimated in the animal 
house one week before experimentation. Before cells injection, a 0.72mg 17-β Estradiol 
60-day release pellet was implanted subcutaneously (Innovative Research of America) 
into each mouse. 2×106 T47D or T47D-LMTK3 cells (or 5×106 MCF7-LMTK3WT and 
MCF7-LMTK3RVxF cells) were resuspended in the total volume of 100µL PBS. Nude 
mice were anaesthetized with 4% isofluorane and their body temperature was maintained 
stable by laying them on a thermal pad. Cells were then injected subcutaneously into the 
flank of the animals by groups (n=8, per group). Tumour growth was analysed by caliper 
measurements every three days and calculated using the formula 1/2 length (mm) × width 
(mm)2. After the mice were sacrificed, primary tumours were excised and formalin fixed. 
Samples were paraffin embedded, cut at 3µm and IHC stained for histological evaluation 
of target proteins expression. This study was conducted under the UK Home Office 
Project License. 
2.2.19 In vitro kinase assay 
To examine whether LMTK3 can phosphorylate KAP1, recombinant LMTK3 kinase 
domain (Genscript) was incubated with full length recombinant human KAP1 protein 
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(Abnova) in kinase buffer (containing 50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM 
EGTA, 1 mM DTT, 0.2 mM orthovanadate, 0.25 mM ATP and 0.3 µCi/µl [γ-32P]ATP) 
for 30 min at 30 °C. Samples were resolved by SDS-PAGE, stained with Coomassie, 
dried and subjected to autoradiography. 
2.2.20 Statistic analyses 
ChIP-seq sequences were mapped to the human genome (hg19) using Bowtie to yield 
unique alignments. Unique peaks were called using MACS. Peak signals were then 
viewed using IGV software and uploaded to the Galaxy / Cistrome online software 
(http://cistrome.org/ap/), where integrative analyses were performed. Heat map of MCF7 
and MDA-MB-231 binding events were generated using ChAsE software.  
Cancer survival analyses were performed using online Kaplan Meier-plotter 
(http://kmplot.com/analysis/) and Oncomine (https://www.oncomine.org). Gene 
expression data were downloaded from TCGA (http://cancergenome.nih.gov/), and 
Pearson correlation test were performed. 
All other data analyses were performed with Prism 6. Data were presented as means ± SD 
or SEM, as indicated in the legends. Statistical significance was assessed using Student’s 
t test and ANOVA tests. Statistical analysis for TMAs was performed with SPSS 16.0 
statistical software (SPSS Inc.). 
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3.1% LMTK3% Promotes% Invasion% in% Breast% Cancer% Through%
GRB2WMediated%Induction%of%Integrin%β1% %
3.1.1 Identification of two bands of LMTK3 protein 
3.1.1.1%Both%bands%of%LMTK3%are%fullWlength%LMTK3%protein.%
When using various commercial available LMTK3 antibodies, we were able to detect two 
bands of LMTK3 through Western blotting. In order to understand more about these two 
bands we performed LC/MS/MS analysis. To further increase the amount of LMTK3 
from whole cell lysates and improve sequence coverage of the protein, an 
immunoprecipitation pull-down experiment was carried out to purify the LMTK3 from 
the lysates of MCF7 cells transiently overexpressing Flag-tagged LMTK3. Following 
antibody detection by Western blotting, two bands of interest were seen at approximately 
240 KDa and 170 KDa on the blotting membrane corresponding to our protein of interest. 
Alignment of the Western blot membrane to a separately CCBB stained gel prior to 
excision of the gel bands of interest was performed (Figure 11). After trypsin digestion, 
samples were preceded to LC/MS/MS identification analysis.  
!
Figure 11 Two bands of LMTK3 purified by gel cut. 
SDS PAGE gel containing a Flag-IP of overexpressed LMTK3 pull-down from an 
MCF-7 cell lysate. Two bands of interest (GG2_1 and GG2_2) were excised and the 
bands of three identical lanes pooled prior to enzymatic digestion and LC/MS/MS 
analysis. ! !
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!
Figure 12 MS analysis of LMTK3 protein bands. 
Mass spectrometry analysis and interrogation of the data against the Uniprot database 
identified two bands for LMTK3, one at 240 kDa (upper panel) and one at 170 kDa 
(lower panel), covering 50% and 41% of the LMTK3 amino acid sequence, respectively. 
The identified peptides are highlighted according to the peptide identification probability 
(green: >95%, yellow: 90%~95%).  
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S erine/threonineBprotein+kinas e+LMTK 3+OS =Homo+s apiens +GN=LMTK 3+PE =2+S V=2
59+unique+peptides ,+60+unique+s pec tra,+60+total+s pec tra,+732/1460+amino+ac ids +(50% +coverage)
M P A P G A L I L L A A V S A S G C L A S P A H P D G F A L G R A P L A P P Y A V V L I S C S G L L A F I F L L L T C L
C C K R G D V G F K E F E N P E G E D C S G E Y T P P A E E T S S S Q S L P D V Y I L P L A E V S L P M P A P Q P S H S
D M T T P L G L S R Q H L S Y L Q E I G S G W F G K V I L G E I F S D Y T P A Q V V V K E L R A S A G P L E Q R K F I S
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E R L W I P L R W A A P E L L G E L H G T F M V V D Q S R E S N I W S L G V T L W E L F E F G A Q P Y R H L S D E E V L
A F V V R Q Q H V K L A R P R L K L P Y A D Y W Y D I L Q S C W R P P A Q R P S A S D L Q L Q L T Y L L S E R P P R P P
P P P P P P R D G P F P W P W P P A H S A P R P G T L S S P F P L L D G F P G A D P D D V L T V T E S S R G L N L E C L
W E K A R R G A G R G G G A P A W Q P A S A P P A P H A N P S N P F Y E A L S T P S V L P V I S A R S P S V S S E Y Y I
R L E E H G S P P E P L F P N D W D P L D P G V P A P Q A P Q A P S E V P Q L V S E T W A S P L F P A P R P F P A Q S S
A S G S F L L S G W D P E G R G A G E T L A G D P A E V L G E R G T A P W V E E E E E E E E G S S P G E D S S S L G G G
P S R R G P L P C P L C S R E G A C S C L P L E R G D A V A G W G G H P A L G C P H P P E D D S S L R A E R G S L A D L
P M A P P A S A P P E F L D P L M G A A A P Q Y P G R G P P P A P P P P P P P P R A P A D P A A S P D P P S A V A S P G
S G L S S P G P K P G D S G Y E T E T P F S P E G A F P G G G A A E E E G V P R P R A P P E P P D P G A P R P P P D P G
P L P L P G P R E K P T F V V Q V S T E Q L L M S L R E D V T R N L L G E K G A T A R E T G P R K A G R G P G N R E K V
P G L N R D P T V L G N G K Q A P S L S L P V N G V T V L E N G D Q R A P G I E E K A A E N G A L G S P E R E E K V L E
N G E L T P P R R E E K A L E N G E L R S P E A G E K V L V N G G L T P P K S E D K V S E N G G L R F P R N T E R P P E
T G P W R A P G P W E K T P E S W G P A P T I G E P A P E T S L E R A P A P S A V V S S R N G G E T A P G P L G P A P K
N G T L E P G T E R R A P E T G G A P R A P G A G R L D L G S G G R A P V G T G T A P G G G P G S G V D A K A G W V D N
T R P Q P P P P P L P P P P E A Q P R R L E P A P P R A R P E V A P E G E P G A P D S R A G G D T A L S G D G D P P K P
E R K G P E M P R L F L D L G P P Q G N S E Q I K A R L S R L S L A L P P L T L T P F P G P G P R R P P W E G A D A G A
A G G E A G G A G A P G P A E E D G E D E D E D E E E D E E A A A P G A A A G P R G P G R A R A A P V P V V V S S A D A
D A A R P L R G L L K S P R G A D E P E D S E L E R K R K M V S F H G D V T V Y L F D Q E T P T N E L S V Q A P P E G D
T D P S T P P A P P T P P H P A T P G D G F P S N D S G F G G S F E W A E D F P L L P P P G P P L C F S R F S V S P A L
E T P G P P A R A P D A R P A G P V E N
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R L E E H G S P P E P L F P N D W D P L D P G V P A P Q A P Q A P S E V P Q L V S E T W A S P L F P A P R P F P A Q S S
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P M A P P A S A P P E F L D P L M G A A A P Q Y P G R G P P P A P P P P P P P P R A P A D P A A S P D P P S A V A S P G
S G L S S P G P K P G D S G Y E T E T P F S P E G A F P G G G A A E E E G V P R P R A P P E P P D P G A P R P P P D P G
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P G L N R D P T V L G N G K Q A P S L S L P V N G V T V L E N G D Q R A P G I E E K A A E N G A L G S P E R E E K V L E
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A G G E A G G A G A P G P A E E D G E D E D E D E E E D E E A A A P G A A A G P R G P G R A R A A P V P V V V S S A D A
D A A R P L R G L L K S P R G A D E P E D S E L E R K R K M V S F H G D V T V Y L F D Q E T P T N E L S V Q A P P E G D
T D P S T P P A P P T P P H P A T P G D G F P S N D S G F G G S F E W A E D F P L L P P P G P P L C F S R F S V S P A L
E T P G P P A R A P D A R P A G P V E N
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Mass spectrometry (MS) suggested the two LMTK3 proteins detected by Western 
blotting at different molecular weights were both full-length (Figure 12), which is further 
confirmed by RNA-seq analysis suggesting that there is no splice variants of LMTK3. 
Further investigation is required to decipher the underlying cause for these two bands. 
We suggest that the reason of the difference of the molecular weights is due to 
posttranslational modifications, such as glycosylation or phosphorylation, similarly to 
LMTK2 (167).  
3.1.1.2% The% lower% band% of% LMTK3% localises% both% in% the% nucleus% and% the% cytoplasm,%
while%the%upper%band%of%LMTK3%only%localises%in%the%cytoplasm.%
Through confocal staining, we found that LMTK3 localises both in the nucleus and the 
cytoplasm (Figure 13A). To understand the functional differences of the two bands of 
LMTK3, we performed cell fractionation assay. Interestingly, we discovered that the 
upper band is specifically localised in the cytoplasm, while the lower band is detected 
both in the cytoplasm and nucleus (Figure 13B), suggesting that the two bands may be 
responsible for the function of LMTK3 in the cytoplasm and nucleus respectively.  
!
Figure 13 Cytoplasmic and nuclear localization of the two bands of LMTK3 
(A) Immunofluorescence staining of LMTK3 in MCF7 and MDA-MB-231 breast cancer 
cells. (B) Western blotting of LMTK3 in cytoplasmic and nuclear cell fractions of 
MDA-MB-231 and MCF7 cells.  
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3.1.2 LMTK3 overexpression promotes breast cancer ! cell proliferation 
and accelerates tumour growth in vivo ! 
3.1.2.1%LMTK3%is%ubiquitously%expressed%in%breast%cancer%cell%lines%
Before defining the role of LMTK3 in vitro, we examined its protein abundance in a 
panel of breast cancer cell lines. As shown in Figure 14, LMTK3 is expressed in all the 
breast cell lines we have tested, with variable abundances. Although we have previously 
addressed that LMTK3 is implicated in ERα positive breast cancer progression, we 
discovered that the protein levels of LMTK3 are surprisingly higher in several ERα 
negative breast cancer cell lines, such as MDA-MB-231 and BT549. Interestingly, only 
the 240 KDa LMTK3 band was increased in the relatively more invasive MDA-MB-231 
and BT549 cells, suggesting that the upper band may be responsible for the cancer cell 
invasiveness. 
!
Figure 14 LMTK3 is ubiquitously expressed in breast cancer cell lines. 
LMTK3 protein abundance in various breast cancer cell lines  
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3.1.2.2%LMTK3%overexpression%promotes%breast%cancer%growth%in%vitro.%
To investigate the role of LMTK3, we stably overexpressed LMTK3 in MCF7 and T47D 
cell lines (Figure 15A), which exhibited less abundance of the upper band of LMTK3 
relative to either MDA-MB-231 or BT549 cells (Figure 14). We found that LMTK3 
overexpression in MCF7 and T47D cells significantly increased the proliferation rate 
compared to the parental cell lines (Figure 15B), as assessed by SRB assays. Moreover, 
with three-dimensional (3D) Matrigel overlay assays, we discovered that 
LMTK3-overexpressing cell lines formed larger colonies, exhibiting a “grape-like” 
morphology as opposed to the established “mass” shape of the parental cells (Figure 
15C). These data support that LMTK3 promotes a signalling profile that results in 
enhanced cell proliferation and invasive features in culture.  
3.1.2.3%LMTK3%overexpression%promotes%breast%cancer%growth%in%vivo.%
To investigate the association of LMTK3 with the growth of breast tumour xenografts, 
T47D or T47D-LMTK3 cells were injected into the mammary fat pads of female Balb/C 
nude mice. As expected from cell culture experiments, LMTK3 overexpression increased 
tumour xenograft growth (Figure 16A), and was associated with increased Ki-67 
abundance, a marker of cell proliferation (Figure 16B), indicative of the tumourigenic 
function of LMTK3 in vivo. 
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Figure 15 LMTK3 overexpression promotes breast cancer growth in vitro. 
(A) LMTK3 stably overexpression in MCF7 and T47D cell lines. (B) Effect of 
overexpression of LMTK3 on the MCF7 and T47D cells proliferation. (C) Effect of 
overexpression of LMTK3 on spheroid formation in MCF7 and T47D cells compared to 
the parental cell lines. Data are means ± SD from three independent experiments. **P < 
0.01, ***P < 0.001, unpaired Student’s t test.  
A B 
C 
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!
Figure 16 LMTK3 overexpression promotes breast cancer growth in vivo 
(A) Quantification of fold difference in tumour size between T47D and T47D-LMTK3 
xenografts at weeks 2 and 6. Data are means ± SD from five T47D-derived xenografts 
and seven T47D-LMTK3–derived xenografts. Representative images of tumours at 6 
weeks are shown. (B) Tumour tissue from (A) was stained for LMTK3 and Ki-67. Scale 
bars, 100 μm. **P < 0.01, ***P < 0.001, unpaired Student’s t test.  
 
 
 
 
A 
B 
! 105!
3.1.3 LMTK3 promotes !cell invasion, motility, and migration ! 
3.1.3.1%LMTK3%positively%regulates%breast%cancer%cell%invasion%
Based on the fact that the more invasive cell lines MDA-MB-231 and BT549 have 
relatively abundant LMTK3 protein (upper band) compared to the less invasive MCF7 
and T47D cells, we questioned whether LMTK3 is involved in the invasion process. To 
elucidate this, we first test the cell invasiveness using Boyden chamber invasion assays. 
We found that increased LMTK3 expression in MCF7 and T47D cells significantly 
promoted cell invasion (Figure 17A), whereas knocking down LMTK3 in the invasive 
MDA-MB-231 and BT549 cell lines inhibited invasion (Figure 17B). Moreover, using 
the hanging drop assay, we found that 3D spheroids formed by MCF7 cells 
overexpressing LMTK3 not only displayed a higher degree of colony dispersion at day 0, 
but also exhibited augmented invasion into the surrounding 3D collagen matrix at day 2 
(Figure 17C). We also observed the formation of membrane protrusions at the cell 
borders, 2 days after the hanging drop test in T47D cells overexpressing LMTK3 (Figure 
17D), indicating that these cells had features of increased cell membrane dynamics and 
mobility. 
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Figure 17 LMTK3 promotes breast cancer cell invasion. 
(A) Fold change in migration through Transwells by MCF7 and T47D cells 
overexpressing LMTK3 compared with parental cells. (B) Fold change in Transwell 
migration by MDA-MB-231 and BT549 cells transfected with LMTK3 small interfering 
RNA (siRNA) (siLMTK3) compared with cells trans- fected with a control siRNA (siCtl). 
Data are means ± SD from three independent experiments. (C) Invasion in a collagen I 
hanging drop assay by MCF7 overexpressing LMTK3 compared with parental cells. 
Images are representative of three experiments. ***P < 0.001, unpaired Student’s t test.  !!!
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3.1.3.2%LMTK3%positively%regulates%breast%cancer%cell%motility%and%migration%
To visualize the contribution of LMTK3 in cell motility, we performed wound-healing 
assays. We observed that the migration was significantly increased in MCF7 cells 
overexpressing LMTK3 compared to the parental cells (Figure 18A), whereas silencing 
LMTK3 markedly inhibited cell migration in MDA-MB-231 cells (Figure 18B). 
Together, these data support that LMTK3 is associated with a more invasive cell 
phenotype. 
 
!
Figure 18 LMTK3 regulates cell migration. 
Wound-healing assays in MCF7 cells overexpressing LMTK3 (A) or MDA-MB-231 cells 
after 72 hr LMTK3 knockdown (B). Data are mean ± SD from three experiments. **P < 
0.01, ***P < 0.001, unpaired Student’s t test.  
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3.1.4 LMTK3 regulates cell invasion and migration, actin cytoskeleton, 
focal adhesion formation, and adhesion to ECM. 
3.1.4.1%LMTK3%promotes%actin%cytoskeleton%and%focal%adhesion%formation% %
Adhesion to the ECM results in the generation of contractile forces and dynamic actin 
polymerization and reorganization (168), which are some of the major remodelling 
changes that occur in the cell during migration and invasion. Cell motility was visualized 
by the enhanced vinculin and focal adhesion kinase (FAK) re-localization at the leading 
edge of cells. To visualize the effect of LMTK3 on actin, vinculin and FAK localization, 
we performed confocal staining of these proteins in MCF7 and MCF7-LMTK3 cells. We 
found that overexpression of LMTK3 increased actin-rich protrusions, vinculin and focal 
adhesion formations on the edge of migrating cells (Figure 19A). Furthermore, we also 
detected an increase of actin-rich protrusions in 3D cultures with LMTK3 overexpression, 
whereas silencing LMTK3 suppressed this activity (Figure 19B).  
!
Figure%19 LMTK3 regulates cell motility. 
(A) Confocal microscopy analysis of F-actin protrusions, Vinculin localization, and FAK 
abundance in MCF7 and MCF7- LMTK3 cells. (B) 3D staining for F-actin in BT549 
cells transfected with siCtl or siLMTK3, and in T47D cells overexpressing LMTK3 
compared with parental cells. Images are representative of three experiments.  
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3.1.4.2%LMTK3%promotes%cell%adhesion%to%ECM% %
As cell invasion is a multistep process controlled by both intracellular and extracellular 
signals that stimulate changes in cytoskeleton formation as well as cell adhesion, we 
questioned whether LMTK3 could also promote cell adhesion to extracellular matrix 
(ECM). Indeed, overexpression of LMTK3 in MCF7 increased the attachment to both 
collagen I and fibronectin, as assessed by cell adhesion assays using purified ECM 
ligands (Figure 20A). Conversely, silencing the endogenous LMTK3 protein in 
MDA-MB-231 cells decreased the cells’ attachment to collagen and fibronectin (Figure 
20B), further supporting the notion that loss of LMTK3 reduces cell motility. 
 
 
 
!
Figure 20 LMTK3 promotes cell adhesion to ECM. 
(A) Cell adhesion assay of MCF7 and MCF7-LMTK3 cells towards indicated ECM ligands. (B) 
Cell adhesion assay of MDA-MB-231 cells transfected with control and LMTK3 siRNA towards 
indicated ECM ligands. Data are means ± SEM (n = 3) *P < 0.05 **P < 0.01, ***P < 0.001, 
unpaired Student’s t test.  
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3.1.5 LMTK3 increases cell invasion and adhesion by promoting the 
protein abundance of integrin β1 and α5. 
3.1.5.1%SILAC%analysis%identifies%LMTK3Wregulated%proteins ! %
To elucidate the molecular mechanisms underlying the regulation of cell invasion and 
motility by LMTK3, we performed stable isotope labelling by amino acids in cell culture 
(SILAC) to identify LMTK3-modulated proteins (Figure 21). Inhibition of LMTK3 
decreased the abundance of several proteins involved in integrin-signalling pathways, 
including integrin subunit α5, talin-1, vinculin, and b-actin–like protein 2 (Figure 21 and 
Figure 22).  
!
Figure 21 SILAC analysis identifies LMTK3-regulated proteins. 
SILAC scatter plot comparison of ratios for total proteins showing altered abundance in 
MCF7 transfected with LMTK3 siRNA relative to those transfected with control siRNA. 
Significance threshold was calculated by a B Significance Test (Sig B). 
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Figure 22 Gene Ontology classification of LMTK3-regulated proteins in MCF7 cells 
using DAVID Functional Annotation tools. 
A functional profile of the most enriched GO biological processes including proteins that 
were increased or decreased after LMTK3 silencing.  
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3.1.5.2%Integrin%β1%and%α5%are%LMTK3Wregulated%proteins ! %
It is well established that the binding of integrins to ECM enhances cell growth and 
migration by transmitting information to the cell and activating bidirectional signalling 
pathways (169). Considering our SILAC data, we explored whether LMTK3 affects the 
expression of different integrin isoforms that have been previously implicated in breast 
cancer by assessing the abundance of integrin subunits after modulating LMTK3 
(170-173). MCF7 and T47D cells overexpressing LMTK3 had increased abundance of 
integrin subunits β1β3 and α5 (Figure 23A). On the contrary, abolishing LMTK3 
expression in MDA-MB-231 and BT549 cell lines reduced the abundance of all three 
integrin subunits (Figure 23A). In MCF7 cells overexpressing LMTK3, we also observed 
a significant increase in the cell surface abundance of integrin subunit β1 (Figure 23B, 
and upper band in Figure 23A), which is described as the activated form of integrin 
subunit β1 that helps cells adhere to the ECM (174). Thus we decided to study further on 
the function of LMTK3 together with integrin β1 and α5.  
!
Figure 23 LMTK3 increases Integrin β1 and α5. 
(A) Western blot for integrin subunits in indicated cell lines (B) Fluorescence-activated 
cell sorting for surface ITGB1 in MCF7 cells transiently overexpressing LMTK3 
compared with control cells. The histogram is representative of, and the data are means ± 
SD from, three experiments relative to cells transfected with the empty vector. *P < 0.05, 
unpaired Student’s t test. 
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3.1.5.3%LMTK3Winduced%invasion%and%adhesion%require%integrin%subunits%β1%and%α5%
To determine whether LMTK3 regulates cell adhesion, invasion, and actin cytoskeleton 
reorganization through the integrin β1 and α5 subunits, we first overexpressed integrin 
subunits β1 or α5 (encoded by ITGB1 and ITGA5, respectively) in MCF7 cells, which 
have low LMTK3 abundance (Figure 24A). We then examined the cell motility, and   
confirmed that both isoforms cell invasion through Matrigel (Figure 24B). The 
overexpression also promoted increased cell adhesion to collagen I and fibronectin 
(Figure 24C). These suggest that integrin β1 and α5 overexpression, which mimicking 
the effect of LMTK3 overexpression, would lead to increased cell motility.  
We then questioned whether the increased cell motility of MCF7-LMTK3 cells is due to 
the up-regulation of integrin β1 and α5. Thus, we silenced β1 or α5 subunits in 
MCF7-LMTK3 cells (Figure 25A) and compared the cell motility with wide type MCF7 
cells. As a result, silencing integrin β1, but not integrin α5, suppressed the invasion of 
MCF7-LMTK3 cells through Matrigel (Figure 25B). Depletion of either β1 or α5 
subunits returned the adhesion exhibited by MCF7-LMTK3 cells to that seen in parental 
cells when cultured on collagen I and fibronectin (Figure 25C). Decreased F-actin 
aggregation was also observed on the periphery of MCF7-LMTK3 cells especially after 
knockdown of integrin β1 subunit (Figure 25D). Considering that these are functional 
heterodimers, these observations can be explained by the fact that silencing of integrin β1 
nearly abolished integrin α5 protein, whereas inhibition of integrin α5 did not have a 
similar effect on integrin β1, therefore affecting the efficiency of these complexes.  
Finally, we overexpressed integrin subunit β1 or α5 together with LMTK3 silencing in 
MDA-MB-231 cells (Figure 26A) and found that integrin restoration could rescue the 
reduction in invasion (Figure 26B) and cell adhesion (Figure 26C) caused by LMTK3 
knockdown. Together, these data indicate that the promotion of cell adhesion and 
invasion elicited by LMTK3 is mediated through the induction of integrin subunits β1 
and α5. 
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Figure 24 Integrin subunits β1 and α5 overexpression mimics the LMTK3-induced 
up-regulation of the motility. 
(A) Western blot for integrin subunits after overexpression in MCF7 cells. (B) Cell 
invasion of MCF7 with integrin subunits overexpression and MCF7-LMTK3 cells. (C) 
Cell adhesion to indicated ECM ligands of MCF7 with integrin subunits overexpression 
and MCF7-LMTK3 cells. Data are means ± SEM (n = 3) *P < 0.05 **P < 0.01, ***P < 
0.001, unpaired Student’s t test.  
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Figure 25 Silencing integrin subunits β1 and α5 subunits return LMTK3-induced 
cell adhesion, invasion and actin skeleton formation. 
(A) Western blot for integrin subunits after silencing in MCF7-LMTK3 cells. (B) Cell 
adhesion to indicated ECM ligands of MCF7 cells and MCF7-LMTK3 cells with integrin 
subunits silencing. (B) MCF7 cells and MCF7-LMTK3 cells with integrin subunits 
silencing. Confocal staining of F-actin of MCF7 cells and MCF7-LMTK3 cells with 
integrin subunits silencing. Data are means ± SEM (n = 3). ***P < 0.001, unpaired 
Student’s t test.  
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Figure 26 Integrin subunits β1 and α5 overexpression rescue LMTK3 
silencing-induced reduction of the motility. 
(A) Western blot for integrin subunits after overexpression in MDA-MB-231 cells with 
LMTK3 silencing. (B) Cell invasion of MDA-MB-231 cells with integrin subunits 
overexpression and LMTK3 silencing. (C) Cell adhesion to indicated ECM ligands of 
MDA-MB-231 cells with integrin subunits overexpression and LMTK3 silencing. Data 
are means ± SEM (n = 3) *P < 0.05 **P < 0.01, ***P < 0.001, unpaired Student’s t test.  
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3.1.6 LMTK3 promotes ITGB1 and ITGA5 transcription through SRF. 
3.1.6.1%LMTK3%promotes%ITGB1%and%ITGA5%transcription%! %
On the basis of the effects of LMTK3 on the abundance of integrin β1 and α5 subunits at 
the protein level, we investigated whether LMTK3 affected these at the transcriptional 
level. Quantitative real-time polymerase chain reaction (qRT-PCR) revealed that LMTK3 
positively regulated ITGA5 and ITGB1 mRNA expression (Figure 27A, B), whereas no 
change in ITGAV mRNA expression was observed (Figure 27C), and ITGB3 was hardly 
detected in MCF7 as previously reported (101). Silencing LMTK3 in MCF7 also reduced 
ITGA5 and ITGB1, but not ITGAV mRNA expression (Figure 27D-G). Considering the 
predominant effect of LMTK3 on integrins β1 and α5, but not on αV, we decided to 
further focus our research on the integrin β1 and α5 functional heterodimer. 
     !
Figure 27 LMTK3 promotes ITGB1 and ITGA5 transcription. 
qRT-PCR for ITGB1 (A), ITGA5 (B) and ITGAV (C) mRNA in MCF7 cells 
overexpressing LMTK3 compared with parental cells or MDA-MB-231 transfected with 
control or LMTK3 siRNA. (D-E) qPCR results of LMTK3 (D), ITGB1 (E), ITGA5 (F) 
and ITGAV (G) after LMTK3 silencing in MCF7 cells Data are means ± SD (n = 3) *P < 
0.05 **P < 0.01, ***P < 0.001. 
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3.1.6.2%LMTK3%promotes%ITGB1%and%ITGA5(promoter%activity% ! %
To further confirm that LMTK3 promotes the transcription of ITGA5 and ITGB1, we 
used two luciferase reporter plasmids containing either the 3000–base pair (bp) region 
upstream of ITGB1 ATG or the 900-bp region upstream of the ITGA5 ATG, respectively. 
LMTK3 overexpression increased the activity of both promoters (Figure 28A, B), 
whereas silencing LMTK3 had opposing effects (Figure 28C, D).  
!
Figure 28 LMTK3 promotes ITGB1 and ITGA5 promoter activity. 
(A, B) Effect of LMTK3 overexpression on ITGB1 (A) and ITGA5 (B) promoter 
activities in MCF7 cells. (C, D) Effect of LMTK3 silencing on ITGB1 (C) and ITGA5 (D) 
promoter activities in MDA-MB-231 cells. Data are means ± S (n = 3) *P < 0.05 **P < 
0.01, ***P < 0.001.  
 
              !
Figure 29 LMTK3 does not regulate ITGB1 and ITGA5 transcription through SP1, 
c-FOS and c-JUN. 
SP1, c-Fos and c-Jun were silenced in MCF7-LMTK3. ITGB1 (A) and ITGA5 (B) mRNA 
levels were measured by qRT-PCR. Data are means ± SD (n = 3) N.S. not significant. 
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3.1.6.3%LMTK3%promotes%ITGB1%and%ITGA5%transcription%through%SRF.% ! %
We then investigated which transcription factor (or factors) mediated integrin induction 
in the presence of increased LMTK3 abundance. We found that several well-known 
regulators of integrin transcription, namely, specificity protein 1 (SP1) and activation 
protein 1 (AP1; which is a heterodimeric complex consisting of c-FOS and c-JUN), were 
unable to promote ITGB1 and ITGA5 transcription in MCF7 cells overexpressing 
LMTK3 (Figure 29A, B). However, knockdown of SRF, which was recently identified 
as a transcription factor for ITGB1 (175, 176), inhibited the activity of reporter constructs 
containing either the ITGB1 or the ITGA5 promoters (Figure 30A, B), similar to that 
containing a known SRF target promoter (FOS) as a positive control (Figure 30C), 
without affecting LMTK3 protein abundance (Figure 30D). To determine whether 
LMTK3 affected SRF binding to the promoter of the gene encoding integrin β1, we 
performed SRF chromatin immunoprecipitation (ChIP) assays in MCF7 cells 
overexpressing LMTK3 compared with parental cells and detected increased endogenous 
SRF binding to an ITGB1 enhancer element (Figure 30E), which contains a putative SRF 
consensus sequence (CArG box) (176) These results suggest that LMTK3 promotes 
integrin subunit b1 abundance at the transcriptional level through SRF. 
To further investigate the role of SRF in LMTK3-induced cell migration and proliferation, 
we treated MCF7 and MCF7-LMTK3 cells with the SRF inhibitor CCG- 1423 (177). We 
found that CCG- 1423 inhibited migration by nearly half in MCF7 cells overexpressing 
LMTK3, compared with less than a third in parental MCF7 cells (Figure 30F), 
suggesting that SRF enhances LMTK3-induced cell migration. However, CCG-1423 
suppressed proliferation more effectively in the parental cells than in those 
overexpressing LMTK3 (Figure 30G), indicating that LMTK3 may promote cell 
proliferation additionally through other pathways. 
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Figure 30 LMTK3 promotes ITGB1 and ITGA5 transcription through SRF. 
(A to D) Effect of SRF silencing on the (A) ITGB1 p3000 promoter, (B) ITGA5 promoter, 
and (C) FOS promoter. (D) LMTK3 protein abundance after SRF silencing. (E) 
ChIP-qPCR assay for SRF binding to proximal enhancer region of ITGB1 gene. 
Cross-linked nuclear extracts of MCF7 and MCF7- LMTK3 were immunoprecipitated 
with SRF antibody (left) or control immunoglobulin G (IgG) (right). (F) Transwell 
migration exhibited by MCF7 and MCF7-LMTK3 cells pre-treated with 1 or 5 µM SRF 
inhibitor CCG-1423 for 24 hours. (G) Proliferation in MCF7 and MCF7-LMTK3 cells 
treated with the indicated concentration of CCG-1423. Data are mean ± SD relative to 
untreated cells, from three independent experiments. *P<0.05, **P<0.01, ***P<0.001.  
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3.1.7 An LMTK3-GRB2 cascade activates CDC42 and subsequently 
SRF. 
3.1.7.1%GRB2%is%an%LMTK3%interacting%protein.% ! %
On the basis of our observations thus far, we investigated how LMTK3 activates SRF. 
Previous work showed that the RTK MET interacts with the adaptor protein GRB2 and 
activates members of the RAS-GTPase family, namely, RAS and Rho subfamilies (178), 
the latter of which activates SRF (179, 180). Immunoprecipitation of endogenous 
proteins in cells (Figure 31A) and GST (glutathione S-transferase)– tagged GRB2 
pull-down assays in vitro (Figure 31B) revealed a direct interaction between LMTK3 and 
GRB2. 
!
Figure 31 LMTK3 interacts with GRB2. 
(A) Immunoprecipitation of LMTK3 and GRB2 in MCF7 cells transfected with vector 
and LMTK3-encoding plasmid. IgG antibodies were used as controls. (B) GST 
pull-down of LMTK3 using recombinant GST-GRB2 protein. GST only was used as a 
control. 
  
 
  
 
 
 
! 122!
3.1.7.2%LMTK3%promotes%the%activity%of%RAS%GTPase%family%cascades%through%increasing%
GRB2WSOS1%interaction.% ! %
We further investigated the downstream effect of the LMTK3-GRB2 interaction. We 
found that overexpression of LMTK3 promoted the interaction between GRB2 and son of 
sevenless homolog 1 (SOS1) (Figure 32A). We then investigated whether LMTK3 
overexpression activates the RAS-GTPase family, which is downstream of GRB2 and 
SOS1 (181). MCF7 and MCF7-LMTK3 cell lysates were incubated with a GST-tagged 
RAF1 protein-binding domain or a GST-tagged PAK1 protein-binding domain, which 
specifically binds to either active RAS or cell division control protein 42 homolog 
(CDC42), a small Rho family GTPase, respectively. As a result, LMTK3 overexpression 
activated both RAS (Figure 32B) and CDC42 (Figure 32C) in MCF7 cells. 
Overexpression of LMTK3 in breast cancer cell lines, which expressed low endogenous 
LMTK3 levels, resulted in activation of the ERK/MAPK pathway as inferred from 
increased phosphorylation of MEK1/2 and ERK1/2, whereas knocking down LMTK3 in 
cells with abundant endogenous LMTK3 appeared to inhibit activation of the pathway 
(Figure 32D). Furthermore, silencing GRB2 inhibited LMTK3-induced ERK/MAPK 
pathway activation (Figure 32E), cell proliferation (Figure 32F), and CDC42 activation 
(Figure 32G), confirming that CDC42 activation after LMTK3 overexpression required 
GRB2. 
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Figure 32 LMTK3 promotes the activity of RAS GTPase family cascades through 
increasing GRB2-SOS1 interaction. 
(A) Immunoprecipitation of GRB2 using SOS1 antibody in MCF7 (−) and 
MCF7-LMTK3 (+) cells. (B and C) Active RAS (B) and CDC42 (C) pull-down assays 
using lysates from MCF7 (−) and MCF7-LMTK3 (+) cells. GTPγS 
[guanosine-5′-(γ-thio)-triphosphate] was used in MCF7 as a positive control. (D) Western 
blot for phosphorylated MEK 1 and 2 (p-MEK1/2) or ERK 1 and 2 (p-ERK1/2) and total 
MEK1/2, or ERK1/2 abundance in cell lines overexpressing LMTK3 or transfected with 
LMTK3 siRNA compared with controls. (E and F) Western blotting for total and 
phosphorylated MEK1/2 and ERK1/2 (E) and cell proliferation (F) in parental and 
LMTK3-overexpressing MCF7 cells transfected with GRB2 siRNA. (G) Active CDC42 
pull-down assay in MCF7-LMTK3 cells treated with control or GRB2 siRNA for 72 
hours. Data are means ± SD (n = 3) *P < 0.05 **P < 0.01, ***P < 0.001. 
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3.1.7.3% LMTK3WGRB2WCDC42% cascade% mediates% SRF% activation% and% subsequently%
intergrins%transcription.% % ! %
Because the data thus far suggested that LMTK3 formed a complex with GRB2 to 
activate CDC42, and LMTK3 induced the abundance of integrin subunits through 
SRF-mediated transcription, we investigated whether CDC42 promoted SRF activity and 
integrin transcription through an LMTK3-GRB2 mechanism. Similar to a study in PC3 
cells, which addressed the function of CDC42 in activating SRF (175), silencing CDC42 
repressed the expression of reporter constructs for SRF activity (Figure 33A) and ITGB1 
and ITGA5 promoter transcription (Figure 33B, C) induced by LMTK3 overexpression 
in MCF7. Silencing GRB2 in MCF7 cells overexpressing LMTK3 reduced ITGB1 and 
ITGA5 mRNA expression (Figure 33D-F). This resulted in a reduced motility phenotype, 
inferred from decreased F-actin staining on the periphery of the cell (Figure 33G), 
decreased cell adhesion to fibronectin (Figure 33H), and decreased cell invasion through 
Matrigel (Figure 33I). 
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Figure 33 LMTK3-GRB2-CDC42 cascade mediates SRF activation and 
subsequently intergrins transcription. 
(A to C) Luciferase reporter assays for FOS (A), ITGB1 p3000 (B), and ITGA5 (C) 
promoter activities in MCF7 and MCF7-LMTK3 cells transfected with CDC42-targeted 
siRNA or control siRNA (for 48 hours) and the indicated luciferase vector (FOS, ITGB1 
p3000, or ITGA5) or luciferase control vector (for an additional 24 hours). (D to F) 
qRT-PCR for GRB2 (D), ITGB1 (E), and ITGA5 (F) mRNA in MCF7-LMTK3 cells 
treated with control or GRB2 siRNA for 72 hours. (G to I) F-actin protrusions formation 
(G), cell adhesion to collagen (H), and cell invasion (I) of MCF7-LMTK3 treated with 
control or GRB2 siRNA for 72 hours. Data are means ± SD (n = 3) *P < 0.05 **P < 0.01, 
***P < 0.001. 
 
! 126!
3.1.8 LMTK3 correlates with integrin β1 in breast cancer. 
3.1.8.1%Integrin%β1%predicts%poor%survival%in%breast%cancer%patients.% % ! %
ITGB1 is predictive of survival in breast cancer patients (170, 182). To further confirm 
these data, we performed immunohistochemical analysis to determine integrin β1 
abundance in 858 breast cancer samples (Figure 34A). We confirmed that increased 
integrin β1 abundance was associated with a shorter overall survival (Figure 34B). 
 !
Figure 34 Integrin β1 predicts clinical outcome of breast cancer. 
(A) Representative images from immunohistochemical staining of integrin β1. The 
absence of signal was scored as ‘0’, low intensity signal was scored as ‘1’, moderate 
intensity signal was scored as ‘2’ and high intensity signal was scored as ‘‘3’’. (B) 
Kaplan-Meier plots demonstrating the association between integrin β1 expression and 
overall survival (p=0.0174) in n=858 breast cancer patients. 
  $  
3.1.8.2%LMTK3%correlates%with%Integrin%β1.%
We found that the abundance of LMTK3 and integrin β1 demonstrated noticeably similar 
patterns in several breast cancer cell lines (Figure 35A). Moreover, we screened 20 
breast cancer cell lines and observed a significant association of LMTK3 and ITGB1 gene 
expression, further confirming the correlation of LMTK3 and ITGB1 at the mRNA level 
(Figure 35B).  
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To investigate the clinical significance of these findings, we first examined the protein 
abundance patterns of LMTK3 and integrin β1 in 16 fresh primary breast cancer tumour 
samples and found a correlation between LMTK3 and integrin β1 abundance by Western 
blotting (Figure 35C). Furthermore, we also detected a significant correlation of LMTK3 
with integrin β1 in patient samples (Figure 35D), consistent with our in vitro and cell 
culture findings that LMTK3 abundance promotes integrin β1 abundance.  
!
Figure 35 LMTK3 correlates with ITGB1 expression. 
(A) LMTK3 and integrin β1 protein expression of indicated cell lines were examined by 
Western blot. (B) LMTK3 and ITGB1 mRNA expressions in indicated cell lines were 
analysed using qPCR. (C) LMTK3 and integrin β1 protein expressions in patient breast 
cancer samples were tested using Western blot. (D) Correlation between LMTK3 and 
integrin β1 expression in 295 breast cancer cases. The subjects were divided into two 
groups on the basis of integrin β1 H-score expression (low H-score <15, high 
H-score >15). The percentages of LMTK3 low and high tumours in the two groups of 
subjects are shown. Data were analysed using two-sided Fisher’s exact test.  
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3.1.9 Discussion 
LMTK3 is implicated in cancer progression and is associated with poor breast cancer 
patient survival (53, 95, 97, 111). As a highly pleiotropic protein, LMTK3 is involved in 
multiple biological processes, including promotion of tumour growth by regulating 
estrogen receptor a (ERα) transcription and stability (53) and conferring endocrine 
resistance by protecting cells from tamoxifen-induced autophagy (112). In this work, we 
defined the involvement of LMTK3 in breast cancer cell motility, migration, and invasion 
through the transcriptional activation of integrins. 
LMTK3 is aberrantly abundant in highly invasive ductal breast cancer cell lines. Two 
isoforms of full-length LMTK3 (about 240 and 170KDa) were detected by Western 
blotting and MS (Figure 12 and 14). The abundance of 240KDa LMTK3, which may be 
a post-translationally modified LMTK3, was notably greater in the more invasive breast 
cancer cell lines (MDA-MB-231 and BT549) than that in the less invasive cell lines 
(ZR75.1, T47D, and MCF7) (Figure 14), suggesting that this band might be involved in 
promoting cell motility. By stably overexpressing LMTK3 in MCF7 and T47D cells and 
transiently silencing the high endogenous LMTK3 abundance in MDA-MB- 231 and 
BT549 cells, we found that LMTK3 not only promoted cell adhesion and invasion but 
also reorganized the cytoskeleton to a more invasive pattern (Figure 17 to 20).  
The abundance of integrin α5 and integrin β1 correlated with that of LMTK3, 
suggesting a role for LMTK3 in integrin regulation (Figure 23). Moreover, our 
observation that exogenous overexpression of integrin subunits α5 and β1 restored cell 
invasion and adhesion suppressed by LMTK3 knockdown further supports the role of 
integrin subunits in cell motility, invasiveness, adhesion and metastasis (175, 176, 
183-185) (Figure 26). However, LMTK3 overexpression was not able to rescue integrin 
silencing–mediated reduction in cell invasion and adhesion (Figure 25), indicating that 
integrins were functionally downstream of LMTK3. Indeed, LMTK3 promoted the 
transcription of ITGA5 and ITGB1 by promoting the binding of the transcription factor 
SRF (Figure 30), supporting reports that SRF binds the ITGB1 promoter 11,12.  
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GRB2 is a common adaptor protein that links RTKs to downstream signalling 
pathways by activating downstream RAS and Rho subfamilies of RAS-GTPases. Here, 
we showed that, similar to other RTKs, LMTK3 directly interacts with GRB2, which then 
activates both RAS and CDC42. RAS activation leads to prominent increase in 
ERK/MAPK pathway. Silencing GRB2 inhibited LMTK3-induced ERK/MAPK 
activation and cell proliferation, which might explain the increased tumour growth 
observed after LMTK3 overexpression. CDC42 activation activates SRF and 
subsequently promotes the transcription of genes encoding integrins (175). In our 
proposed model, GRB2 silencing in cell lines overexpressing LMTK3 suppressed 
integrin-encoding gene expression, as well as cell adhesion and invasion. SRF inhibition 
effectively inhibited LMTK3-induced migration but did not suppress LMTK3-induced 
proliferation, implying that LMTK3 regulates cell proliferation through GRB2 through 
the RAS-ERK/MAPK pathway and cell motility through the CDC42-SRF pathway, 
which results in enhanced ITGB1 and ITGA5 expression (Figure 36).  
Increased integrin β1 abundance is associated with poorer breast cancer patient 
survival. However, these studies were performed with relatively small patient sample 
sizes. In our study, we examined 858 cases of primary breast cancer and confirmed a 
significant association of increased integrin β1 abundance with poorer overall survival 
(Figure 34). Notably, we detected a significant positive correlation between LMTK3 and 
integrin β1 in both breast cancer cell lines and patient samples (Figure 35), suggesting a 
potentially cooperative role for LMTK3 and integrin β1 in human breast cancer 
progression.  
Despite the involvement of LMTK3 in integrin regulation and signalling, it is 
possible of course that LMTK3 could affect cell motility and invasiveness through other 
pathways. Using SILAC quantitative proteomics in cells deficient for LMTK3, we 
identified several downstream LMTK3 targets, apart from integrins, that are involved in 
breast cancer cell invasion, such as talin (186) and vinculin (187) (Figure 22). These 
proteins are relevant not only for integrin signalling but also for other pathways 
associated with cancer cell invasion (188). Moreover, identification of other proteins or 
ligands that are able to modulate LMTK3 (positively or negatively) would provide more 
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information about the upstream pathways implicated in LMTK3 signalling and will be 
useful in our attempts to successfully target LMTK3 in breast cancer.  
        !
Figure 36 Schematic model illustrating the LMTK3 signalling on integrins. 
LMTK3 interacts with GRB2, leading to increased GRB2 binding with SOS. This 
promotes RAS and CDC42 activation (exchange from GDP to GTP forms). CDC42 
activation stimulates SRF activity and increase SRF binding to integrin promoter, thus 
leading to integrin transcriptional activation.  
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3.2% LMTK3% Represses% Tumour% SuppressorWLike% Genes%
through%Chromatin%Remodelling%in%Breast%Cancer% %
3.2.1 The nuclear localization of LMTK3 
3.2.1.1%LMTK3%nuclear%localization%is%importin%α2Wdependent.%
As addressed in the previous section, two bands of LMTK3 were detected by Western 
blotting, among which, the lower band is able to translocate into the nucleus (Figure 
13B).  As the importin protein family is known to mediate macromolecules 
translocation from the cytoplasm to the nucleus (189), we decided to investigate whether 
importins are responsible for LMTK3 translocation. After silencing importin α2 and 
importin β1 individually, we detected a notable reduction in nuclear LMTK3 levels, with 
an increase in its cytoplasmic proportion after importin α2 but not importin β1 
knockdown (Figure 37), suggesting that LMTK3 translocation is an importin 
α2-dependent, importin β1-independent manner, which was discovered previously (190).   
              !
Figure 37 LMTK3 nulcear translocation is importin α2-dependent. 
Western blotting of LMTK3 in cytoplasmic and nuclear cell fractions of MDA-MB-231 
cells transfected with importin β1 and importin α2 siRNAs for 72 hours. 
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3.2.1.2%Identifying%potential%NLSs%of%LMTK3.%
As NLS is required for the nuclear import of protein, we then questioned what are the 
potential NLSs of LMTK3. Using different NLS prediction databases, we found a few 
potential NLSs of LMTK3, summarised in Figure 38.  
    
!
Figure 38 Identifying potential NLSs of LMTK3 using online NLS prediction 
databases. 
Red boxes represents the three most potential NLSs. 
To further investigate this, we mutated a few amino acids of these potential NLSs of 
LMTK3 and overexpressed these mutants in MCF7 cells. As importin α is responsible for 
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interacting with the NLS of a cargo, we therefore suggested that the NLS-mutant of 
LMTK3 would lose the binding with importin α2. Interestingly, we found that when 
compared to the WT LMTK3, mutating the single mutation on 1353aa was sufficient to 
reduce the interaction with importin α2, while single mutation on 921aa was not adequate 
to do so; mutating 1375, 1376 and 1377aa resulted in loss of interaction with importin α2. 
Noteworthy, mutating all four amino acids between 917 to 921aa also resulted in the loss 
of interaction, however, mutating 4 consecutive amino acids may result in unexpected 
conformational changes of LMTK3 that could cause loss of its ability to interact with 
importin (Figure 39A). We subsequently overexpressed GFP-tagged mutants of LMTK3 
into MCF7 cells to view the subcellular localization of exogenous LMTK3. We 
discovered that 1353aa and 1375-1377aa mutants were significantly present outside the 
nucleus when compared to the WT LMTK3 (Figure 39B), suggesting that these two 
sequences may be the most potential LMTK3 NLSs.  
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Figure 39 Identifying NLSs of LMTK3. 
(A) Indicated FLAG-tagged NLS mutants of LMTK3 were overexpressed into MCF7. 
FLAG-IPs were performed and the interactions of these mutants with importin α2 were 
analysed. (B) GFP-tagged NLS mutants of LMTK3 were overexpressed into MCF7 and 
the GFP intensity was viewed under the confocal microscope (right). The ratios of GFP 
intensity in the cytoplasm and nucleus were quantified (Left). Student t-test was 
performed. ** p<0.01. 
 
3.2.2 LMTK3 is a chromatin-binding protein 
3.2.2.1%GenomeWwide%mapping%identifies%LMTK3Wchromatin%binding%profile.%
To decipher the function of LMTK3 in the nucleus, we mapped the genome-wide profile 
of LMTK3-chromatin interactions by chromatin immunoprecipitation sequencing 
(ChIP-seq) in the ERα positive/MCF7 and the ERα negative/MDA-MB-231 cell lines. 
We observed 3,086 loci in MCF7 and 24,516 loci in MDA-MB-231 wherein LMTK3 is 
located to the chromatin (Figure 40A-C). Similar to other DNA binding proteins, 
! 135!
LMTK3 localization at promoter intervals is relatively more evolutionary conserved 
compared to that at the distal (enhancer) intervals (Figure 40D) (191). Genes marked by 
LMTK3 show a significant enrichment in gene ontology (GO) terms associated with 
transcription regulation, tyrosine kinase signalling and pathways in cancer.  
 
 
 
!
Figure 40 Genome-wide binding events of LMTK3 in MCF7 and MDA-MB-231 
cells. 
(A, B) Genomic distributions of LMTK3 binding events in MCF7. (C) Heat map showing 
LMTK3 binding events in MCF7 and MDA-MB-231 cells. (D) Conservation plot of 
LMTK3 binding events at promoter intervals (red) and distal intervals (blue). 
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3.2.2.2%LMTK3%is%a%DNA%binding%protein%independent%of%ERα.% %
Based on our previous work showing that LMTK3 interacts and phosphorylates ERα, 
which, in turn promotes TFF1 expression (53), we questioned whether 
LMTK3-chromatin binding events are ERα-dependent. Interestingly, we observed that 
LMTK3 binding in MCF7 (ERα positive) and MDA-MB-231 (ERα negative) have a high 
similarity (Figure 41A) with a high correlation (R2=0.77) (Figure 41B). Supporting the 
notion that chromatin-bound LMTK3 function may be independent of ERα, we found no 
noticeable overlap and correlation between LMTK3 and ERα bindings (Figure 41C).  
!
Figure 41 LMTK3 binding events are identical in MCF7 and MDA-MB-231. 
(A) Binding of LMTK3 at the promoter of BAP1, GPAM, RBM42 and the distal interval 
in MCF7 and MDA-MB-231 cells. (B) The correlation of LMTK3 binding signals in 
MCF7 and MDA-MB-231 breast cancer cell lines. (C) Venn diagram presenting the 
overlap of LMTK3 and ERα binding events in MCF7. (D) LMTK3 enrichments around 
ERα peaks in MCF7 cells. (E) LMTK3 ChIP in MCF7 cells after 48h treatment of 
fulvestrant or ethanol. Western blotting for ERα is shown. 
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3.2.2.3% LMTK3% binding% events% are% associated% with% both% repressive% and% active%
chromatin%markers.%
To further characterize LMTK3 binding behaviour, we then tested the correlation of 
binding events of LMTK3 with two groups of chromatin biomarkers (histone and 
transcription factors (TFs)): repressive promoter markers (H3K27me3, H3K9me3 and 
SUZ12) and active promoter or enhancer markers (H3K4me1, H3K4me3, NANOG, p300 
and TAF1). Interestingly, we found that LMTK3 binds chromatin at both repressive and 
active (Figure 42A, B) promoters, suggesting that there is a different binding profile of 
LMTK3 compared to the ones of other known RTKs (192, 193).  
!
Figure 42 LMTK3 binding events are associated with both repressive and active 
chromatin markers. 
(A) Clustering of genome-wide binding data sets with LMTK3. The color indicates the 
similarity based on the Pearson correlation of the ChIP-seq peaks. (B) H3K9me3, 
H3K27me3, H3K4me2, H3K4me3, H3K27ac, Pol2, SUZ12 and NCOR enrichments 
around LMTK3 peaks in MCF7 cells.  
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3.2.2.4%Validation%of%the%LMTK3%binding%events.%
We then validated shared LMTK3 binding using ChIP-qPCR for the most enriched 
LMTK3-binding genes (Figure 43A). Next, to confirm that the bindings are LMTK3 
specific, we constructed stable LMTK3-knockout (KO) MDA-MB-231 cells using a 
CRISPR/CAS9 technique by transfecting MDA-MB-231 cells with plasmids containing 
hCAS9 and 2 guiding RNA targeting the exon 12 of LMTK3 (Figure 43B). On the other 
hand, we also used previously established MCF7 cells stably overexpressing LMTK3 
(MCF7-LMTK3) for the ChIP validations. As a result, LMTK3 binding events were 
notably higher in MCF7-LMTK3 compared to that in MCF7 (Figure 43C), and were 
barely detected in LMTK3-KO MDA-MB-231 cells (Figure 43D), suggesting that the 
bindings detected are LMTK3-specific.  
    !
Figure 43 Validation of LMTK3 binding events in MCF7 and MDA-MB-231 cells. 
(A) ChIP-qPCR validations of LMTK3 bindings in MCF7 and MDA-MB-231. (B) 
Targeting Exon 12 of LMTK3 using CRISPR/CAS9. (C, D) ChIP-qPCR of LMTK3 
bindings in MCF7 and MCF7-LMTK3 (C) and MDA-MB-231 and LMTK3 KO 
MDA-MB-231 (D). Data are means ± SD (n = 3) * p<0.05, ** p<0.01, *** p<0.001. 
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To investigate the binding event of LMTK3 in vivo, we injected MCF7-LMTK3 cells 
subcutaneously into nude mice, harvested the tumour and performed LMTK3 ChIP. We 
discovered a similar binding pattern of LMTK3 in the xenograft studies compared with 
that in cell lines (Figure 44A). Finally, we also confirmed LMTK3 bindings in both 
ERα+ and ERα- breast cancer patient samples (Figure 44B). In summary, our results 
highlight that nuclear LMTK3 is a chromatin-binding protein, whose activity is 
independent of ERα status. 
 
 
!
Figure 44 Validation of LMTK3 binding events in vivo. 
(A) ChIP-qPCR of LMTK3 bindings in MCF7-LMTK3 cells implanted xenograft. (B) 
ChIP-qPCR of LMTK3 bindings in human breast cancer tissues. Patient 1: ER+ PR+ 
HER2-; Patient 2: ER+, HER-; Patient 3: ER+, PR+, HER-; Patient 4: ER- PR- HER2+. 
Quantitative data are presented as averages ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
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3.2.3 Motif and RIME analyses identify KAP1 as an LMTK3-accociated 
protein in chromatin binding. 
3.2.3.1%Motif%analysis%identifies%potential%LMTK3%interacting%partners.%
Similar to other RTKs, LMTK3 is unlikely to have a DNA-binding domain. Therefore 
binding of LMTK3 at DNA requires sequence-specific transcription factors that interact 
with LMTK3. Motif analysis provided a number of potential interacting partners of 
LMTK3 (Figure 45).  
!
Figure 45 Motif analysis of LMTK3 ChIP-seq data. 
Selected examples of conserved TF motifs significantly enriched within the interval 
regions associated with LMTK3. 
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3.2.3.2% RIME% analysis% identifies% KAP1% as% an% LMTK3Wassociated% protein% in% chromatin%
binding.%
In order to further address which of these candidates might be interacting partners of 
LMTK3 during DNA binding, we performed RIME (166) assay to and discovered 196 
LMTK3-associated proteins (Figure 46 and Table 10). Interestingly, KAP1 was 
enriched in both analyses. We validated the interaction between LMTK3 and KAP1 by 
immunoprecipitation (Figure 47A). In addition, we found a notable correlation between 
global LMTK3 and KAP1 binding events (Figure 47B), We further confirmed KAP1 as 
an LMTK3-binding partner by performing KAP1 re-ChIP after LMTK3 ChIP (Figure 
47C). In addition, we also detected a similar binding profile of LMTK3 and KAP1 
(Figure 47D). These data substantiate that KAP1 is a LMTK3 binding partner in 
chromatin binding.  
           !
Figure 46 RIME identifies LMTK3 interacting partners on the chromatin. 
LMTK3 RIME in MCF7 identified potential LMTK3-associated proteins in DNA 
binding.  
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Table 10 Identified LMTK3 interacting partners on the chromatin by RIME. 
AHNK DDX5 FXR1 HS90B NHRF1 RBM14 RS16 SYFA 
ALDOA DDX6 FXR2 HSP71 NONO RBM3 RS17L  TADBP 
ANXA2 DHX36 G3BP1 IF4A1 NOP16 RBM4 RS2 TBA1A  
ATX2 DHX9 G3BP2 IF4B NOP58 RBM47 RS24 TBB4B 
ATX2L DYHC1 G3P IF4G1 NP1L1 RBMX RS26 TCP4 
BAF EF1A2 GEMI5 IF4H NUCL RENT1 RS28 TCPZ 
CAPR1 EF1B GRSF1 ILF2 PABP1 RL11 RS3 THOC4 
CAZA1  EF1D H13 ILF3 PAIRB RL12 RS3A TIAR 
CBX3 EF1G H2A1B  IMA2 PATL1 RL18 RS6 TIF1B 
CC124 EF2 H2AY KHDR1 PCBP2 RL19 RS7 TKT 
CCDC9 EIF3A H2B1B  KPYM PDE3B RL23A RS8 TRI25 
CDV3 EIF3C H31T  LAP2A PGK1 RL27A RTCB UBP10 
CIRBP ELAV1 H4 LARP1 PLEC RL3 SERA UBP2L 
CLIC1 ENOA HMGB1 LARP4 PPIA RL38 SF3B2 WIBG 
CO3 ERF1 HNRH1 LMNA PRC2A RL4 SFPQ XRCC6 
COF1 ERF3A  HNRH3 LMNB1 PRDX1 RL6 SND1 YBOX2 
CPSF6 ESRP1 HNRL2 LRC47 PRDX2 RL7A SRC8 YTHD2 
CRIP2 F120A HNRPD LS14B PRDX6 ROA0 SRP14 YTHD3 
CSDE1 FAS HNRPF MATR3 PROF1 ROA1 SRRM2 ZC3H8 
DAZP1 FLNA HNRPK MBNL1 PSPC1 ROA2 SRSF2 ZN131 
DBPA FMR1 HNRPL MIF PTBP1 ROA3 SRSF3 ZN326 
DD19A  FUBP1 HNRPQ MK67I PUM1 ROAA SRSF6 
 
DDX1 FUBP2 HNRPR MOV10 PUR9 RRMJ3 SRSF9 
 
DDX17 FUBP3 HNRPU MYEF2 PURA RS10 STAU1 
 
DDX3X FUS HS90A NEDD8 RAN RS14 STAU2 
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Figure 47 KAP1 is an LMTK3 interacting partner. 
(A) Western blotting showing the immnunoprecipitation of LMTK3 and KAP1 in MCF7. 
(B) KAP1 enrichment around LMTK3 peaks. (C) qPCR results showing Re-ChIP 
experiments using KAP1 antibody after LMTK3 ChIP. (D) Examples of LMTK3-KAP1 
overlap based on snapshots of ChIP-seq data for indicated genes. 
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3.2.4 PP1α stabilizes LMTK3/KAP1 interaction and mediates 
KAP1-dephosphorylation at LMTK3-KAP1 bound chromatin regions, 
resulting in chromatin condensation and gene repression. 
3.2.4.1%LMTK3%is%not%a%kinase%of%KAP1.%
We then investigated whether the LMTK3/KAP1 interaction is a kinase-substrate process. 
No phosphorylation was observed after performing in vitro kinase assay using 
recombinant LMTK3 kinase domain (encompassing aa 149-444) as source of enzyme 
activity and GST-KAP1 as substrate (Figure 48A). On the contrary, endogenous KAP1 
phosphorylation at Ser824 was suppressed after LMTK3 overexpression (Figure 48B), 
while increased after LMTK3 silencing (Figure 48C).  
        !
Figure 48 LMTK3 negatively regulates KAP1 phosphorylation. 
(A) in vitro kinase assay testing LMTK3 kinase domain (KD) phosphorylation on KAP1 
and positive control (B) Immunofluorescence staining of phosphor-KAP1 (S824) and 
LMTK3 in MCF7 and MCF7-LMTK3 cells treated with doxorubicin for 1 hr. 
Quantification of relative phosphor-KAP1 intensity is shown. Student’s t test was used 
for statistical analysis. ***p < 0.001. (C, D) Western blotting of indicated proteins in 
MCF7 and MCF7-LMTK3 (C) and MCF7-LMTK3 cells restored with LMTK3 siRNAs 
(D) treated with doxorubicin. 
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3.2.4.2%LMTK3WPP1α%interaction%is%responsible%for%the%dephosphorylation%of%KAP1.%
The results above suggest that other proteins such as phosphatases might be involved in 
the LMTK3-KAP1 complex. As PP1α is a known KAP1 phosphatase and predicted 
LMTK3 interaction partner (194), we tested whether PP1α is involved in LMTK3/KAP1 
interaction. Interestingly, silencing of PP1α reduced the interaction between 
LMTK3-KAP1 (Figure 49A). We thus generated GST-LMTK3 constructs and LMTK3 
mutations at the PP1α-docking motif (PP1_RVxF) of LMTK3 (Figure 49B). As 
anticipated, a significant decrease in LMTK3-PP1α binding was detected in both mutants 
(LMTK3RVxF_1 and LMTK3RVxF_2), with a subsequent reduction in LMTK3/KAP1 
interaction (Figure 49B, C). These results suggest that PP1α is crucial for stabilizing the 
LMTK3- KAP1 complex. 
KAP1 phosphorylation is critical in global chromatin decondensation (195, 196), 
leading to the derepression of several basal KAP1-repressed genes (197, 198). Therefore, 
we were interested in elucidating the function of LMTK3-PP1α-KAP1 interaction on 
KAP1 phosphorylation status as well as its repressive function. As basal levels of KAP1 
phosphorylation are barely detected, we used doxorubicin, a KAP1-Ser824 
phosphorylation inducer, as a molecular tool to study the LMTK3-PP1α-KAP1 function 
on KAP1 phosphorylation. We further discovered that silencing PPP1CA (PP1α 
encoding gene) rescued the reduced Ser824 phosphorylation of KAP1 in MCF7-LMTK3 
cells (Figure 50A), indicating that LMTK3 requires PP1α to dephosphorylate KAP1. 
Silencing of PP1β, however, did not rescue the reduced phosphorylation of KAP1 
induced by LMTK3 (Figure 50B). Interestingly, we noticed that there was no increase in 
KAP1 and PP1α interaction after LMTK3 overexpression (Figure 50C), suggesting that 
LMTK3 might promote PP1α dephosphorylation on KAP1 through increasing PP1α 
activity rather than its interaction with KAP1.  
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Figure 49 PP1α stabilizes LMTK3/KAP1 interaction. 
(A) Immunoprecipitation of KAP1 and PP1α with LMTK3 in MCF7 lysates with and 
without PPP1CA silencing for 72 hr. (B) (Left) a schematic representation of 
PP1α-interacting motif (RVxF motif) on LMTK3, and indicated GST constructs. (Right) 
GST pull-down of PP1α using wide-type LMTK3 construct (GST-Δ10WT) and two RVxF 
motif mutants (GST-Δ10RVxF_1 and GST-Δ10RVxF_2). (C) FLAG Immunoprecipitation 
performed after 24 hr transient overexpression of FLAG-LMTK3 WT and two mutants 
(FLAG-LMTK3 RVxF_1 and FLAG-LMTK3 RVxF_2). 
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Figure 50 LMTK3 suppresses KAP1 Ser824 phosphorylation through PP1α but not 
PP1β. 
(A) Western blotting of indicated proteins in MCF7 and MCF7-LMTK3 cells transfected 
with PPP1CA siRNA for 72 hr and treated with doxorubicin for 1 hr. (B) Western 
blotting of indicated proteins in MCF7 and MCF7-LMTK3 cells transfected with 
PPP1CB siRNA for 72 hr and treated with doxorubicin for 1 hr. (C) Immunoprecipitation 
of KAP1 with PP1α in MCF7 and MCF7-LMTK3 lysates. 
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3.2.4.3% LMTK3% induces% the% dephosphorylation% of% KAP1% at% LMTK3Wbound% chromatin%
regions%and%results%in%condensed%chromatin%and%gene%repression.%
We further questioned whether the reduced KAP1 phosphorylation is predominantly 
observed at LMTK3-bound regions, and whether this would result in chromatin 
condensation. To clarify this, we performed LMTK3 and KAP1 immunoprecipitation 
using chromatin-bound MCF7-LMTK3 cell lysates. The ratio of pKAP1/KAP1 in 
LMTK3 immunoprecipitated chromatin complex is significantly lower than that in KAP1 
immunoprecipitated chromatin complex (Figure 51A), suggesting that LMTK3 
suppresses KAP1 phosphorylation specifically at LMTK3-bound regions. Moreover, 
open chromatin is more enriched in MCF7 compared to MCF7-LMTK3 cells (Figure 
51B), suggesting that the region-specific dephosphorylation of KAP1 by LMTK3 could 
suppress chromatin decondensation. Following, we tested whether 
LMTK3/PP1α/KAP1-mediated chromatin condensation can lead to gene silencing. 
Overexpression of wild-type (WT) LMTK3 but not the mutant that abolishes its 
interaction with PP1α and KAP1 (LMTK3RVxF_2) suppresses indicated gene expression 
(Figure 51C), due to the fact that the latter lost its DNA-binding activity (Figure 51D).  
In summary, these results demonstrate that an LMTK3-PP1α interaction suppresses 
KAP1 phosphorylation, resulting in chromatin condensation and transcriptional 
repression. 
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Figure 51 LMTK3 induces the dephosphorylation of KAP1 at LMTK3-bound 
chromatin regions and results in condensed chromatin and gene repression. 
(A) Immunoprecipitation of p-KAP1 (Ser824) and KAP1 with LMTK3 and KAP1 using 
chromatin-bound MCF7-LMTK3 cell lysate (upper panel). LMTK3- (LMTK3-associated) 
and KAP1-immunoprecipitated (Global) p-KAP1/KAP1 ratios are shown (lower panel). 
(B) FAIRE-qPCR in MCF7 and MCF7-LMTK3 at indicated regions. (C) RT-qPCR of 
LMTK3-bound genes expression in MCF7 and MCF7-LMTK3WT and 
MCF7-LMTK3RVxF cells. (D) FLAG ChIP-qPCR of LMTK3-bound chromatin regions in 
MCF7-LMTK3WT and MCF7-LMTK3RVxF (FLAG-tagged) cells. Quantitative data are 
presented as averages ± SEM. Student’s t test was used for statistical analysis. *p < 0.05, 
**p < 0.01, ***p < 0.001.  
. 
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3.2.5 LMTK3 and KAP1 suppress gene expression at distal regions by 
tethering chromatin to the nuclear periphery. 
3.2.5.1%LMTK3%and%KAP1%are%associated%with%H3K9me3%marked%heterochromatin.%
In order to decipher the function of LMTK3 chromatin binding, we separated LMTK3 
and KAP1 binding events into promoter regions that are 1kb preceding the transcription 
starting site and the rest as distal intervals. A recent study suggested that KAP1 is highly 
associated with H3K9me3 marked heterochromatin (199), (200, 201), and interacts with 
lamin A, a well-characterized constituent of the nuclear lamina (202), which is associated 
with inactive chromatin regions (203-205). Despite the function of LMTK3 in chromatin 
condensation and transcriptional silencing, we found that distal intervals bound by 
LMTK3 (or KAP1) are associated with H3K9me3 modifications (Figure 52A). We thus 
investigated the role of LMTK3 and KAP1 distal binding in the context of transcriptional 
repression. We discovered that LMTK3 (Figure 52B) and KAP1 (Figure 52C) 
co-localise with H3K9me3 both in the center and at the inner nuclear membrane, using 
confocal microscopy.  
      !
Figure 52 LMTK3 and KAP1 are associated with H3K9me3. 
(A) H3K9me3 signal profiles around the promoter (red) and the distal (black) intervals 
bound by LMTK3 (upper panel) and KAP1 (lower panel). (B and C) Confocal staining of 
LMTK3 (B), KAP1 (C) and H3K9me3 in MCF7.  
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3.2.5.2%LMTK3%and%KAP1%tether%the%heterochromatin%to%the%nuclear%periphery.%
Studies have shown that gene transcription is suppressed when H3K9me3 marked 
heterochromatin is tethered to the nuclear periphery (161, 165, 206). Therefore, we 
investigated if LMTK3 and KAP1 are implicated in this process. When KAP1 was 
silenced, we noticed a partial loss of H3K9me3 staining on the inner nuclear membrane 
(Figure 53A); similarly, we found overexpression of LMTK3 significantly increased the 
proportion of H3K9me3 heterochromatin staining on the periphery (Figure 53B) 
compared to control cells, suggesting that LMTK3 and KAP1 are involved in 
heterochromatin repositioning process.  
         !
Figure 53 LMTK3 and KAP1 regulate H3K9me3-marked heterochromatin 
repositioning to the nuclear periphery. 
(A and B) Confocal staining of H3K9me3 and Lamin A/C in MCF7 cells transfected with 
siCtl or siKAP1 (A) or MCF7 cells and MCF7-LMTK3 cells (B). H3K9me3 signals at 
the nuclear periphery were quantified.  
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To clarify whether LMTK3 interacts with the nuclear lamina, we used a series of 
GST-LMTK3 truncated protein constructs (Figure 54A) and performed in vitro 
GST-pull-down assays. Notably, part of the structurally disordered domains of LMTK3 
(Δ3 and Δ4) were found to interact with lamin A (Figure 54B), suggesting that LMTK3 
may function as a scaffold protein inducing heterochromatin repositioning at the nuclear 
periphery by interacting with Lamin A. Interestingly, we also detected a significant 
overlap of LMTK3 distal binding regions with lamin-associated domains (LADs) (156), 
supporting that LMTK3-associated regions are located at and interacted with the nuclear 
lamina (Figure 54C). In aggregate, these results suggest that the LMTK3-KAP1 complex 
appears involved in tethering heterochromatin to the nuclear periphery. 
!
Figure 54 LMTK3 interacts with Lamin. 
(A and B) Mapping of LMTK3 direct interacting proteins to domains of LMTK3 using 
GST-pull-down assay. (A) shows schematic diagrams of GST-tagged LMTK3 
truncations derivatives that were incubated with whole MCF7 cell lysate, and precipitated 
using a GST antibody. (B) shows the immunoprecipitates tested by western blotting. (C) 
Venn diagram presenting the overlap of DamID LADs and LMTK3. P value was 
calculated using Genomic Association Test (GAT) (207). 
. 
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 To further confirm that LMTK3 is involved in the tethering process, we monitored 
the sub-nuclear localization of the specific genomic regions bound by LMTK3, using 
DNA fluorescence in situ hybridization (FISH) with bacterial artificial chromosome 
(BAC) probes mapped to genomic regions where LMTK3 bound. We found an increase 
in FISH signals detected at the nuclear periphery when LMTK3 was overexpressed 
(Figure 55A). The H3K9me3 signal was mostly increased upon LMTK3 overexpression 
at these regions, presenting a significant association with the increased FISH signals 
(Figure 55B).  
 
!
Figure 55 LMTK3 promotes chromatin repositioning and H3K9me3 modification. 
(A) Projections of confocal FISH images with probe covering LMTK3 distal binding 
regions. FISH signals of the BAC clone RP11-54O14 are shown. (B) Percentage of FISH 
signals at the nuclear periphery is plotted against the H3K9me3 enrichments detected by 
H3K9me3 ChIP-qPCR within LMTK3-bound distal regions. 
 
 
 
3.2.5.3%LMTK3Winduced%Chromatin%repositioning%suppresses%adjacent%gene%expression.%
To extend these observations and evaluate the transcriptional effect of active localization 
of LMTK3 bound regulatory region to the nuclear periphery, we analysed the expression 
patterns of genes around LMTK3 distal binding regions with RNA-seq data. We chose 
the genes located near the distal intervals bound by LMTK3 (potential nuclear lamina 
anchors), and separated them into 3 groups: less than 100kb (<100kb) (18 genes), 
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between 100kb and 200kb (100~200kb) (14 genes) and between 200kb and 500kb 
(200~500kb) (39 genes) distance from LMTK3 binding sites (Figure 56A). We then 
compared the expression levels of the groups according to their expression values from 
RNA-seq. Notably the expression levels of genes that are more distant from LMTK3 
binding sites (100~200kb and 200~500kb) were relatively higher (Figure 56B). We 
further confirmed that LMTK3 might suppress nearby gene expression by testing the 
expression of certain genes near LMTK3 distal regions (Figure 56C). These imply that 
LMTK3 binding at distal regulatory regions may be involved in suppressing nearby genes 
expression through tethering the heterochromatin to the nuclear periphery. 
            !
Figure 56 LMTK3 suppresses adjacent gene expression. 
(A and B) Genes were divided into 3 groups based on their distance to the nearest distal 
intervals bound by LMTK3 (A). Their expression levels were obtained by RNA-seq 
analysis (B). (C) qPCR of LMTK3 distal bound genes expression in MCF7 and 
MCF7-LMTK3WT cells. Quantitative data are presented as averages ± SD. Student’s t test 
was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. 
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3.2.6 LMTK3, PP1α and KAP1 are co-expressed in breast cancers and 
collaborate in suppressing the expression of tumour suppressor-like 
genes. 
3.2.6.1%LMTK3Wrepressed%genes%behave%like%tumour%suppressors.%
To examine the clinical implication of transcriptional repression due to LMTK3 DNA 
binding, we chose the top LMTK3 and KAP1 binding genes at the promoter intervals and 
the top genes near the distal intervals and tested the clinical correlation of their mean 
expression levels and relapse free survivals (RFS) in breast cancer patients. Lower 
expression of genes bound by LMTK3 at promoter intervals (Figure 57A) and genes near 
LMTK3 bindings at the distal intervals (Figure 57B) were correlated with poorer RFS, 
suggesting that LMTK3-bound genes behave like tumour suppressor genes. 
!
Figure 57 LMTK3-repressed genes correlate with poor RFS. 
(A) Kaplan-Meier plots demonstrating the association of the mean expression profile of 
the available top 30 genes bound by LMTK3 at promoter intervals with relapse free 
survival (p=5.1e-12) in n=3455 breast cancer patients. (B) Kaplan-Meier plots 
demonstrating the association of the mean expression profile of the top 10 genes nearby 
LMTK3 distal-binding intervals with relapse free survival (p=1.4e-9) in n=3455 breast 
cancer patients. 
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We also found that LMTK3 expression is negatively correlated with the expression of 
several LMTK3-bound genes in breast cancer patient samples (TCGA database). As 
examples, the expression of LMTK3 is negatively correlated with that of Group 1 genes: 
GPAM (Figure 58A), GLOD4 (Figure 58B) and RLF (Figure 58C); and Group 2 genes 
RABGAP1L (Figure 58D), EIF2B1 (Figure 58E) and LALBA (Figure 58F) which are 
groups of LMTK3-bound genes at promoter and distal intervals, respectively. This 
supports the hypothesis that LMTK3 directly regulates the transcription of 
LMTK3-bound genes in vivo as well as in our cell line models.  
!
Figure 58 LMTK3 negatively correlates with LMTK3-bound gene expression in 
patient samples. 
Pearson Correlation of the expressions of LMTK3 and LMTK3-target genes in TCGA 
breast cancer datasets. The correlation of LMTK3 and GPAM (A), GLOD4 (B) and RLF 
(C), RABGAP1L (D), EIF2B1 (E) and LALBA (F) are shown as representatives of 
LMTK3-bound genes at the promoter and distal intervals.  
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In agreement with previous studies, LMTK3 is significantly overexpressed in breast 
cancer (Figure 59A). Therefore, we then decided to investigate the clinical impacts of the 
LMTK3 binding partners: KAP1 and PP1α. KAP1 and PPP1CA are significantly 
overexpressed in breast tumours compared to normal tissues (Figure 59A-C). In addition, 
high expression of KAP1 and PPP1CA are associated with lower patients RFS (Figure 
60A, C) and overall survival (Figure 60B, D). We further questioned whether LMTK3, 
PPP1CA and KAP1 co-express in breast cancer. Our analyses revealed a positive 
correlation between the expression of LMTK3 and KAP1 (Figure 61A), LMTK3 and 
PPP1CA (Figure 61B) as well as KAP1 and PPP1CA (Figure 61C), but not LMTK3 and 
PPP1CB (Figure 61D) in patient samples (TCGA). These suggest that LMTK3, PP1α 
and KAP1 collaborate in breast cancer progression, leading to poorer survival rates by 
inhibiting a number of tumour suppressor-like genes.  
!
Figure 59 LMTK3, KAP1 and PPP1CA are overexpressed in cancer tissues. 
(A) The expression profiles of LMTK3, KAP1 and PPP1CA in 63 normal breast tissues 
and 536 breast cancer tissues. Data are presented as averages ± SD. Student’s t test was 
used for statistical analysis. (B and C) Heat maps of KAP1 (A) and PPP1CA (B) 
expressions in 43 paired normal and breast cancer tissues, obtained from 
http://canevolve.org based on GSE15852. 
. 
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     !
Figure 60 KAP1 and PPP1CA are associated with poorer RFS and OS. 
(A) Kaplan-Meier plots demonstrating the association between KAP1 expression and 
relapse free survival (p=6e-4) in n=3455 breast cancer patients. (B) Kaplan-Meier plots 
demonstrating the association between KAP1 expression and overall survival (p=0.01) in 
n=1115 breast cancer patients. (C) Kaplan-Meier plots demonstrating the association 
between PPP1CA expression and relapse free survival (p=9.1e-9) in n=3455 breast 
cancer patients. (D) Kaplan-Meier plots demonstrating the association between PPP1CA 
expression and overall survival (p=0.032) in n=1115 breast cancer patients. 
. 
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Figure 61 LMTK3 correlates with KAP1 and PPP1CA, but not PPP1CB. 
(A-D) Correlation of the expressions of LMTK3, KAP1 and PPP1CA in TCGA breast 
cancer datasets. LMTK3 and KAP1 (A), LMTK3 and PPP1CA (B), KAP1 and PPP1CA 
(C) and LMTK3 and PPP1CB (D) are shown. 
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3.2.7 The DNA-binding activity is crucial for LMTK3-mediated tumour 
growth in vitro and in vivo. 
To further investigate whether the transcriptional repression of tumour suppressor-like 
genes by LMTK3 is important for tumour cell growth, we examined the tumour growth 
rates of WT LMTK3 (MCF7- LMTK3WT) and the LMTK3 mutant that lost the DNA 
binding activity (MCF7- LMTK3RVxF) in vitro and in vivo. The cells overexpressing the 
mutant proliferate significantly slower than the ones overexpressing WT LMTK3 (Figure 
62A). Moreover, mice injected with MCF7-LMTK3RVxF cells also developed smaller 
tumours compared to the WT ones (Figure 62B, C). These indicate that abolishing the 
DNA binding ability of LMTK3 on the tumour suppressor-like genes would inhibit 
tumour progression. 
      !
Figure 62 The DNA-binding activity is crucial for LMTK3-mediated tumour growth 
in vitro and in vivo. 
(A) SRB proliferation assay of MCF7-LMTK3WT and MCF7-LMTK3RVxF cells. (B) 
Xenografts of BALB/c nude mice subcutaneously injected with MCF7-LMTK3WT and 
MCF7-LMTK3RVxF cells. Red boxes present the tumours. (C) Tumour volumes of 
xenografts of mice subcutaneously injected with MCF7-LMTK3WT and 
MCF7-LMTK3RVxF cells. Quantitative data are presented as averages ± SD. Student’s t 
test was used for statistical analysis. ***p < 0.001. 
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In summary, we propose a model where nuclear LMTK3 mediates chromatin 
remodelling by: 1) interacting with KAP1 and PP1α. The latter dephosphorylates KAP1 
at LMTK3-specific chromatin binding regions, promoting chromatin condensation and 
transcriptional repression, and 2) tethering the chromatin to the nuclear lamina through 
interaction with lamin A. These events result in LMTK3 inducing transcriptional 
repression of its targeted tumour suppressor-like genes and thereby supporting cancer cell 
survival and tumour growth (Figure 63). 
 
 
 
!
Figure 63 The graphical summary of the chromatin remodelling and the 
transcriptional co-repressor behaviour of LMTK3. 
Schematic illustrating the mechanism of chromatin remodelling mediated by nuclear 
LMTK3: LMTK3 binds PP1α through its C-terminal domains and interacts with KAP1 
and dephosphorylates KAP1 on Ser824, which results in chromatin condensation. 
Meanwhile, a part of the LMTK3 disordered domain tethers the whole heterochromatin 
complex to the nuclear lamina through interacting with Lamin A. These result in the 
transcriptional repression of LMTK3-bound tumour suppressor-like genes. 
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3.2.8 Discussion 
As mentioned in the previous section, the cytoplasmic LMTK3 plays roles in regulating 
integrin-associated metastatic potential (89) and ERα transcriptional activity (53) in 
breast cancer. In this section, we describe a role of nuclear LMTK3 and reveal that its 
chromatin binding and gene regulation are mediated via its scaffold behaviour, the first 
time an RTK has been ascribed such a role lending credence to the importance of spatial 
organization in signal propagation. While scaffolding proteins are typically devoid of 
catalytic activity, its presence here (by virtue of the fact it is an active RTK) is likely to 
have a far greater impact on signal processing that anticipated by its kinase function alone. 
We propose this dual function contributes to tumourigenesis by enhancing signalling 
complexity. 
Being an RTK, LMTK3 is unlikely to have a direct DNA binding domain, suggesting 
the existence of other interacting partners for its chromatin association. We discovered 
that the chromatin-binding events of LMTK3 are ERα-independent and little overlap 
between the binding genes of LMTK3 and ERα was observed (Figure 41). In addition, 
ERα was not detected in the RIME analysis. These results appear initially to be 
contradictory with our previous finding describing LMTK3 as an ERα regulator (as 
shown by modulating the transcription of TFF1, an ERα-regulated gene) (53).  However, 
the binding of LMTK3 and ERα to DNA are independent procedures. The regulation of 
ERα by LMTK3 is a transient phosphorylation process that occurs in the cytoplasm, 
which results in activation of ERα, translocation into the nucleus and binding to specific 
DNA regions. The process via which LMTK3 itself translocate to the nucleus, interacts 
with transcription factors (other than ERα), which eventually leads to DNA binding is 
mediated via other mechanisms, one of which is described herein. Therefore, the 
interaction of LMTK3 with ERα and its phosphorylation at the cytoplasm does not 
necessarily mean that this complex exists and acts together inside the nucleus and 
subsequently binds to the chromatin. 
Thus, in order to identify potential partners of LMTK3 in chromatin binding, RIME 
assay was employed and several proteins involved in transcriptional repression were 
detected, many of which were found to interact with silenced chromatin, and their 
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bindings were associated with enriched H3K9me3 signals (199). Interestingly, only 
LMTK3 bindings at distal (enhancer) intervals were associated with H3K9me3 
enrichment (Figure 52), suggesting a distinct regulation of LMTK3 at promoter and 
enhancer intervals. 
 Studies have shown that molecular tethering of H3K9me3 marked heterochromatin 
to the nuclear periphery results in transcriptional repression of genes located in these 
regions (161, 165, 206). Herein, we demonstrate that LMTK3 functions as a scaffold 
protein linking heterochromatin to the nuclear lamina (Figure 54). In addition, we show 
that the expression levels of genes close to LMTK3-bound regions are relatively lower, 
further suggesting that localization to the periphery suppresses the expression of these 
genes (Figure 56).  
Apart from its well-defined kinase domain, LMTK3 contains many intrinsically 
disordered regions (http://www.disprot.org/), which may participate in facilitating 
protein-protein interactions implicated in a number of cellular processes (208, 209). We 
identified lamin A as a direct interacting partner of LMTK3 that could be at least partly 
responsible for the tethering process of the heterochromatin to the nuclear lamina, which 
results in chromatin remodelling and H3K9me3 modification and subsequent tumour 
suppressor-like genes repression. Our model (Figure 63) infers assembly of an LMTK3 
‘signalosome’ leading to dynamic regulation determined by overall module composition 
as opposed to individual activity, with subsequent transcriptional effects.  
On an evolutionary scale, recombination of catalytic and regulatory or scaffold 
domains could happen through exon shuffling, and it is probable that modular 
architecture is more conducive for rapid emergence of novel types of regulatory 
mechanisms. Although it is very difficult to test this argument experimentally, it is 
interesting to note that organism complexity seems to correlate more with the number and 
diversity of regulatory domains, and not with the number of integrated components (such 
as catalytic domains) comprising a network (210). LMTK3 lacks classical scaffolding 
domain signatures (e.g. PPI domains such as SH3, PDZ) but in common with other 
scaffolding proteins it binds signalling molecules both directly and indirectly. Looking at 
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the known examples of known scaffold proteins, it seems that this group of signalling 
proteins is heterogeneous and it is unlikely that all scaffolds are linked through common 
ancestry. This is supported by the diverse, unrelated ways scaffolds can come into 
existence (e.g. active components turn into scaffolds or scaffolds that form by random 
associations) and LMTK3 can thus be categorized as a non-classical ‘randomly created’ 
scaffold. The efforts within this study including genomic ChIP are necessary to decipher 
these roles; unfortunately, comparative genomics, where protein sequences derived from 
sequenced genomes are compared, has a very low chance to identify scaffolding 
interactions; even inferring binary connections between annotated gene products is 
difficult. 
Despite being bound to repressive promoters and enhancers, LMTK3 is also able to 
bind to active promoters (Figure 42B) via other proteins, amongst them CREB1. Our 
LMTK3 ChIP-seq data revealed that CREB1 motif is one of the most enriched ones. In 
addition, CREB1 shares binding regions with LMTK3 at the promoters of PTPN11, 
PELP1 and RPS6KB2. LMTK3 overexpression promotes the expression of these genes 
generally characterized as oncogenes in breast cancer (211-214).   
KAP1 was shown to be overexpressed in a number of cancers (215-217). Here we 
demonstrated that when co-expressed with LMTK3, KAP1 functions as an oncogenic 
transcriptional co-repressor through suppressing the expression of a number of tumour 
suppressor-like genes (Figure 57 and 58). KAP1 phosphorylation, especially at Ser824 
has been shown to help chromatin decondensation and represents an inhibitory 
post-translational modification for its co-repressive function (195, 196); (198); (197); its 
phosphorylation is known to be regulated by protein phosphatase 1 family members PP1α 
and PP1β (218). In our work, we suggest that LMTK3 specifically interacts with PP1α, 
which suppresses KAP1 phosphorylation at LMTK3-chromatin associated regions, 
thereby maintaining the co-repressor function of this complex. In addition, KAP1 
phosphorylation is a DNA damage marker (195, 196). Our result show that KAP1 
phosphorylation is suppressed during doxorubicin treatment when LMTK3 is 
overexpressed, which suggests that LMTK3 abundance might delay the induction of 
DNA damage upon doxorubicin treatment. However, the contribution of LMTK3 in this 
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process requires further investigation, which might further highlight its role in cancer cell 
survival.  
 Taken together, we provide evidence that LMTK3 functions as a transcriptional 
co-repressor through interacting with PP1α and KAP1, and as a scaffold protein by 
tethering the heterochromatin to the nuclear lamina, resulting in the chromatin 
remodelling and the transcriptional repression of LMTK3-bound tumour suppressor-like 
genes. The idea that an RTK could behave as a scaffold protein opens up new avenues for 
future research of all of these molecules. 
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4.1%The%role%of%LMTK3%in%breast%cancer%invasion%
The role of LMTK3 in breast cancer was initially described as an ERα regulator. LMTK3 
activates ESR1 gene transcription through FOXO3, as well as phosphorylates ERα and 
prevents it from degradation, resulting in the activation of ERα signalling and breast 
cancer progression. Interestingly, LMTK3 expression is detected in most of breast cancer 
cell lines, including the ERα-negative ones. Furthermore, in general the protein 
abundance of LMTK3 in the majority of triple-negative breast cancer lines seems higher 
than the one in the other lines; LMTK3 expression has stronger correlation with poor 
prognosis in ER negative cancer compared to the ER positive one. These suggest that 
LMTK3 may play a role in breast cancer progression other than regulating ERα. Since 
high invasive potential is one of the most significant feature of triple-negative breast 
cancer cells, we hypothesized that LMTK3 might be involved in the invasion process. 
4.1.1 Summary of findings 
LMTK3 protein abundance in highly invasive MDA-MB-231 and BT549 cells is higher 
than that in the less invasive MCF7 and T47D cells. In order to study whether 
overexpressing LMTK3 in these cells lines would promote their invasive potential, we 
first established MCF7 and T47D cell lines stably overexpressing LMTK3. We 
confirmed that LMTK3 overexpression promotes cancer growth in vitro and in vivo. 
Subsequently, we discovered that LMTK3 overexpression in MCF7 and T47D cells 
enhanced their invasiveness, while silencing LMTK3 in MDA-MB-231 and BT549 cells 
showed opposite effect, suggesting that LMTK3 is indeed involved in the invasion 
process of breast cancer. Furthermore, we detected that LMTK3 overexpression regulates 
cytoskeleton remodelling by increasing the F-actin-rich protrusions, vinculin and FAK 
redistribution at the leading edge of the cells. As a consequence of the remodelling, 
LMTK3 positively regulates cell adhesion to specific ECM ligands.  
 To investigate the underlying mechanism of the function of LMTK3 in invasion, we 
performed a SILAC experiment, which identified a pile of LMTK3-regulated proteins. 
From the list of cell motility-related proteins identified, we found LMTK3 could promote 
integrin family proteins, particularly integrin α5 and integrin β1 expression through 
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activation of the SRF transcription factor. Here, similar to several RTKs (such as EGFR 
family), LMTK3 interacts with GRB2, resulting in the activation of classical RAS 
oncogene pathway and its collateral CDC42 pathway, thereby activating SRF. Then, we 
confirmed that the increased integrin abundance is responsible for LMTK3-induced cell 
invasion, cytoskeleton formation and adhesion to ECM. 
 Finally, we addressed that LMTK3 protein and gene expressions are correlated with 
those of integrin β1 not only in a set of breast cancer cell lines, but also in human breast 
cancer tissues. These findings highlight the function of LMTK3 on regulating integrins 
and the breast cancer invasion progress. 
4.1.2 Future directions 
We have addressed that LMTK3 is implicated in the breast cancer invasion and migration 
processes, especially in triple-negative breast cancer, is exciting, however this needs 
further investigation.  
• As invasion and adhesion to the ECM are the first step of metastasis for cancer 
cells, we further need to address the implication of LMTK3 in vivo by using a 
metastatic mouse model. 
• In this work, we addressed that LMTK3 activates SRF through CDC42, however, 
other alternative mechanisms merit investigation, including the possibility that 
LMTK3 might activate SRF through direct phosphorylation. In support of this 
hypothesis, in silico analysis revealed potential phosphorylation sites of SRF 
targeted by LMTK3 that are currently under examination. Moreover, the topology 
of LMTK3 (cytoplasmic, nuclear and to a lesser degree in the cell membrane) 
implies that LMTK3 may be capable of shuttling between subcellular 
compartments upon specific stimuli (i.e. posttranslational modifications) and 
other cellular conditions. Therefore, understanding the exact role(s) of LMTK3 in 
different cellular compartments is imperative. In order to characterize substrates 
phosphorylated by LMTK3, a high-throughput in vitro kinase assay screen is in 
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progress that will further help us uncover the signalling pathways that LMTK3 is 
implicated in and decipher its contribution in disease. 
• From the SILAC experiment, there are several other LMTK3-regulated proteins 
involved in the regulation cell motility, such as talin, a protein linking integrin 
and cytoskeleton, and can induce integrin “inside out” activation. From our 
preliminary result, we found that talin protein abundance is also positively 
regulated by LMTK3. How LMTK3 regulates talin could be an interesting future 
project. 
• A recent study (219) generated subpopulations of ER negative breast cancer cells 
that develop primary tumour and metastasis more efficient than their parental 
populations at low cell number through in vivo selection. The authors sequenced 
these population and discovered several elevated genes that could promote tumour 
re-initiation. Although not studied in this work, LMTK3 is one of the top genes on 
this list. This work strongly supports our work, while also provides an insight that 
the involvement of LMTK3 in governing primary and metastatic tumour 
re-initiation, which worth further investigation. 
4.1.3 Conclusion 
In conclusion, we present a model of the pro-invasion function of LMTK3: 
LMTK3-GRB2 cascade activates RAS and CDC42 small GTPase, resulting in the 
activation of SRF transcription factor, which promotes integrins transcription.  
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4.2%The%role%of%LMTK3%in%transcriptional%regulation%
As the previous studies on LMTK3 are focused on its cytoplasmic role, the fact that a 
great proportion of LMTK3 protein is located in the nucleus should not be ignored. IHC 
staining of patient breast tumours revealed that nuclear LMTK3 is similarly important in 
predicting breast cancer prognosis. Therefore, we tended to investigate the nuclear 
function of LMTK3. 
4.2.1 Summary of findings 
As studies have shown that only a few RTKs can bind chromatin and regulate gene 
transcription, we hypothesized that LMTK3 might be able to bind chromatin as well. To 
validate this, we performed ChIP-seq to identify LMTK3 global binding events in MCF7 
and MDA-MB-231, which are ER positive and ER negative breast cancer cells, 
respectively. After validating the antibody specificity, we confirmed that LMTK3 indeed 
binds DNA both at promoter and distal regulatory regions. Interestingly, we discovered 
that LMTK3 binding events in both cell lines are highly similar, while LMTK3 and ERα 
binding events are barely correlated. In addition, anti-estrogen treatment had no effect on 
LMTK3 bindings. These indicate that LMTK3 DNA binding events are ERα-independent. 
We then discovered that LMTK3 could bind both active and repressive promoters; 
nevertheless, its bindings were more associated with repressive promoters, indicating that 
LMTK3 may induce transcriptional repression. We therefore decided to focus on the 
potential transcriptional repression role of LMTK3 in the study. 
 Considering the fact that it lacks a DNA binding domain, LMTK3 requires binding 
partner(s). Combining the motif analysis and RIME assay, we chose KAP1 from both 
analyses as a potential binding partner of LMTK3. Interestingly, LMTK3 does not act as 
a kinase when interacting with KAP1 on the chromatin; instead, it dephosphorylates 
KAP1 on Ser824 through activating phosphatase PP1α. Noteworthy, the 
dephosphorylation of KAP1 by LMTK3 is specific to LMTK3-associated region, 
suggesting a highly specific effect. This dephosphorylation would result in sustained 
chromatin condensation and transcriptional silencing. 
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 Subsequently, we also detected that LMTK3 bindings are highly associated with 
transcriptional silenced LADs, majority of which are located at the nuclear periphery. 
Moreover, LMTK3 is implicated in tethering LMTK3-associated regions to the nuclear 
periphery, inducing H3K9me3 modification and transcriptional repression. 
 We then discovered that LMTK3 also negatively correlated with its associated genes 
in clinical samples (TCGA), and the majority of LMTK3 associated genes behave like 
tumour suppressors, which are associated with good prognosis. 
 Finally, we observed that mutation of the domain responsible for LMTK3-DNA 
binding resulted in reduced tumour progression in vivo, suggesting that the DNA binding 
activity of LMTK3, which suppresses a number of tumour suppressor-like genes, is 
important for the oncogenic role of LMTK3. 
4.2.2 Future directions 
This work opened up a new direction for the research on LMTK3. Therefore, there are 
several aspects that can be further investigated. 
• Importantly, as we mentioned, LMTK3 can also bind active promoters, which 
apparently is not mediated through KAP1. Therefore, what is (are) the other 
binding partner(s)? One of the candidates from our recent result could be 
CREB1, which collaborate with LMTK3 in binding a few oncogenes such as 
PELP1, RPS6KB2, CCNA2 and PTPN11. As shown in Figure 64, 
LMTK3-CREB1 shared binding regions are highly associated with active 
markers, distinct to the LMTK3-KAP1 module, suggesting that despite 
repressing a number of tumour suppressor-like genes, LMTK3 could also 
activate a few oncogenes using a different binding partner. This is worth 
investigating. 
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Figure 64 The [LMTK3KAP1] and [LMTK3CREB1] modules are associated with 
distinct combinations of chromatin regulators. 
Average binding profiles at regions bound by LMTK3, KAP1 and CREB1. LMTK3 and 
KAP1 shared regions are named [LMTK3KAP1]; LMTK3 and CREB1 shared regions 
are named [LMTK3CREB1]. Cluster 1 shows high binding intensity of [LMTK3KAP1], 
while Cluster 2 shows high binding intensity of [LMTK3CREB1]. 
 
• Apart from the well-defined kinase domain, LMTK3 has a long disordered 
domain that may participate in facilitating protein-protein interactions (such as 
LMTK3-PP1α and LMTK3-Lamin A interaction discussed in this project) 
implicated in a number of cellular processes. Although we suggested that 
LMTK3 could be categorized as a non-classical ‘randomly created’ scaffold, 
further investigation is needed. For example, is this scaffold function helping 
strengthen the kinase-substrate interaction, which would benefit the 
phosphorylation process; or is it specific to the kinase-independent function as is 
addressed in this work? 
• Our preliminary result shows that although MCF10A cells have equal amount of 
LMTK3 protein compared to MCF7, the DNA binding activity of LMTK3 
seems to be much weaker (tested by ChIP-PCR on a number LMTK3 binding 
regions). This raises the question whether LMTK3 DNA bindings at these given 
regions (tumour suppressor-like genes) are cancer-specific? More importantly, 
does LMTK3 bind DNA or not in normal breast cells or tissues? These can be 
answered after performing a LMTK3 ChIP-seq in MCF10A or normal breast 
tissues.  
• Following the aspect above, does LMTK3 bind DNA in other cancer types? 
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4.2.3 Conclusion 
In conclusion, we provide evidence that LMTK3 functions as a transcriptional 
co-repressor through interacting with PP1α and KAP1, and as a scaffold protein by 
tethering the heterochromatin to the nuclear lamina, resulting in the chromatin 
remodelling and the transcriptional repression of LMTK3-bound tumour suppressor-like 
genes.  
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The Kinase LMTK3 Promotes Invasion in
Breast Cancer Through GRB2-Mediated
Induction of Integrin b1
Yichen Xu,1 Hua Zhang,1 Lei C. Lit,1,2 Arnhild Grothey,1 Maria Athanasiadou,1,3
Marianna Kiritsi,1 Ylenia Lombardo,1 Adam E. Frampton,1 Andrew R. Green,4 Ian O. Ellis,4
Simak Ali,1 Heinz-Josef Lenz,5 Maya Thanou,3 Justin Stebbing,1* Georgios Giamas1*†
Lemur tyrosine kinase 3 (LMTK3) is associated with cell proliferation and endocrine resistance in breast
cancer. We found that, in cultured breast cancer cell lines, LMTK3 promotes the development of a meta-
static phenotype by inducing the expression of genes encoding integrin subunits. Invasive behavior in
various breast cancer cell lines positively correlated with the abundance of LMTK3. Overexpression of
LMTK3 in a breast cancer cell line with low endogenous LMTK3 abundance promoted actin cytoskeleton
remodeling, focal adhesion formation, and adhesion to collagen and fibronectin in culture. Using SILAC
(stable isotope labeling by amino acids in cell culture) proteomic analysis, we found that LMTK3 increased
the abundance of integrin subunits a5 and b1, encoded by ITGA5 and ITGB1. This effect depended on the
CDC42 Rho family guanosine triphosphatase, which was in turn activated by the interaction between
LMTK3 and growth factor receptor–bound protein 2 (GRB2), an adaptor protein that mediates receptor
tyrosine kinase–induced activation of RAS and downstream signaling. Knockdown of GRB2 suppressed
LMTK3-induced CDC42 activation, blocked ITGA5 and ITGB1 expression promoted by the transcription
factor serum response factor (SRF), and reduced invasive activity. Furthermore, abundance of LMTK3
positively correlated with that of the integrin b1 subunit in breast cancer patient’s tumors. Our findings
suggest a role for LMTK3 in promoting integrin activity during breast cancer progression and metastasis.
INTRODUCTION
Lemur tyrosine kinase 3 (LMTK3), a member of the receptor tyrosine kinase
(RTK) family, is implicated in breast cancer growth and endocrine resistance.
Inhibition of LMTK3 expression sensitizes BT474 cells to tamoxifen in
culture and in a mouse xenograft model (1, 2), whereas increased LMTK3
expression correlates with poor overall and disease-free survival (3), suggest-
ing that it contributes to breast cancer progression and metastasis.
Although our current knowledge highlights the oncogenic role of LMTK3,
very little is known about the LMTK3-regulated pathways and its involve-
ment in invasion and metastasis. These two multistep processes are con-
trolled by both extracellular and intracellular signals that stimulate changes
in cell adhesion and cytoskeleton formation, and the central role of integrins
in these procedures is well characterized (4). Integrins are heterodimers that
are composed of a and b chains, which further consist of 18 and 8 subunits,
respectively. Among them, a5b1 integrin binds directly to components of
the extracellular matrix (ECM), such as collagen and fibronectin, and
enhances cell motility and invasiveness. Several studies suggest that al-
tered a5 and b1 integrin subunit abundance correlates with tumor growth
and metastasis, leading to increased disease progression and decreased pa-
tient survival (5–9).
The gene encoding growth factor receptor–bound protein 2 (GRB2),
an adaptor protein, is ubiquitously expressed but overexpressed in breast
cancer cell lines and tissue samples (10, 11). GRB2 directly associates
with RTKs and activates downstream RAS guanosine triphosphatase
(GTPase) and extracellular signal–regulated kinase and mitogen-activated
protein kinase (ERK/MAPK) (12, 13), as well as the Rho GTPase family,
which then activates downstream transcription factors, resulting in cyto-
skeleton reorganization and cell invasion (14). Among those transcription
factors, serum response factor (SRF) binds to the serum response element
(SRE) in the promoter region of target genes and is involved in many cel-
lular processes, including cell growth, differentiation, and cancer cell in-
vasion (15, 16).
Here, we investigated the role of LMTK3 in breast cancer cell growth,
motility, and invasiveness. Our findings place LMTK3 on the map of well-
known oncogenic signaling cascades and link a new kinase to integrin
activity in tumorigenesis.
RESULTS
LMTK3 overexpression promotes breast cancer
cell proliferation in culture and accelerates tumor
growth in vivo
We previously showed that LMTK3 knockdown decreases cell prolifer-
ation in breast cancer cells (1). To further investigate the contribution of
LMTK3 on cell growth, we first examined its expression patterns in a
panel of breast cancer cell lines. LMTK3 was ubiquitously present in
all cell lines studied at variable abundances (Fig. 1A). Mass spectrometry
(MS) confirmed the existence of two full-length LMTK3 proteins that
were detected on the Western blot at different molecular weights (about
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240 and 170 kD) (fig. S1, A and B). Although the underlying cause for
the two bands requires further investigation [similar observations for
LMTK2 suggest a posttranslational modification, such as glycosylation
or phosphorylation (17)], only the 240-kD LMTK3 band was increased
in the relatively more proliferative and invasive MDA-MB-231 and BT549
cells. To investigate the role of LMTK3, we stably overexpressed LMTK3 in
MCF7 and T47D cell lines (Fig. 1B), which had exhibited less abundance of
the larger (240 kD) form of LMTK3 relative to either MDA-MB-231 or
BT549 cells (Fig. 1A). We found that LMTK3 overexpression significant-
ly increased the proliferation rate in MCF7 and T47D cells compared to
either parental line (Fig. 1, C and D) and promoted the formation of larger
colonies, as assessed by three-dimensional (3D) Matrigel overlay assays,
exhibiting a “grape-like” morphology as opposed to the established “mass”
shape of the parental cells (18) (Fig. 1, E and F). These data support that
LMTK3 promotes a signaling profile that results in enhanced cell prolif-
eration and invasive features in culture.
To investigate the association of LMTK3 with the growth of breast tumor
xenografts, T47D or T47D-LMTK3 cells were injected into the mammary
fat pads of female Balb/C nude mice. As expected from cell culture experi-
ments, LMTK3 overexpression increased tumor xenograft growth (Fig. 1G),
and was associated with increased Ki-67 abundance, a marker of cell prolif-
eration (Fig. 1H), indicative of the tumorigenic function of LMTK3 in vivo.
LMTK3 promotes
cell invasion, motility,
and migration
To elucidate the role of LMTK3
in invasion and migration behav-
ior in cells,weusedBoydencham-
ber assays. Increased LMTK3
expression in MCF7 and T47D
cells significantly promoted cell
migration (Fig. 2A), whereas
knocking downLMTK3 in the in-
vasiveMDA-MB-231 and BT549
cell lines inhibited migration (Fig.
2B). Moreover, using the hang-
ing drop assay, we found that
3D spheroids formed by MCF7
cells overexpressing LMTK3 not
only displayed a higher degree of
colony dispersion at day 0 (Fig.
2C) but also exhibited augmented
invasion into the surrounding 3D
collagenmatrix at day2 (Fig. 2C).
We also observed the formation
of membrane protrusions at the
cell border 2 days after the hang-
ing drop test in T47D cells over-
expressing LMTK3 (fig. S2A),
indicating that these cells had
features of increased cell mem-
brane dynamics and mobility.
To visualize the contribution
of LMTK3 in cell motility, we per-
formed wound-healing assays
and observed that migration was
significantly increased in MCF7
cells overexpressingLMTK3com-
pared to the parental cells (Fig.
2D), whereas silencing LMTK3
markedly inhibited cell migration in MDA-MB-231 cells (Fig. 2E).
Together, these data support that LMTK3 is associatedwith amore invasive
cell phenotype.
LMTK3 promotes actin cytoskeleton remodeling, focal
adhesion formation, and adhesion to the ECM
Adhesion to the ECM results in the generation of contractile forces and
dynamic actin polymerization and reorganization (19), which are some of
the major remodeling changes that occur in the cell during migration and
invasion. Cell motility was visualized by the enhanced vinculin and focal
adhesion kinase (FAK) relocalization at the leading edge of cells. We
found that overexpression of LMTK3 increased actin-rich protrusions
and focal adhesion formations on the edge of migrating cells in both
2D and 3D cultures, whereas silencing LMTK3 suppressed these activities
(Fig. 2, F and G). Live imaging analysis showed that LMTK3 overexpres-
sion stimulated protrusion formation (movie S1, A and B). Overexpression
of LMTK3 in MCF7 (Fig. 2H) increased the attachment to both collagen I
and fibronectin, as assessed by cell adhesion assays using purified ECM
ligands. Conversely, knocking down the high endogenous LMTK3 abun-
dance in MDA-MB-231 cells decreased the cells’ attachment to collagen
and fibronectin (Fig. 2I), further supporting the notion that loss of LMTK3
reduces cell motility.
Fig. 1. LMTK3 promotes breast cancer growth in vitro and
in vivo. (A) LMTK3 protein abundance in various breast cancer
cell lines. (B to F) Effect of overexpression of LMTK3 (B) on the
proliferation (C and D) and spheroid formation (E and F) in
MCF7 and T47D cells compared to the parental cell lines. Data
are means ± SD from three independent experiments. (G)
Quantification of fold difference in tumor size between T47D
and T47D-LMTK3 xenografts at weeks 2 and 6. Data are
means ± SD from five T47D-derived xenografts and seven
T47D-LMTK3–derived xenografts. Representative images of
tumors at 6 weeks are shown. (H) Tumor tissue from (G) was
stained for LMTK3 and Ki-67. Scale bars, 100 µm. **P < 0.01,
***P < 0.001, unpaired Student’s t test.
R E S E A R C H A R T I C L E
www.SCIENCESIGNALING.org 17 June 2014 Vol 7 Issue 330 ra58 2
 on July 17, 2015
http://stke.sciencemag.org/
Downloaded from 
Fig. 2. LMTK3 regulates cell invasion and migration, actin cytoskeleton,
focal adhesion formation, and adhesion to ECM. (A) Fold change in
migration through Transwells by MCF7 and T47D cells overexpressing
LMTK3 compared with parental cells. (B) Fold change in Transwell mi-
gration by MDA-MB-231 and BT549 cells transfected with LMTK3
small interfering RNA (siRNA) (siLMTK3) compared with cells trans-
fected with a control siRNA (siCtl). Data are means ± SD from three
independent experiments. (C) Invasion in a collagen I hanging drop
assay by MCF7 overexpressing LMTK3 compared with parental cells.
Images are representative of three experiments. (D and E) Wound-
healing assays in MCF7 cells overexpressing LMTK3 (D) or MDA-
MB-231 cells after LMTK3 knockdown (E). Data are mean ± SD from
three experiments. (F) Confocal microscopy analysis of F-actin protru-
sions, viniculin localization, and FAK abundance in MCF7 and MCF7-
LMTK3 cells. (G) 3D staining for F-actin in BT549 cells transfected with
siCtl or siLMTK3, and in T47D cells overexpressing LMTK3 compared
with parental cells. Images in (C), (F), and (G) are representative of
three experiments. (H and I) Cell adhesion to indicated ECM ligands.
Data are means ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001,
unpaired Student’s t test.
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LMTK3 increases cell invasion and adhesion by
promoting the abundance of integrin b1 and a5
To elucidate the molecular mechanisms underlying the regulation of cell
invasion and motility by LMTK3, we performed stable isotope labeling by
amino acids in cell culture (SILAC) to identify LMTK3-modulated pro-
teins. Inhibition of LMTK3 decreased the abundance of several proteins
involved in integrin-signaling pathways, including integrin subunit a5,
talin-1, vinculin, and b-actin–like protein 2 (Fig. 3A, fig. S3, and table
S1). It is well established that the binding of integrins to ECM enhances
cell growth and migration by transmitting information to the cell and ac-
tivating bidirectional signaling pathways (4). Considering our SILAC data,
we explored whether LMTK3 affects the expression of different integrin
isoforms that have been previously implicated in breast cancer by assessing
the abundance of integrin subunits after modulating LMTK3 (8, 20–22).
MCF7 and T47D cells overexpressing LMTK3 had increased abundance
of integrin subunits b1, b3, and a5 (Fig. 3B). On the contrary, knocking
down LMTK3 in MDA-MB-231 and BT549 cell lines reduced the abun-
dance of all three integrin subunits (Fig. 3B). In MCF7 cells overexpressing
LMTK3, we also observed a significant increase in the cell surface abun-
dance of integrin subunit b1 (Fig. 3C, and upper band in Fig. 3B), which is
described as the activated form of integrin subunit b1 that helps cells adhere
to the ECM (23).
To determine whether LMTK3 regulates cell adhesion, invasion, and
actin cytoskeleton reorganization through the integrin b1 and a5 subunits,
we overexpressed integrin subunits b1 or a5 (encoded by ITGB1 and ITGA5,
respectively) in MCF7 cells, which have low LMTK3 abundance, and con-
firmed that both isoforms increased cell adhesion to collagen I and fibro-
nectin (Fig. 4, A and B) and promoted invasion through Matrigel (Fig. 4C)
similarly to overexpression of
LMTK3. On the contrary, deple-
tion of either b1 or a5 subunits
(Fig. 4D) returned the adhesion
exhibited by MCF7-LMTK3 cells
to that seen in parental cells when
cultured on collagen I and fibro-
nectin (Fig. 4, D and E). Silencing
integrinb1, but not integrina5, sup-
pressed the invasion of MCF7-
LMTK3 cells through Matrigel
(Fig. 4F). Decreased F-actin ag-
gregation was also observed on
the periphery of MCF7-LMTK3
cells especially after knockdown
of integrin b1 subunit (Fig. 4G).
Considering that these are func-
tional heterodimers, these obser-
vations can be explained by the
fact that silencing of integrin b1
nearly abolished integrin a5 pro-
tein, whereas inhibition of integ-
rina5 did not have a similar effect
on integrin b1, therefore affect-
ing the efficiency of these com-
plexes. Finally, we overexpressed
integrin subunit b1 or a5 in MDA-
MB-231 cells and found that in-
tegrin restoration could rescue
the reduction in cell adhesion
and invasion caused by LMTK3
knockdown (Fig. 4, H to J).
Together, these data indicate that the promotion of cell adhesion and
invasion elicited by LMTK3 is mediated through the induction of integrin
subunits b1 and a5.
LMTK3 promotes ITGB1 and ITGA5 transcription
through SRF
On the basis of the effects of LMTK3 on the abundance of integrin b1 and
a5 subunits at the protein level, we investigated whether LMTK3 affected
these at the transcriptional level. Quantitative real-time polymerase chain
reaction (qRT-PCR) revealed that LMTK3 positively regulated ITGA5 and
ITGB1 mRNA expression, whereas no change in ITGAV mRNA expres-
sion was observed, and ITGB3 was hardly detected in MCF7 as previously
reported (24) (Fig. 5, A and B, and fig. S4, A to E). Considering the pre-
dominant effect of LMTK3 on integrins b1 and a5, but not on aV, we de-
cided to further focus our research on the integrin b1 and a5 functional
heterodimer.
To further confirm that LMTK3 promotes the transcription of ITGA5
and ITGB1, we used two luciferase reporter plasmids containing either the
3000–base pair (bp) region upstream of ITGB1 ATG or the 900-bp region
upstream of the ITGA5 ATG, respectively. LMTK3 overexpression in-
creased the activity of both promoters (Fig. 5, C and D), whereas silencing
LMTK3 had opposing effects (Fig. 5, E and F).
We then investigated which transcription factor (or factors) mediated
integrin induction in the presence of increased LMTK3 abundance. We
found that several well-known regulators of integrin transcription, namely,
specificity protein 1 (SP1) and activation protein 1 (AP1; which is a hetero-
dimeric complex consisting of c-FOS and c-JUN), were unable to promote
ITGB1 and ITGA5 transcription in MCF7 cells overexpressing LMTK3
Fig. 3. ITGA5 and ITGB1 are LMTK3-regulated proteins. (A) SILAC scatter plot comparison of ratios for total
proteins showing altered abundance in MCF7 transfected with LMTK3 siRNA relative to those transfected with
control siRNA. Significance threshold was calculated by a B Significance Test (Sig B). (B) Western blot for integrin
subunits in either MCF7 or T47D overexpressing LMTK3 compared with those transfected with an empty vector,
or BT549 or MDA-MB-231 cells transfected with LMTK3 siRNA compared with controls. (C) Fluorescence-activated
cell sorting for surface ITGB1 in MCF7 cells transiently overexpressing LMTK3 compared with control cells. The
histogram is representative of, and the data are means ± SD from, three experiments relative to cells transfected
with the empty vector. *P < 0.05, unpaired Student’s t test.
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(fig. S4, F and G). However, knockdown of SRF, which was recently iden-
tified as a transcription factor for ITGB1 (25, 26), inhibited the activity of
reporter constructs containing either the ITGB1 or the ITGA5 promoters
(Fig. 5, G and H), similar to that containing a known SRF target promoter
(FOS) as a positive control (Fig. 5I), without affecting LMTK3 protein
abundance (Fig. 5J). To determine whether LMTK3 affected SRF binding
to the promoter of the gene encoding integrin b1, we performed SRF chro-
matin immunoprecipitation (ChIP) assays in MCF7 cells overexpressing
LMTK3 compared with parental cells and detected increased endogenous
SRF binding to an ITGB1 enhancer element (Fig. 5K), which contains a
putative SRF consensus sequence
(CArG box) (26). These results
suggest that LMTK3 promotes in-
tegrin subunit b1 abundance at the
transcriptional level through SRF.
To further investigate the role
of SRF in LMTK3-induced cell
migration and proliferation, we
treatedMCF7andMCF7-LMTK3
cells with the SRF inhibitor CCG-
1423 (27). We found that CCG-
1423 inhibited migration by nearly
half in MCF7 cells overexpress-
ing LMTK3, compared with less
than a third in parentalMCF7cells
(fig. S5A), suggesting that SRF
enhances LMTK3-induced cell
migration. However, CCG-1423
suppressed proliferation more ef-
fectively in the parental cells than
in those overexpressing LMTK3
(fig. S5B), indicating thatLMTK3
may promote cell proliferation ad-
ditionally through other pathways.
An LMTK3-GRB2 cascade
activates CDC42 and
subsequently SRF
On the basis of our observations
thus far, we investigated how
LMTK3 activates SRF. Previous
work showed that the RTKMET
interacts with the adaptor protein
GRB2 and activates members of
the RAS-GTPase family, namely,
RAS and Rho subfamilies (14),
the latter of which activate SRF
(28, 29). Immunoprecipitation of
endogenous proteins in cells and
GST (glutathione S-transferase)–
tagged GRB2 pull-down assays
in vitro revealed a direct interac-
tion between LMTK3 and GRB2
(Fig. 6, A and B), and overexpres-
sion of LMTK3 promoted the in-
teraction between GRB2 and son
of sevenless homolog 1 (SOS1)
(Fig. 6C). We then investigated
whether LMTK3 overexpression
activated the RAS-GTPase family,
which is downstream of GRB2 and SOS1 (30). MCF7 and MCF7-LMTK3
cell lysates were incubated with a GST-tagged RAF1 protein-binding domain
or a GST-tagged PAK1 protein-binding domain, which specifically binds to
either active RAS or cell division control protein 42 homolog (CDC42), a
small Rho family GTPase, respectively. As a result, LMTK3 overexpression
activated both RAS (Fig. 6D) and CDC42 (Fig. 6E) in MCF7 cells. Over-
expression of LMTK3 in breast cancer cell lines, which had weak endoge-
nous LMTK3 abundance, increased ERK/MAPK pathway activation as
inferred from increased phosphorylation of MEK1/2 and ERK1/2, whereas
knocking down LMTK3 in cells with abundant endogenous LMTK3 appeared
Fig. 4. LMTK3-induced invasion
and adhesion require integrin
subunits b1 and a5. (A to C) West-
ern blot for integrin subunits (A),
cell adhesion (B), and [invasion/
migration] (C) in MCF7 cells over-
expressing integrin subunit b1 or
a5 compared with cells overex-
pressing LMTK3or a control vector.
(D to G) As in (A) to (C) in MCF7
cells overexpressing LMTK3 and
transfected with siRNA against integrin subunit b1 or a5 compared with cells transfected with control siRNA or
parental cells. (G) F-actin staining in cells as in (D) to (G). (H to J) Western blot for integrin subunits (A), cell
adhesion (B), and [invasion/migration] (C) inMDA-MB-231 cells transfectedwith siRNA against LMTK3 and over-
expressing integrin subunit b1 or a5 compared with controls. All images and Western blots are representative of
three experiments, and data aremeans ± SD from three experiments. *P<0.05, **P<0.01, ***P<0.001, unpaired
Student’s t test.
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to inhibit activation of the pathway (fig. S6A). Furthermore, silencing GRB2
inhibited LMTK3-induced ERK/MAPK pathway activation, cell proliferation
(fig. S6C), and CDC42 activation (Fig. 6F), confirming that CDC42 activation
after LMTK3 overexpression required GRB2.
Because the data thus far suggested that LMTK3 formed a complex with
GRB2 to activate CDC42, and LMTK3 induced the abundance of integrin
subunits through SRF-mediated transcription, we investigated whether
CDC42 promoted SRF activity and integrin transcription through an
LMTK3-GRB2 mechanism. Similar to a study in PC3 cells, which ad-
dressed the function of CDC42 in activating SRF (25), silencing CDC42
repressed the expression of reporter constructs for SRF activity (fig. S6F)
and ITGB1 and ITGA5 promoter transcription (fig. S6,G andH) induced by
LMTK3overexpression inMCF7. SilencingGRB2 inMCF7 cells overexpres-
sing LMTK3 reduced ITGB1 and
ITGA5mRNA expression (Fig. 6,
G to I). This resulted in a reduced
motility phenotype, inferred from
decreased F-actin staining on the
periphery of the cell (Fig. 6J), de-
creased cell adhesion to fibro-
nectin (Fig. 6K), and decreased
cell invasion through Matrigel
(Fig. 6L).
Given that integrins can me-
diate CDC42 activation (31), we
investigatedwhether the observed
CDC42 activation was mediated
either by the LMTK3-GRB2 cas-
cadeorby increased integrinb1 in-
duced by LMTK3 through other
mechanisms (fig. S6D). We found
that in the absence of integrin b1
(fig. S6E), LMTK3 overexpression
could still promote CDC42 acti-
vation in MCF7 cells (fig. S6E),
confirming that CDC42 activation
ismediated by LMTK3 but possi-
bly independently of integrin b1.
LMTK3 correlates with
integrin b1 in breast cancer
ITGB1 is predictive of survival
in breast cancer patients (8, 9).
We found that the abundance of
LMTK3 and integrin b1 demon-
strated noticeably similar patterns
in several breast cancer cell lines
(Fig. 7A).Moreover,we screened
20 breast cancer cell lines and ob-
served a significant association
of LMTK3 and ITGB1 gene ex-
pression, further confirming the
correlation of LMTK3 and ITGB1
at the mRNA level (Fig. 7B).
To investigate the clinical sig-
nificanceof these findings,we first
examined the protein abundance
patterns of LMTK3 and integrin
b1 in 16 fresh primary breast can-
cer tumor samples and found a
correlation between LMTK3 and integrin b1 abundance by Western blot
(Fig. 7C). To further confirm these data,we performed immunohistochemical
analysis to determine integrin b1 abundance in 858 breast cancer samples
(fig. S7A). We confirmed that increased integrin b1 abundance was asso-
ciated with a shorter overall survival (fig. S7B), and a significant corre-
lation of LMTK3with integrin b1was detected in patient samples (Fig. 7D),
consistentwith our invitro and cell culture findings that LMTK3 abundance
promotes integrin b1 abundance.
DISCUSSION
LMTK3 is implicated in cancer progression and is associated with poor
breast cancer patient survival (1, 3, 32, 33). As a highly pleiotropic protein,
Fig. 5. LMTK3 promotes integrin-coding gene transcription through SRF. (A and B) qRT-PCR for ITGB1 (A) and
ITGA5 (B) mRNA in MCF7 cells overexpressing LMTK3 compared with parental cells or MDA-MB-231 trans-
fected with control or LMTK3 siRNA. (C and D) Effect of LMTK3 overexpression on ITGB1 (C) and ITGA5 (D)
promoter activities in MCF7 cells. (E and F) Effect of LMTK3 silencing on ITGB1 (E) and ITGA5 (F) promoter
activities in MDA-MB-231 cells. (G to J) Effect of SRF silencing on the (G) ITGB1 p3000 promoter, (H) ITGA5
promoter, and (I) FOS promoter. (J) LMTK3 protein abundance after SRF silencing. (K) ChIP-qPCR assay for
SRF binding to proximal enhancer region of ITGB1 gene. Cross-linked nuclear extracts of MCF7 and MCF7-
LMTK3 were immunoprecipitated with SRF antibody (left) or control immunoglobulin G (IgG) (right). All data
are means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001.
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LMTK3 is involved in multiple biological processes, including promo-
tion of tumor growth by regulating estrogen receptor a (ERa) transcrip-
tion and stability (1) and conferring endocrine resistance by protecting
cells from tamoxifen-induced autophagy (2). Here, we defined the involve-
ment of LMTK3 in breast cancer cell motility, migration, and invasion
through the transcriptional activation of integrins.
LMTK3 is aberrantly abundant in highly invasive ductal breast cancer cell
lines. Two isoforms of full-length LMTK3 (about 240 and 170 kD) were de-
tected byWestern blotting andMS. The abundance of 240-kD LMTK3, which
may be a posttranslationally modified LMTK3, was notably greater in the
more invasive breast cancer cell lines (MDA-MB-231 and BT549) than that
in the less invasive lines (ZR75.1, T47D, andMCF7), suggesting that this band
is likely involved inpromotingcellmotility. By stably overexpressing LMTK3
in MCF7 and T47D cells and transiently silencing the high endogenous
LMTK3 abundance in MDA-MB-
231 and BT549 cells, we found
that LMTK3 not only promoted
cell adhesion and invasionbut also
reorganized the cytoskeleton to a
more invasive pattern.
The abundance of integrin
a5 and integrin b1 correlated with
that of LMTK3, suggesting a role
for LMTK3 in integrin regulation.
Moreover, our observation that ex-
ogenous overexpression of integ-
rin subunits a5 and b1 restored
cell invasion and adhesion sup-
pressed by LMTK3 knockdown
further supports the role of integrin
subunits in cell motility, invasive-
ness, adhesion, and metastasis
(25,26,34–36).However,LMTK3
overexpression was not able to
rescue integrin silencing–mediated
reduction in cell invasion and ad-
hesion, indicating that integrins
were functionally downstream of
LMTK3. Indeed, LMTK3 pro-
moted the transcription of ITGA5
and ITGB1 by promoting the
binding of the transcription factor
SRF, supporting reports that SRF
binds the ITGB1promoter (25,26).
GRB2 is a common adaptor
protein that links RTKs to down-
stream signaling pathways by ac-
tivating downstreamRAS andRho
subfamilies ofRAS-GTPases.Here,
we showed that, similar to other
RTKs, LMTK3 directly interacts
with GRB2, which then activates
bothRASandCDC42.RASactiva-
tion leads to prominent increase in
ERK/MAPK pathway. Silencing
GRB2 inhibited LMTK3-induced
ERK/MAPKactivationandcellpro-
liferation, which explains the in-
creased tumor growth observed after
LMTK3 overexpression. CDC42
activation activates SRF and subsequently promotes the transcription of genes
encoding integrins (25). In our proposed model, GRB2 silencing in cell lines
overexpressing LMTK3 suppressed integrin-encoding gene expression, aswell
as cell adhesion and invasion. SRF inhibition effectively inhibited LMTK3-
induced migration but did not suppress LMTK3-induced proliferation, im-
plying that LMTK3 regulates cell proliferation through GRB2 through the
RAS-ERK/MAPK pathway and cell motility through the CDC42-SRF path-
way, which results in enhanced ITGB1 and ITGA5 expression (Fig. 7E).
Increased integrin b1 abundance is associated with poor breast cancer
patient survival (8, 9). However, these studies were performed with relatively
small patient sample sizes. In our study, we examined 858 cases of primary
breast cancer and confirmed a significant association of increased integrin
b1 abundance with poor overall survival. Notably, we detected a significant
positive correlation between LMTK3 and integrin b1 in both breast cancer
Fig. 6. LMTK3 regulates cell motility, CDC42 activation, and integrin-
coding gene expression through direct interaction with GRB2.
(A) Immunoprecipitation of LMTK3 and GRB2 in MCF7 cells trans-
fected with vector and LMTK3-encoding plasmid. IgG antibodies
were used as controls. (B) GST pull-down of LMTK3 using recombi-
nant GST-GRB2 protein. (C) Immunoprecipitation of GRB2 using
SOS1 antibody in MCF7 (−) and MCF7-LMTK3 (+) cells. (D and E)
Active RAS (D) and CDC42 (E) pull-down assays using lysates from
MCF7 (−) and MCF7-LMTK3 (+) cells. GTPgS [guanosine-5′-(g-thio)-
triphosphate] was used in MCF7 as a positive control. (F) Active
CDC42 pull-down assay in MCF7-LMTK3 cells treated with control
or GRB2 siRNA for 72 hours. (G to I) qRT-PCR for GRB2 (G), ITGB1 (H), and ITGA5 (I) mRNA in MCF7-LMTK3
cells treated with control or GRB2 siRNA for 72 hours. (J to L) F-actin protrusions formation (J), cell adhesion to
collagen (K), and cell invasion of MCF7-LMTK3 treated with control or GRB2 siRNA for 72 hours (L). All data are
means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001.
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cell lines and patient samples, suggesting a potentially cooperative role for
LMTK3 and integrin b1 in human breast cancer progression.
Despite the involvement ofLMTK3 in integrin regulation and signaling, it
is possible of course that LMTK3 could affect cell motility and invasiveness
through other pathways. Using SILAC quantitative proteomics in cells defi-
cient for LMTK3, we identified several downstream LMTK3 targets, apart
from integrins, that are involved in breast cancer cell invasion, such as talin
(37) and vinculin (38). These proteins are relevant not only for integrin
signaling but also for other pathways associated with cancer cell invasion
(39).Moreover, identificationof other proteins or ligands that are able tomod-
ulate LMTK3 (positively or negatively) would provide more information
about the upstream pathways implicated in LMTK3 signaling and will be
useful in our attempts to successfully target LMTK3 in breast cancer.
MATERIALS AND METHODS
Cell lines and reagents
Human breast cancer cell lines (MCF7, T47D, MDA-MB-231, BT549,
and ZR75.1) were purchased from the American Type Culture Collection
and were cultured in Dulbecco’s
modiﬁedEagle’smedium(DMEM)
supplemented with 10% fetal calf
serum (FCS) and 1% penicillin
and streptomycin. Stable LMTK3-
expressing MCF7 and T47D were
generated by transfection of full-
length LMTK3 plasmid, using
FuGENEHD (Promega) accord-
ing to the manufacturer’s instruc-
tions. Transfected cells were then
selected in the presence of G418
(1000mg/ml; Invitrogen)for2weeks,
and surviving clones were pooled
and cultured in the supplemented
DMEM in the presence of G418
(500 mg/ml).
Purified human ECM lig-
ands (collagen I, fibronectin, vitro-
nectin, and laminin 1) and Matrigel
were purchased from BD Biosci-
ences. siRNA targeting LMTK3
(H00114783-R02) was purchased
from Abnova, and those target-
ing ITGB1 (SI00300573), ITGA5
(SI02654841),GRB2 (SI00300328),
SRF (SI00150983), and CDC42
(SI02757328) were purchased
from Qiagen. Cells were plated
and transfected using HiPerFect
(Qiagen) following the manu-
facturer’s instructions for 72 or
96 hours and harvested for PCR
or Western blotting.
Human full-length LMTK3
(Myc-orFLAG-tagged) inpCMV6
vectorwaspurchasedfromOriGene.
Humanb1ora5 integrin–expressing
plasmids were purchased from
Addgene. Human full-length
GRB2 in pGEX-2T vector was a gift from J. E. Ladbury (University of
Texas MD Anderson Cancer Center). The human ITGA5 promoter region
(−908/+241) luciferase plasmidwas a gift fromS.Kim (TherapeuticAntibody
Research Center, Korea Research Institute of Bioscience and Bio-
technology). Human ITGB1 promoter region luciferase plasmid was a gift
from R. Grosse (Institute of Pharmacology, University of Heidelberg, Ger-
many). Cells were plated and transfected using FuGENE HD (Promega),
following the manufacturer’s instructions, for 24 hours and harvested for
PCR, Western blotting, and luciferase reporter assays.
Western blotting
Cells were lysed by scraping with radioimmunoprecipitation assay (RIPA)
buffer (Sigma-Aldrich). Lysates were boiled using NuPAGE 4× SDS
sample buffer (Invitrogen), and proteins were separated using SDS–
polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto Hybond
enhanced chemiluminescence (ECL) supernitrocellulose membranes (GE
Healthcare). The membranes were blocked in tris-buffered saline (TBS)
containing 0.1% (v/v) Tween 20 and 5% (w/v) nonfat milk for 1 hour
and then were probed overnight with primary antibody. The membranes
were washed with TBS containing 0.1% (v/v) Tween 20 and incubated with
Fig. 7. LMTK3 correlates with ITGB1 expression. (A) LMTK3 and integrin b1 protein expression of indicated cell lines
were examined by Western blot. (B) LMTK3 and ITGB1 mRNA expressions in indicated cell lines were analyzed using
qPCR. (C) LMTK3 and integrin b1 protein expressions in patient breast cancer samples were tested using Western blot.
(D) Correlation between LMTK3 and integrin b1 expression in 295 breast cancer cases. The subjects were divided into
two groups on the basis of integrin b1 H-score expression (low H-score <15, high H-score >15). The percentages of
LMTK3 low and high tumors in the two groups of subjects are shown. Data were analyzed using two-sided Fisher’s
exact test. (E) Model of LMTK3 signaling. LMTK3 interacts with GRB2, leading to increased GRB2 binding with SOS.
This promotes RAS and CDC42 activation (exchange fromGDP to GTP forms). CDC42 activation stimulates SRF activity
and increase SRF binding to integrin promoter, thus leading to integrin transcriptional activation.
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horseradish peroxidase (HRP)–conjugated antibody to rabbit IgG or
mouse IgG (each raised in goat and used at 1:1000 dilution) for 1 hour.
Immunocomplexes were detected with ECL.
3D Matrigel assay
Laminin-rich basement membrane matrix (Matrigel) for 3D cultures was
obtained from BD Biosciences. Cells (1 × 104) were trypsinized and sus-
pended in 2% (v/v) Matrigel in DMEM containing 10% FCS and seeded
over a layer of polymerized 100% Matrigel in eight-well chamber slides.
Phase-contrast or confocal micrographs of representative fields were taken
after 5 to 8 days.
Collagen I hanging drop assay
MCF7 and MCF7-LMTK3 cells were cultured to 90% confluence, de-
tached by 0.05% trypsin and 1 mM EDTA, and resuspended in complete
DMEM culture. Cells were counted and diluted to a concentration of 2.5 ×
106 cells/ml. Phosphate-buffered saline (PBS; 5 ml) was added to the bot-
tom of two 60-mm dishes. The lids were inverted and twenty 10-ml droplets
of cell suspension were added onto the bottom of the lid of each dish. The
lids were inverted onto the PBS-filled bottom chamber and incubated at
37°C. Once sheets were formed, aggregated cells were transferred to a
coverslip coated with collagen I and incubated at 37°C and 5% CO2 until
spheroids formed (in the data, “day 0” measurement was obtained after
30 min; “day 2” was assessed at 48 hours).
Cell proliferation assay
MCF7 and T47D cells stably expressing LMTK3 or empty vector were
seeded in 96-well plates (3000 cells per well). Cells were fixed every 24 hours
by gentle addition of 100 ml of 40% trichloroacetic acid (TCA) (w/v) (final
concentration of 10% TCA) per well. Plates were incubated for 1 hour at 4°C,
washed five times with distilled water, and stained with 100 ml of sulforho-
damine B (SRB) solution 0.4% (w/v) in 1% acetic acid for 1 hour at room
temperature. Unbound dye was removed by washing plates five times with
1% acetic acid. Bound stain was solubilized by the addition of 100 ml of
10 mM tris base. Absorbance was determined on an automated plate reader
(96-well microtiter) at 492 nm.
Invasion assay
Matrigel was diluted 1:5 in serum-free DMEM and evenly coated in a 24-
well 8-mm Transwell chamber and placed in 24-well plates. Cells (1 × 105)
were added to upper chambers after three washes with serum-free DMEM.
Medium (300 ml) containing 10% FCS was added below the Transwell
chamber. Cultures were maintained for 48 hours for MDA-MB-231 and
BT549 cells, or 72 hours for MCF7 and T47D cells. Membranes were re-
moved, stained with crystal violet or DAPI (4′,6-diamidino-2-phenylindole),
and pictures were taken using EVOS FL Cell Imaging System.
Immunofluorescence analysis
Cells plated on coverslips were washed with PBS and fixed with 4% form-
aldehyde at room temperature for 10 min, then incubated in 0.2% Triton
X-100 for 10 min. Coverslips were then blocked with blocking buffer
[10% human AB serum (H4522 Sigma) in PBS] and incubated with
primary antibody diluted in the same buffer followed by either FITC (fluores-
cein isothiocyanate) orTexasRed–conjugated secondaryantibodies for1hour
each at room temperature. DAPI was used to stain nuclei. Pictures were
taken with a Zeiss 410 LSM confocal microscope.
Adhesion assay
Each well of the 96-well plates was coated with 50 ml of ECM ligands
(10 mg/ml) diluted in PBS [collagen: C3867, Sigma; fibronectin: F1141,
Sigma; vitronectin: V8379, Sigma; laminin: L6274, Sigma; fibronectin,
vitronectin, and laminin were diluted in PBS to make stock (50 mg/ml)]
and incubated overnight at 4°C. Plates were washed with PBS and blocked
with 1.5% bovine serum albumin in PBS for 2 hours at 37°C. Cells were
washed with PBS and detached with 20 mM EDTA in PBS. Cells were
then washed with serum-free DMEM three times and resuspended in the
same medium to a concentration of 2 × 105 cells/ml. Plates were washed
with PBS three times, and 100 ml of cell suspension was added to each
well, incubated at 37°C for 30min, and gentlywashedwith PBS three times
to remove unattached cells. Attached cells were fixed with 10% TCA and
stained with 0.4% SRB solution. Absorbance was read at 492 nm.
Quantitative real-time polymerase chain reaction
RNAwas harvested using RNeasy Kit (Qiagen) and reverse-transcribed to
cDNA (complementary DNA) using High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Life Technologies). qRT-PCR used
TaqMan or SYBR Green assays (Applied Biosystems). SYBR Green
Primers were purchased from Qiagen: ITGB1 (QT00068124), ITGB3
(QT00044590), ITGA5 (QT00080871), ITGAV (QT00051891), and
GAPDH (QT01192646). TaqMan probes were purchased from Applied
Biosystems: LMTK3 (Hs01090715_m1), GRB2 (Hs00257910_s1), and
GAPDH (Hs02786624_g1).
Active RAS and CDC42 pull-down assay
The presence of RAS–GTP (guanosine 5′-triphosphate) and CDC42-GTP
in cell lysates was measured using RAS Activation Assay Kit (Millipore)
and Rac1 and CDC42 Activation Assay Kit (Millipore).
Luciferase reporter assay
MDA-MB-231 cells were transfected with siRNA targeting LMTK3 or
control siRNA for 48 hours and transfected with FOS, ITGB1, and ITGA5
reporter genes for another 24 hours. MCF7 cells were transfected with full-
length LMTK3 or empty vector together with reporter genes for 24 hours.
Luciferase reporter assays were performed with Dual-Luciferase Reporter
Assay System (Promega) following the manufacturer’s instructions. FOS
and ITGB1 reporter genes were a gift from D. Brandt and R. Grosse (Uni-
versity of Marburg, Germany). ITGA5 reporter gene was provided by
S. Kim (Korea Research Institute of Bioscience and Biotechnology).
Xenograft mouse models
Balb/Cnudemice 7 to 8weeks of agewere purchased fromHarlanLaboratories
UK Ltd., and all the procedures were carried out under Home Office license
authority and local ethics. T47D cells stably expressingLMTK3or vectorwere
cultured inDMEMcontaining10%FCSand injected subcutaneously intomice
at a concentration of 2 × 106 cells, eight mice per group. Tumor volumeswere
measured every 2 days using a caliper. Experiments were terminated 6 weeks
after cell injection. Primary tumors were excised and formalin-fixed.
Clinical specimens, TMAs, immunohistochemistry,
and scoring
Tissue microarrays (TMAs) containing 858 primary operable breast cancer
cases from the previously validated Nottingham Tenovus Primary Breast
Carcinoma Series wereused.Thecohort comprisedwomenagedup to70years,
who presented between 1986 and 1999. Appropriate ethics committee approval
was obtained. LMTK3 scoring was performed as previously described (1).
ITGB1 rabbit monoclonal antibody (ab115146, Abcam) was optimized to
a working concentration (4 mg/ml) on full-face excisional tissue sections.
Subsequently, 858 breast cancer TMA cases comprising 4-mm-thick formalin-
fixed paraffin-embedded tissue cores were immunostained with the optimized
ITGB1antibodyon theLeicaBOND-MAXautomated systemaccording to the
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manufacturer’s instructions. ITGB1 immunohistochemical staining and scoring
were performed as previously described (8). TMA scoring was performed by
two independent investigators (Y.X. and H.Z.). High-resolution digital
imaging (NanoZoomer, Hamamatsu Photonics) at ×20 magnification with
a Web-based interface (Distiller, SlidePath Ltd.) was used. All cases were
scored without knowledge of the clinicopathological or outcome data.
Mass spectrometry
Protein gel bands corresponding to LMTK3 were excised, reduced with
dithiothreitol, and alkylated with iodoacetamide (both Sigma) before di-
gestion with trypsin (Roche Diagnostics). Peptides were extracted from
the gel pieces using two washes of 50 mM ammonium bicarbonate
(NH4HCO3) and acetonitrile, lyophilized, and resuspended with 50 mM
NH4CO3. Chromatographic separations were performed with an EASY-nLC
system (Thermo Fisher Scientific). Peptides were resolved by reversed-
phase chromatography on a 75-mmC18 EASY column using a linear gradient
of acetonitrile (5 to 40%) in 0.1% formic acid. The gradient was delivered to
elute the peptides at a flow rate of 300 nl/min over 60 min. The eluate was
ionized by electrospray ionization using an Orbitrap Velos Pro (Thermo
Fisher Scientific) operating under Xcalibur v2.2. The instrument was oper-
ated in automated data-dependent switchingmode, selecting precursor ions
on the basis of their intensity for sequencing by collision-induced disso-
ciation (CID) using a Top20most intense ion method. TheMS/MS analy-
seswere conducted using collision energy profiles that were chosen on the
basis of the mass-to-charge ratio (m/z) and the charge state of the peptide.
Data processing
Mass spectral raw data were processed in to peak lists including parent ion
and fragment ion m/z values using Proteome Discoverer v1.3 (Thermo
Fisher Scientific). The following parameters were used: MS survey mini-
mum precursor mass 350 daltons, maximum precursor mass 10,000 dal-
tons; and MS/MS-ITMS in MS2 with CID fragmentation. Peak lists were
searched against the UniProt/SwissProt database and peptides identified by
probability matching to mass values generated from theoretical fragmenta-
tion of peptides using Mascot software v2.2 (http://www.matrixscience.
com)with the following search parameter specifications: precursor ionmass
tolerance 10 parts per million (ppm); fragment ion mass tolerance 0.8 dalton;
tryptic digest with up to three missed cleavages; variable modifications: acetyl
(protein N-term), carbamidomethylation (C), Gln->pyro-glu (N-term Q), oxi-
dation (M). False discovery rate was set to 0.01 (strict) to 0.05 (relaxed).
Database-generated files (.Dat) were uploaded into Scaffold 3 (v3.6.4)
software (http://www.proteomesoftware.com). All samples were aligned in
this software for easier interpretation and validation of MS/MS-based pep-
tide assignments and protein identifications. Peptide assignments were ac-
cepted if they contained at least two unique peptide assignments and were
established at 100% identification probability by the Protein Prophet
algorithm (40). Peptides identified below these probabilities were accepted
after manual inspection of the raw data to ensure that fragment ions cor-
rectly match the assigned sequence.
Statistical analysis
All data analyses were performed with Prism. Data were presented as
means ± SD or SEM, as indicated in the legends. Statistical significance
was assessed using Student’s t test. Statistical analysis for TMAs was per-
formed with SPSS 16.0 statistical software (SPSS Inc.).
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Fig. S1. MS analysis of LMTK3 protein bands.
Fig. S2. LMTK3 promotes migration in T47D cells.
Fig. S3. Gene Ontology classification of LMTK3-regulated proteins in MCF7 cells using
DAVID Functional Annotation tools.
Fig. S4. LMTK3 promotes integrin expression.
Fig. S5. SRF is required for LMTK3-regulated cell migration but not for LMTK3-induced
proliferation.
Fig. S6. LMTK3 promotes cancer cell proliferation through a GRB2-RAS-ERK/MAPK
pathway and cell invasion through a GRB2-CDC42-SRF-integrin pathway.
Fig. S7. Integrin b1 abundance predicts clinical outcome in breast cancer patients.
Table S1. SILAC analysis of LMTK3-silenced MCF7 cells.
Movie S1. LMTK3 promotes MCF7 cell motility.
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SUMMARY
LMTK3 is an oncogenic receptor tyrosine kinase
(RTK) implicated in various types of cancer, including
breast, lung, gastric, and colorectal cancer. It is local-
ized indifferent cellular compartments, but its nuclear
functionhasnotbeen investigatedso far.Wemapped
LMTK3 binding across the genome using ChIP-seq
and found that LMTK3 binding events are corre-
lated with repressive chromatin markers. We further
identified KRAB-associated protein 1 (KAP1) as a
binding partner of LMTK3. The LMTK3/KAP1 interac-
tion is stabilized by PP1a, which suppresses KAP1
phosphorylation specifically at LMTK3-associated
chromatin regions, inducing chromatin condensation
and resulting in transcriptional repression of LMTK3-
bound tumor suppressor-like genes. Furthermore,
LMTK3 functions at distal regions in tethering the
chromatin to the nuclear periphery, resulting in
H3K9me3 modification and gene silencing. In sum-
mary, we propose a model where a scaffolding func-
tion of nuclear LMTK3 promotes cancer progression
through chromatin remodeling.
INTRODUCTION
Lemur tyrosine kinase 3 (LMTK3), a member of the receptor tyro-
sine kinase family (RTK), has been identified previously as an es-
trogen receptor a (ERa) regulator (Giamas et al., 2011) implicated
in endocrine resistance in breast cancer (Stebbing et al., 2013).
However, LMTK3 is expressed in both ERa+ and ERa! breast
cancers, suggesting that it plays different cellular roles indepen-
dent of ERa status. Our recent work has revealed that elevated
cytoplasmic LMTK3 abundance in triple-negative breast cancer
promotes tumor invasion and metastasis (Xu et al., 2014), which
provided an example of the ERa-independent action of LMTK3.
Interestingly, both nuclear and cytoplasmic expression of
LMTK3 are correlated with tumor grade and patient survival
(Stebbing et al., 2012). However, the exact function of the
nuclear LMTK3 has not been determined so far.
Several receptor tyrosine kinases (RTKs) havebeen reported to
localize in the nucleus, where they can regulate gene expression
(most likely transactivation) through binding to euchromatin
(Hung et al., 2008; Lin et al., 2001; Lo et al., 2005; Peng et al.,
2001; Wang et al., 2004). According to these reports, nuclear
RTKs are present in the nucleoplasm instead of the nuclear
lamina. In most cells, at least one class of heterochromatin is
positioned at the nuclear lamina, resulting in gene repression (An-
drulis et al., 1998; Finlan et al., 2008;Guelen et al., 2008; Kumaran
and Spector, 2008; Peric-Hupkes et al., 2010; Reddy et al., 2008;
Solovei et al., 2013; Towbin et al., 2012). Previous studies also
propose that heterochromatin relocation to the nuclear lamina
might occur via active tethering mediated by discrete molecular
complexes (Chubbet al., 2002;Poleshko et al., 2013). Theseperi-
nuclear heterochromatin hotspots are enriched with histone 3
lysine 9 dimethylation (H3K9me2) and trimethylation (H3K9me3)
modifications, which are usually associated with a number of
heterochromatin binding proteins such as KRAB-associated
protein 1 (KAP1/TIF1b/TRIM28), a binding partner of histone-
lysine N-methyltransferase SETDB1 (Grewal and Jia, 2007; Niel-
sen et al., 1999; Ryan et al., 1999; Zeng et al., 2010).
KAP1 is a transcriptional co-repressor whose activity is
regulated by post-translational modifications such as phosphor-
ylation and sumoylation. When phosphorylated, KAP1 affects
global chromatin decondensation (Ziv et al., 2006), which, in
turn, results in the derepression of KAP1-bound genes such as
those involved in cell-cycle arrest and apoptosis (Lee et al.,
2007; Li et al., 2007). It has been shown that KAP1 phosphoryla-
tion is regulated by protein phosphatases 1a (PP1a) and 1b
(PP1b), which are responsible for the maintenance of its repres-
sive function (Li et al., 2010).
In this study, we investigate the function of nuclear LMTK3
through mapping genome-wide chromatin interaction sites of
LMTK3 in breast cancer. We find that LMTK3 suppresses the
expression of tumor suppressor-like genes by tethering the
chromatin to the nuclear periphery, functioning as a catalytic
scaffold protein. Binding of LMTK3 to chromatin is mediated
via the interaction with PP1a and KAP1. The formation of this
complex leads to the suppression of KAP1 phosphorylation,
in turn strengthening this unique transcriptional repression
function. We show that a protein kinase has scaffolding prop-
erties, creating a system to enhance signaling complexity in
carcinogenesis.
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RESULTS
Genome-wideMapping Identifies the LMTK3-Chromatin
Binding Profile
We have previously identified LMTK3 as a potential therapeutic
target in breast cancer that is expressed in ERa+ and ERa!
breast cancer, whose expression carries prognostic signifi-
cance in both subgroups. As shown previously (Xu et al.,
2014), two specific LMTK3 bands are detected by western
blot analysis. We now demonstrate that LMTK3 localizes both
in the nucleus and in the cytoplasm of MCF7 and MDA-MB-
231 cells. The upper band is specifically localized in the cyto-
plasm, and the lower band is detected both in the cytoplasm
and in the nucleus, which suggests that the lower band is the
one that mainly functions in the nucleus (Figures S1A and
S1B). Because the importin protein family is known to mediate
macromolecules translocation from the cytoplasm to the nu-
cleus (Weis, 2003), we decided to investigate whether importins
are responsible for LMTK3 translocation by knocking down im-
portin a2 and importin b1 individually. We detected a notable
reduction in nuclear LMTK3 levels, with an increase in its cyto-
plasmic proportion after importin a2 but not importin b1 knock-
down (Figure S1C), suggesting that LMTK3 translocation is
mediated in an importin a2-dependent/importin b1-independent
manner, which has also been reported previously (Kotera et al.,
2005).
To decipher the function of LMTK3 in the nucleus, we mapped
the genome-wide profile of LMTK3-chromatin interactions by
chromatin immunoprecipitation sequencing (ChIP-seq) in the
ERa+/MCF7 and the ERa!/MDA-MB-231 cell lines.We observed
3,086 loci in MCF7 and 24,516 loci in MDA-MB-231, in which
LMTK3 is located to the chromatin (Figures S1D and S1E).
Based on our previous work showing that LMTK3 interacts
with and phosphorylates ERa, which, in turn, promotes TFF1
expression (Giamas et al., 2011), we questioned whether
LMTK3-chromatin binding events are ERa-dependent. Interest-
ingly, we observed that LMTK3 binding in MCF7 (ERa+) and
MDA-MB-231 (ERa!) have a high similarity (Figures 1A and
S1D) with a high correlation (R2 = 0.77) (Figure 1B). Supporting
the notion that chromatin-bound LMTK3 function may be inde-
pendent of ERa, we found no noticeable overlap and correlation
between LMTK3 and ERa binding (Figures S1F and S1G). More-
over, there were no significant changes in the enrichment of
selected LMTK3 binding genes in MCF7 cells upon fulvestrant-
mediated ERa degradation (Figure S1H), further suggesting
that the DNA binding events of LMTK3 are ERa-independent.
To further characterize the LMTK3 binding behavior, we then
tested the correlation of binding events of LMTK3 with two
groups of chromatin biomarkers (histone and transcription fac-
tors [TFs]): repressive promoter markers (histone 3 lysine 27 tri-
methylation [H3K27me3], H3K9me3, and SUZ12) and active
promoter or enhancer markers (histone 3 lysine 4 monomethyla-
tion [H3K4me1], histone H3 lysine 4 trimethylation [H3K4me3],
NANOG, p300, and TAF1). Interestingly, we found that LMTK3
binds chromatin at both repressive and active (Figures 1C, 1D,
and S1I) promoters, suggesting that there is a different binding
profile of LMTK3 compared with the ones of other known RTKs
(Lin et al., 2001; Wang et al., 2004).
Next, we validated LMTK3 bindings using ChIP-qPCR for
the most enriched LMTK3-binding genes. To confirm that the
bindings are LMTK3-specific, we constructed stable LMTK3
knockout (KO) MDA-MB-231 cells using a clustered regularly in-
terspaced short palindromic repeats (CRISPR)/CAS9 technique
by transfecting MDA-MB-231 cells with plasmids containing
hCAS9 and 2 guiding RNAs targeting exon 12 of LMTK3. Positive
clones showed a 112-base pair (bp) deletion (Figure S1J), and
clones with significant LMTK3 protein deletion were selected
(Figure S1K). Interestingly, we could not generate complete
LMTK3 KO MCF7 cells using the CRISPR technique. This may
be due to the fact that LMTK3 is so crucial for MCF7 cell growth
that LMTK3 KO cell clones stopped proliferating and could
not be selected. Therefore, we used our previously established
MCF7 cells stably overexpressing LMTK3 (MCF7-LMTK3). As a
result, LMTK3 binding events were notably higher in MCF7-
LMTK3 cells compared with MCF7 cells (Figure 1E) and were
barely detected in LMTK3-KO MDA-MB-231 cells (Figure 1F),
suggesting that the bindings detected are LMTK3-specific.
To investigate the binding event of LMTK3 in vivo, we injected
MCF7-LMTK3 cells subcutaneously into nude mice, harvested
the tumors, and performed LMTK3 ChIP. We discovered a
similar binding pattern of LMTK3 in the xenograft studies
compared with that in cell lines (Figure 1G). Finally, we also
confirmed LMTK3 bindings in both ERa+ and ERa! breast can-
cer patient samples (Figure 1H). In summary, our results highlight
that nuclear LMTK3 is a chromatin-binding protein whose activ-
ity is independent of ERa status.
Motif and RIME Analyses Identify KAP1 as an
LMTK3-Associated Protein in Chromatin Binding
Similar to other RTKs, LMTK3 is unlikely to have a DNA-binding
domain. Therefore, binding of LMTK3 at DNA requires seq-
uence-specific transcription factors that interact with LMTK3.
A motif analysis provided a number of potential interacting
partners of LMTK3 (Figure 2A). We performed rapid immunopre-
cipitation mass spectrometry of endogenous proteins (RIME)
(Mohammed et al., 2013) to further address which of these can-
didates might be interacting partners of LMTK3 during DNA
binding and discovered 196 LMTK3-associated proteins (Fig-
ures 2B and S2; Table S1). Interestingly, KAP1 was enriched in
both analyses. We validated the interaction between LMTK3
and KAP1 by immunoprecipitation (Figure 2C). In addition, we
found a notable correlation between global LMTK3 and KAP1
binding events by comparing the ChIP-seq signals of LMTK3
and KAP1 (from the HEK293 cell line) (Figure 2D). We further
confirmed KAP1 as an LMTK3-binding partner by performing
KAP1 re-ChIP after LMTK3 ChIP (Figure 2E). In addition, we
also detected a similar binding profile of LMTK3 and KAP1 (Fig-
ure 2F). These data substantiate that KAP1 is an LMTK3 binding
partner in chromatin binding.
PP1a Stabilizes the LMTK3/KAP1 Interaction
and Mediates KAP1 Dephosphorylation at
LMTK3-KAP1-Bound Chromatin Regions, Resulting in
Chromatin Condensation and Gene Repression
We then investigated whether the LMTK3/KAP1 interaction is a
kinase-substrate process. No phosphorylation was observed
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after performing an in vitro kinase assay using the recombinant
LMTK3 kinase domain (encompassing amino acids [aas] 149-
444) as a source of enzyme activity and glutathione S-trans-
ferase (GST)-KAP1 as a substrate (Figure S3A). On the contrary,
endogenous KAP1 phosphorylation at Ser824 was suppressed
after LMTK3 overexpression (Figures S3B and S3C). Because
PP1a is a known KAP1 phosphatase and a predicted LMTK3
interaction partner (Hendrickx et al., 2009), we tested whether
PP1a is involved in the LMTK3/KAP1 interaction. Interestingly,
silencing of PP1a reduced the interaction between LMTK3 and
KAP1 (Figure 3A). We therefore generated GST-LMTK3 con-
structs and LMTK3 mutations at the PP1a docking motif
(PP1_RVxF) of LMTK3 (Figure 3B). As anticipated, a significant
decrease in LMTK3-PP1a binding was detected in both mutants
Figure 1. Identification of Genome-wide LMTK3 Binding Sequences with ChIP-Seq
(A) Binding of LMTK3 at the promoter of BAP1, GPAM, RBM42, and the distal interval in MCF7 and MDA-MB-231 cells.
(B) The correlation of LMTK3 binding signals in the MCF7 and MDA-MB-231 breast cancer cell lines.
(C) Clustering of genome-wide binding datasets with LMTK3. The color indicates similarity based on the Pearson correlation of the ChIP-seq peaks. The R2 values
of the correlation between LMTK3 bindings and SUZ12, H3K9me3, H3K27me3, H3K4me1, H3K4me3, NANOG, TAF1, and p300 binding are 0.53, 0.41, 0.48, 034,
0.4, 0.11, 0.26, and 0.27, respectively.
(D) H3K9me3 and H3K27me3 enrichment around LMTK3 peaks in MCF7 cells.
(E and F) ChIP-qPCR of LMTK3 bindings in MCF7 and MCF7-LMTK3 (E) and MDA-MB-231 and LMTK3 KO MDA-MB-231 cells (F).
(G) ChIP-qPCR of LMTK3 binding in an MCF7-LMTK3 cell-implanted xenograft.
(H) ChIP-qPCR of LMTK3 binding in human breast cancer tissues. Patient 1, ER+ PR+HER2!; patient 2, ER+, HER!; patient 3, ER+, PR+, HER!; patient 4, ER!PR!
HER2+.
Quantitative data are presented as mean ± SD from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.
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(LMTK3RVxF_1 and LMTK3RVxF_2), with a subsequent reduction in
the LMTK3/KAP1 interaction (Figures 3B and 3C). These results
suggest that PP1a is crucial for stabilizing the LMTK3-KAP1
complex.
KAP1 phosphorylation is critical in global chromatin decon-
densation (White et al., 2006; Ziv et al., 2006), leading to the
derepression of several basal KAP1-repressed genes (Lee
et al., 2007; Li et al., 2007). Therefore, we were interested in
elucidating the function of the LMTK3-PP1a-KAP1 interaction
on KAP1 phosphorylation status as well as its repressive func-
tion. Because basal levels of KAP1 phosphorylation are barely
detected, we used doxorubicin, a KAP1-Ser824 phosphorylation
inducer, as a molecular tool to study the LMTK3-PP1a-KAP1
effect on KAP1 phosphorylation. We further discovered that
silencing PPP1CA (a PP1a-encoding gene) rescued the reduced
Ser824 phosphorylation of KAP1 in MCF7-LMTK3 cells (Fig-
ure 3D), indicating that LMTK3 requires PP1a to dephosphory-
late KAP1. Silencing of PP1b, however, did not rescue the
reduced phosphorylation of KAP1 induced by LMTK3 (Fig-
ure S3D). Interestingly, we noticed that there was no increase
in KAP1 and PP1a interaction after LMTK3 overexpression
(Figure S3E), suggesting that LMTK3 might promote PP1a
Figure 2. KAP1 Is an Interacting Partner of LMTK3 in Chromatin Binding
(A) Selected examples of conserved TF motifs enriched within the interval regions associated with LMTK3.
(B) LMTK3 RIME in MCF7 cells identified potential LMTK3-associated proteins in DNA binding.
(C) Western blotting (WB) showing the immunoprecipitation (IP) of LMTK3 and KAP1 in MCF7 cells.
(D) KAP1 enrichment around LMTK3 peaks.
(E) qPCR results showing re-ChIP experiments using a KAP1 antibody after LMTK3 ChIP.
(F) Examples of LMTK3-KAP1 overlap based on snapshots of ChIP-seq data for the indicated genes.
See also Figure S2 and Table S1.
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Figure 3. PP1a Stabilizes the LMTK3/KAP1 Interaction and Suppresses KAP1 Phosphorylation on Ser824 at LMTK3-Binding Regions
(A) Immunoprecipitation of KAP1 and PP1a with LMTK3 in MCF7 cell lysates with and without PPP1CA silencing for 72 hr.
(B) Left: schematic of the PP1a-interacting motif (RVxF motif) on LMTK3 and the indicated GST constructs. Right: GST pull-down of PP1a using a wild-type
LMTK3 construct (GST-D10WT) and two RVxF motif mutants (GST-D10RVxF_1 and GST-D10RVxF_2). TM, transmembrane.
(C) FLAG immunoprecipitation performed after 24 hr of transient overexpression of FLAG-LMTK3WT and two mutants (FLAG-LMTK3RVxF_1 and FLAG-
LMTK3RVxF_2).
(D) Western blotting of the indicated proteins in MCF7 and MCF7-LMTK3 cells transfected with PPP1CA small interfering RNA (siRNA) for 72 hr and treated with
doxorubicin for 1 hr.
(legend continued on next page)
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dephosphorylation on KAP1 through increasing PP1a activity
rather than its interaction with KAP1.
We further questioned whether the reduced KAP1 phosphor-
ylation is predominantly observed at LMTK3-bound regions
and whether this would result in chromatin condensation. To
clarify this, we performed LMTK3 and KAP1 immunoprecipita-
tion using chromatin-bound MCF7-LMTK3 cell lysates. The ratio
of pKAP1/KAP1 in the LMTK3 immunoprecipitated chromatin
complex is significantly lower than that in the KAP1 immunopre-
cipitated chromatin complex (Figure 3E), suggesting that LMTK3
suppresses KAP1 phosphorylation specifically at LMTK3-bound
regions. Moreover, open chromatin is more enriched in MCF7
compared with MCF7-LMTK3 cells (Figure 3F), suggesting
that the region-specific dephosphorylation of KAP1 by LMTK3
could suppress chromatin decondensation. Then we tested
whether LMTK3/PP1a/KAP1-mediated chromatin condensation
can lead to gene silencing. Overexpression of wild-type (WT)
LMTK3, but not the mutant that abolishes its interaction with
PP1a and KAP1 (LMTK3RVxF_2), suppresses indicated gene
expression (Figure 3G) because of the fact that the latter lost
the DNA-binding activity at these regions (Figure 3H). In sum-
mary, these results demonstrate that an LMTK3-PP1a interac-
tion suppresses KAP1 phosphorylation, resulting in chromatin
condensation and transcriptional repression.
LMTK3 and KAP1 Suppress Gene Expression at Distal
Regions by Tethering Chromatin to the Nuclear
Periphery
To decipher the function of LMTK3 chromatin binding, we sepa-
rated LMTK3 and KAP1 binding events into promoter regions
that are 1 kb preceding the transcription starting site and the
rest as distal intervals. A recent study has suggested that
KAP1 is highly associated with H3K9me3-marked heterochro-
matin (Bartke et al., 2010), (Iyengar et al., 2011; Vogel et al.,
2006) and interacts with lamin A, a well characterized constituent
of the nuclear lamina (Roux et al., 2012) that is associated with
inactive chromatin regions (Kind et al., 2013; Peric-Hupkes
et al., 2010; Sadaie et al., 2013). Despite the function of
LMTK3 in chromatin condensation and transcriptional silencing,
we found that distal intervals bound by LMTK3 (or KAP1) are
associated with H3K9me3 modifications (Figure S4A). We there-
fore investigated the role of LMTK3 and KAP1 distal binding in
the context of transcriptional repression. We discovered, using
confocal microscopy, that LMTK3 (Figure 4A) and KAP1 (Fig-
ure S4B) co-localize with H3K9me3 both in the center and at
the inner nuclear membrane. Studies have shown that gene tran-
scription is suppressed when H3K9me3-marked heterochro-
matin is tethered to the nuclear periphery (Finlan et al., 2008;
Reddy et al., 2008; Towbin et al., 2012). Therefore, we investi-
gated whether LMTK3 and KAP1 are implicated in this process.
When KAP1 was silenced, we noticed a partial loss of H3K9me3
staining on the inner nuclear membrane (Figure S4C). Similarly,
we found that overexpression of LMTK3 significantly increased
the proportion of H3K9me3 heterochromatin staining on the
periphery (Figure 4B) compared with control cells, whereas
LMTK3 deletion in MDA-MB-231 cells had the opposite effect
(Figure S4D), suggesting that LMTK3 and KAP1 are involved in
the heterochromatin repositioning process. To clarify whether
LMTK3 interacts with the nuclear lamina, we used a series of
GST-LMTK3 truncated protein constructs (Figure 4C) and per-
formed in vitro GST pull-down assays. Notably, part of the struc-
turally disordered domains of LMTK3 (D3 and D4) were found to
interact with lamin A (Figure 4C), suggesting that LMTK3 may
function as a scaffold protein inducing heterochromatin reposi-
tioning at the nuclear periphery by interactingwith Lamin A. Inter-
estingly, we also detected a significant overlap of LMTK3 distal
binding regions with lamin-associated domains (LADs) (Guelen
et al., 2008), supporting the hypothesis that LMTK3-associated
regions are located at and interact with the nuclear lamina
(Figure 4D). In aggregate, these results suggest that the
LMTK3-KAP1 complex appears to be involved in tethering
heterochromatin to the nuclear periphery.
To detect the sub-nuclear localization of the specific genomic
regions bound by LMTK3, we performed DNA fluorescence
in situ hybridization (FISH) with bacterial artificial chromosome
(BAC) probes mapped to genomic regions where LMTK3 bound.
We found an increase in FISH signals of the LMTK3-bound
region (RP11-54O14) detected at the nuclear periphery when
LMTK3 was overexpressed, whereas no significant change
was observed in the non-LMTK3-bound region (RP11-113M21)
(Figure 4E). The H3K9me3 signal was mostly increased upon
LMTK3 overexpression at these regions, presenting a significant
association with the increased FISH signals (Figure 4F).
To extend these observations and evaluate the transcriptional
effect of active localization of the LMTK3-bound regulatory
region to the nuclear periphery, we analyzed the expression pat-
terns of genes around LMTK3 distal binding regions with RNA
sequencing (RNA-seq) data. We chose the genes located near
the distal intervals bound by LMTK3 (potential nuclear lamina an-
chors) and separated them into three groups: less than 100 kb
(<100 kb) (18 genes), between 100 and 200 kb (100!200 kb)
(14 genes), and between 200 and 500 kb (200!500kb) (39 genes)
distance from LMTK3 binding sites (Figure 4G). We then
compared the expression levels of the groups according to their
expression values from RNA-seq. Notably, the expression levels
of genes that are more distant from LMTK3 binding sites
(100!200 kb and 200!500 kb) were relatively higher (Figure 4H).
Interestingly, we detected a limited number of genes near
LMTK3 distal binding sites. This can be explained by the fact
that LMTK3 binding regions are highly associated with
(E) Immunoprecipitation of p-KAP1 (Ser824) and KAP1 with LMTK3 and KAP1 using chromatin-bound MCF7-LMTK3 cell lysate (upper panel). LMTK3- (LMTK3-
associated) and KAP1-immunoprecipitated (Global) p-KAP1/KAP1 ratios are shown (lower panel).
(F) Formaldehyde-assisted isolation of regulatory elements (FAIRE)-qPCR in MCF7 and MCF7-LMTK3 cells at the indicated regions.
(G) qPCR of LMTK3-bound gene expression in MCF7, MCF7-LMTK3WT, and MCF7-LMTK3RVxF cells.
(H) FLAG ChIP-qPCR of LMTK3-bound chromatin regions in MCF7-LMTK3WT and MCF7-LMTK3RVxF (FLAG-tagged) cells.
Quantitative data are presented as mean ± SEM from three experiments. Student’s t test was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. See
also Figure S3.
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Figure 4. Distally Binding LMTK3 Tethers H3K9me3-Marked Heterochromatin to the Nuclear Periphery and Suppresses Nearby Gene
Expression
(A) Confocal staining of LMTK3 and H3K9me3 in MCF7 cells. DAPI, 40,6-diamidino-2-phenylindole.
(B) Confocal staining of H3K9me3 and Lamin A/C in MCF7 and MCF7-LMTK3 cells. H3K9me3 signals at the nuclear periphery were quantified.
(legend continued on next page)
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lamin-associated domains that were found to be gene-poor re-
gions (Guelen et al., 2008; Meuleman et al., 2013; Peric-Hupkes
et al., 2010; Pickersgill et al., 2006). We also confirmed that
LMTK3 might suppress nearby gene expression by testing the
expression of certain genes near LMTK3distal regions (Figure 4I).
This implies that LMTK3 binding at distal regulatory regions
may be involved in suppressing nearby gene expression through
tethering the heterochromatin to the nuclear periphery.
LMTK3, PP1a, and KAP1 Are Co-expressed in Breast
Cancers and Collaborate in Suppressing the Expression
of Tumor Suppressor-like Genes
To examine the clinical implication of transcriptional repression
because of LMTK3 DNA binding, we chose the top LMTK3 and
KAP1 binding genes at the promoter intervals and the top genes
near the distal intervals and tested the clinical correlation of their
mean expression levels and relapse-free survivals (RFSs) in
breast cancer patients. A lower expression of genes bound
by LMTK3 at promoter intervals (Figure 5A) and genes near
LMTK3 bindings at the distal intervals (Figure 5B) were corre-
lated with poorer RFS, suggesting that LMTK3-bound genes
behave like tumor suppressor genes.
We also found that LMTK3 expression is negatively correlated
with the expression of several LMTK3-bound genes in breast
cancer patient samples (The Cancer Genome Atlas [TCGA]
database). As examples, the expression of LMTK3 is negatively
correlated with that of GPAM (Figure 5C) and RABGAP1L
(Figure 5D), which are LMTK3-bound genes at promoter and
distal intervals, respectively. This supports the hypothesis that
LMTK3 directly regulates the transcription of LMTK3-bound
genes in vivo as well as in our cell lines models.
In agreement with previous studies, LMTK3 is significantly
overexpressed in breast cancer (Figure 5E). Therefore, we
decided to investigate the clinical impact of the LMTK3 binding
partners KAP1 and PP1a. KAP1 and PPP1CA are significantly
overexpressed in breast tumors compared with normal tissues
(Figure 5E, S5A, and S5B). In addition, high expression of
KAP1 and PPP1CA is associated with worse patient RFS (Fig-
ures 5F and 5G) and overall survival (Figures S5C and S5D).
We also questionedwhether LMTK3,PPP1CA, andKAP1 co-ex-
press in breast cancer. Our analyses revealed a positive correla-
tion between the expression of LMTK3 and KAP1 (Figure 5H),
LMTK3 and PPP1CA (Figure 5I), as well as KAP1 and PPP1CA
(Figure 5J) but not LMTK3 and PPP1CB (Figure S5E) in patient
samples (TCGA). These suggest that LMTK3, PP1a, and KAP1
collaborate in breast cancer progression, leading to poorer
survival rates by inhibiting a number of tumor suppressor-like
genes.
DNA-Binding Activity Is Crucial for LMTK3-Mediated
Tumor Growth In Vitro and In Vivo
We also investigated whether the previously described prolif-
eration advantage of LMTK3 in MCF7 cells (Xu et al., 2014) is
ERa-mediated. We observed that, upon ERa removal via fulves-
trant treatment, the proliferation of both MCF7 and MCF7-
LMTK3 cells was significantly suppressed. However, in the
absence of ERa, MCF7-LMTK3 cells could still proliferate faster
than MCF7 cells (Figure S6A). Moreover, knockout of LMTK3 in
the ERa! MDA-MB-231 cells resulted in a slight but statistically
significant reduction in cell proliferation (Figure S6B). Taken
together, these results suggest that the involvement of LMTK3
in cell growth could partly depend on ERa but can also be sub-
ject to its transcriptional repression of tumor suppressor-like
genes through DNA binding.
We then examined, in vitro and in vivo, the tumor growth rates
of WT LMTK3 (MCF7-LMTK3WT) and LMTK3 mutant (MCF7-
LMTK3RVxF) cells that lost their DNA binding activity. MCF7-
LMTK3RVxF cells proliferated significantly slower compared
with MCF7-LMTK3WT cells (Figure 6A). Moreover, mice injected
with MCF7-LMTK3RVxF cells also developed smaller tumors
compared with WT cells (Figures 6B and 6C). These data indi-
cate that abolishing the DNA binding ability of LMTK3 on tumor
suppressor-like genes inhibits tumor progression.
In summary, we propose amodel in which nuclear LMTK3me-
diates chromatin remodeling by interacting with KAP1 and PP1a
(the latter dephosphorylates KAP1 at LMTK3-specific chromatin
binding regions, promoting chromatin condensation and tran-
scriptional repression) and tethering the chromatin to the nuclear
lamina through interaction with lamin A. These events result in
LMTK3 inducing transcriptional repression of its targeted tumor
suppressor-like genes and, thereby, supporting cancer cell sur-
vival and tumor growth (Figure 7).
DISCUSSION
We have previously demonstrated the role of cytoplasmic
LMTK3 in regulating integrin-associated metastatic potential
(Xu et al., 2014) and ERa transcriptional activity (Giamas et al.,
2011) in breast cancer. Here we describe a role of nuclear
LMTK3 and reveal that its chromatin binding and gene regulation
are mediated via its scaffold behavior. This is the first time that
an RTK has been ascribed such a role, lending credence to
(C) Mapping of LMTK3 directly interacting proteins to constructs of LMTK3 using a GST pull-down assay. Left: schematics of GST-tagged LMTK3 truncation
derivatives incubated with whole MCF7 cell lysate and precipitated using a GST antibody. Right: immunoprecipitates tested by western blotting.
(D) The overlap of DamID LADs and LMTK3. The p value was calculated using a genomic association test (GAT) (Heger et al., 2013).
(E) Projections of confocal FISH images with a probe covering LMTK3 distal binding regions in MCF7 and MCF7-LMTK3 cells. FISH signals of the BAC clones
RP11-54O14 and RP11-113M21 (non-LMTK3-bound region) are shown.
(F) The percentage of FISH signals at the nuclear periphery is plotted against the H3K9me3 enrichments detected by H3K9me3 ChIP-qPCRwithin LMTK3-bound
distal regions. RP11-113M21 was used as a negative control.
(G and H) Genes were divided into three groups based on their distance to the nearest distal intervals bound by LMTK3. Their expression levels were obtained by
RNA-seq analysis.
(I) qPCR of LMTK3 distally bound gene expression in MCF7 and MCF7-LMTK3WT cells.
Quantitative data are presented as mean ± SD. Student’s t test was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
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the importance of spatial organization in signal propagation.
Although scaffolding proteins are typically devoid of catalytic ac-
tivity, its presence here (by virtue of the fact that it is an active
RTK) is likely to have a far greater impact on signal processing
that anticipated by its kinase function alone. We propose that
this dual function contributes to tumorigenesis by enhancing
signaling complexity.
Being an RTK, LMTK3 is unlikely to have a direct DNA binding
domain, suggesting the existence of other interacting part-
ners for its chromatin association. We discovered that the
Figure 5. LMTK3, PP1a, and KAP1 Co-express in Breast Cancer and Collaborate in Suppressing the Expression of Tumor Suppressor-like
Genes
(A) Kaplan-Meier plots demonstrating the association of the mean expression profile of the available top 30 genes bound by LMTK3 at promoter intervals with
relapse-free survival (p = 5.1 3 10!12) in 3,455 breast cancer patients. HR, hazard ratio.
(B) Kaplan-Meier plots demonstrating the association of the mean expression profile of the top ten genes near LMTK3 distal binding intervals with relapse-free
survival (p = 1.4 3 10!9) in 3,455 breast cancer patients.
(C and D) Correlation of the expression of LMTK3 and LMTK3 target genes in TCGA breast cancer datasets. The correlation of LMTK3 and GPAM (C) and
RABGAP1L (D) is shown as representatives of LMTK3-bound genes at the promoter and distal intervals, respectively.
(E) The expression profiles of LMTK3,KAP1, andPPP1CA in 63 normal breast tissues and 536 breast cancer tissues. Data are presented asmean ±SD. Student’s
t test was used for statistical analysis.
(F) Kaplan-Meier plots demonstrating the association between KAP1 expression and relapse-free survival (p = 6 3 10!4) in n = 3455 breast cancer patients.
(G) Kaplan-Meier plots demonstrating the association between PPP1CA expression and relapse free survival (p = 9.1 3 10!9) in 3,455 breast cancer patients.
(H–J) Correlation of the expression of LMTK3,KAP1, and PPP1CA in TCGA breast cancer datasets. LMTK3 and KAP1 (H), LMTK3 and PPP1CA (I), and KAP1 and
PPP1CA (J) are shown.
Kaplan-Meier plots were obtained from http://kmplot.com/. TCGA datasets were obtained from https://tcga-data.nci.nih.gov/tcga/. Correlation statistical
analysis was done using Pearson correlation test. See also Figure S5.
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chromatin-binding events of LMTK3 are ERa-independent, and
little overlap between the binding genes of LMTK3 and ERa
was observed. In addition, ERa was not detected in the RIME
analysis. These results appear to be initially contradictory with
our previous finding describing LMTK3 as an ERa regulator (as
shown by modulating the transcription of TFF1, an ERa-regu-
lated gene) (Giamas et al., 2011). However, the binding of
LMTK3 and ERa to DNA is an independent procedure. The regu-
lation of ERa by LMTK3 is a transient phosphorylation process
that occurs in the cytoplasm, which results in activation of
ERa, translocation into the nucleus and binding to specific
DNA regions. The process by which LMTK3 itself translocates
to the nucleus and interacts with transcription factors (other
than ERa), which eventually leads to DNA binding is mediated
via other mechanisms, one of which is described here. There-
fore, the interaction of LMTK3 with ERa and its phosphorylation
at the cytoplasm does not necessarily mean that this complex
exists and acts together inside the nucleus and, subsequently,
binds to the chromatin.
Therefore, to identify potential partners of LMTK3 in chromatin
binding, a RIME assay was employed, and several proteins
involved in transcriptional repression were detected, many of
which were found to interact with silenced chromatin, and their
bindings were associated with enriched H3K9me3 signals
(Bartke et al., 2010). Interestingly, only LMTK3 bindings at distal
(enhancer) intervals were associated with H3K9me3 enrichment,
suggesting a distinct regulation of LMTK3 at promoter and
enhancer intervals.
Studies have shown that molecular tethering of H3K9me3-
marked heterochromatin to the nuclear periphery results in tran-
scriptional repression of genes located in these regions (Finlan
et al., 2008; Reddy et al., 2008; Towbin et al., 2012). Here we
demonstrate that LMTK3 functions as a scaffold protein linking
Figure 6. DNA-Binding Activity Is Crucial for
LMTK3-Mediated Tumor Growth In Vitro
and In Vivo
(A) Sulforhodamine B (SRB) proliferation assay of
MCF7-LMTK3WT and MCF7-LMTK3RVxF cells.
(B) Xenografts of BALB/c nude mice subcutane-
ously injected with MCF7-LMTK3WT and MCF7-
LMTK3RVxF cells. Red boxes present the tumors
on day 28.
(C) Tumor volumes of xenografts of mice sub-
cutaneously injected with MCF7-LMTK3WT and
MCF7-LMTK3RVxF cells on day 14.
Quantitative data are presented as mean ± SD.
Student’s t test was used for statistical analysis.
***p < 0.001. See also Figure S6.
heterochromatin to the nuclear lamina.
In addition, we show that the expression
levels of genes close to LMTK3-bound re-
gions are relatively lower, suggesting that
localization to the periphery suppresses
the expression of these genes.
Apart from its well defined kinase
domain, LMTK3 contains many intrinsi-
cally disordered regions (http://www.
disprot.org/), which may participate in facilitating protein-protein
interactions implicated in a number of cellular processes (Kathir-
iya et al., 2014; van der Lee et al., 2014). We identified lamin A as
a direct interacting partner of LMTK3 that could be at least partly
responsible for the tethering process of heterochromatin to
the nuclear lamina, which results in chromatin remodeling and
H3K9me3 modification and subsequent tumor suppressor-like
gene repression. Our model (Figure 7) infers the assembly of
an LMTK3 ‘‘signalosome,’’ leading to dynamic regulation deter-
mined by overall module composition as opposed to individual
activity, with subsequent transcriptional effects.
On an evolutionary scale, recombination of catalytic and reg-
ulatory or scaffold domains could happen through exon shuf-
fling, and it is probable that a modular architecture is more
conducive for the rapid emergence of novel types of regulatory
mechanisms. Although it is very difficult to test this argument
experimentally, it is interesting to note that organism complexity
seems to correlate more with the number and diversity of regu-
latory domains and not with the number of integrated compo-
nents (such as catalytic domains) comprising a network (Bhatta-
charyya et al., 2006). LMTK3 lacks classical scaffolding domain
signatures (e.g., protein-protein interaction [PPI] domains such
as SH3 and PDZ), but, in common with other scaffolding pro-
teins, it binds signaling molecules both directly and indirectly.
Looking at the known examples of known scaffold proteins, it
seems that this group of signaling proteins is heterogeneous,
and it is unlikely that all scaffolds are linked through a common
ancestry. This is supported by the diverse, unrelated ways by
which scaffolds can come into existence (e.g., active compo-
nents turn into scaffolds or scaffolds that form by random asso-
ciations), and LMTK3 can therefore be categorized as a non-
classical, ‘‘randomly created’’ scaffold. The efforts within this
study, including genomic ChIP, are necessary to decipher these
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roles. Unfortunately, comparative genomics, where protein se-
quences derived from sequenced genomes are compared, has
a very low chance to identify scaffolding interactions, and even
inferring binary connections between annotated gene products
is difficult.
Despite being bound to repressive promoters and enhancers,
LMTK3 is also able to bind to active promoters (Figure S1I) via
other proteins, among them CREB1. Our LMTK3 ChIP-seq
data revealed that the CREB1 motif is one of the most enriched
ones. In addition, CREB1 shares binding regions with LMTK3
at the promoters of PTPN11, PELP1, and RPS6KB2. LMTK3
overexpression promotes the expression of these genes, gener-
ally characterized as oncogenes, in breast cancer (Aceto et al.,
2012; Pe´rez-Tenorio et al., 2011; Rajhans et al., 2007; Roy
et al., 2012).
KAP1 has been shown to be overexpressed in a number of
cancers (Beer et al., 2002; Silva et al., 2006; Yokoe et al.,
2010). Here we demonstrate that, when co-expressed with
LMTK3, KAP1 functions as an oncogenic transcriptional co-
repressor through suppressing the expression of a number of
tumor suppressor-like genes (Figure 5). KAP1 phosphorylation,
especially at Ser824, has been shown to help chromatin decon-
densation and represents an inhibitory post-translational modifi-
cation for its co-repressive function (White et al., 2006; Ziv et al.,
2006); (Lee et al., 2007); (Li et al., 2007), and its phosphorylation
is known to be regulated by the protein phosphatase 1 family
members PP1a and PP1b (Li et al., 2010). In our work, we sug-
gest that LMTK3 specifically interacts with PP1a, which sup-
presses KAP1 phosphorylation at LMTK3-chromatin associated
regions, thereby maintaining the co-repressor function of this
complex. In addition, KAP1 phosphorylation is a DNA damage
marker (White et al., 2006; Ziv et al., 2006). Our results show
that KAP1 phosphorylation is suppressed during doxorubicin
treatment when LMTK3 is overexpressed, which suggests that
LMTK3 abundance might delay the induction of DNA damage
upon doxorubicin treatment. However, the contribution of
LMTK3 in this process requires further investigation, whichmight
further highlight its role in cancer cell survival.
Collectively, we demonstrate that LMTK3 functions as a tran-
scriptional co-repressor through interactingwith PP1a andKAP1
and as a scaffold protein by tethering heterochromatin to the nu-
clear lamina, resulting in chromatin remodeling and transcrip-
tional repression of LMTK3-bound tumor suppressor-like genes.
The idea that an RTK could behave as a scaffold protein opens
up potential avenues for future research of these molecules.
EXPERIMENTAL PROCEDURES
Human Primary Tumor Samples
Institutional board approval was obtained for all work on tissue samples in
accordance with the Declaration of Helsinki.
Cell Culture and Generation of LMTK3 CRISPR Knockout Cells
Human breast cancer cell lines (MCF7 and MDA-MB-231) were purchased
from the American Type Culture Collection and were cultured in DMEM sup-
plemented with 10% fetal calf serum (FCS) and 1% penicillin and strepto-
mycin. Stable LMTK3-expressing MCF7 cells were generated and cultured
as described previously (Xu et al., 2014).
For experimental details for the generation of LMTK3 knockout cells, please
refer to the Supplemental Experimental Procedures.
ChIP-Seq Analysis
For experimental details, please refer to the Supplemental Experimental
Procedures.
Bioinformatic and Statistical Analyses
Peaks were called usingmodel-based analysis for ChIP-seq (MACS) under the
following recommended settings: bandwidth, 300; p value cutoff, 1 3 10!5;
mfold range, 10, 30. The false discovery rate (FDR) cutoff was 0.001 (0.1%)
for all peaks. Peaks and raw signals were then uploaded to and analyzed
with Galaxy and Cistrome.
RIME
RIME was performed as described previously (Mohammed et al., 2013) using
an LMTK3 antibody (Abnova, catalog no. H00114783-M02).
FISH
For experimental details, please refer to the Supplemental Experimental
Procedures.
Xenograft Mouse Models
BALB/c nude mice 7–8 weeks of age were purchased from Harlan Labora-
tories UK, and all procedures were carried out under Home Office license au-
thority and local ethics. MCF7-LMTK3WT and MCF7-LMTK3RVxF cells were
cultured in DMEM containing 10% FCS and 0.5 mg/ml of G418 and injected
subcutaneously into mice (seven mice/group) at a concentration of 5 3 106
cells/mouse. Tumor volumes were measured every 2 days using a caliper.
Public Data Sources
The following ChIP-seq peaks and raw signals were downloaded from the
Encyclopedia of DNA Elements (ENCODE): H3K9me3, H3K27me3, H3K27ac,
H3K4me1, H3K4me3, Pol2, TAF1, and P300 are generated from MCF7
Figure 7. Graphical Summary of Chro-
matin Remodeling and Transcriptional Co-
repressor Behavior of LMTK3
A schematic illustration ofmechanism of chromatin
remodeling mediated by nuclear LMTK3. LMTK3
binds PP1a through its C-terminal domains and
interacts with KAP1 and dephosphorylates KAP1
at Ser824, which results in chromatin condensa-
tion. Meanwhile, a part of the LMTK3 disordered
domain tethers the whole heterochromatin com-
plex to the nuclear lamina through interacting with
Lamin A. These result in the transcriptional
repression of LMTK3-bound tumor suppressor-like
genes.
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cells; SUZ12 andNCOR are generated fromK562 cells; and KAP1 is generated
from HEK293 cells. ERa peaks and raw signals generated in MCF7 cells were
downloaded from a previous publication (Hurtado et al., 2008).
Patient survival data were acquired from http://www.kmplot.com.
Clinical correlation data were acquired from http://www.cbioportal.org and
http://www.canevolve.org.
Statistical Analysis
ChIP-seq analyses were done using Galaxy/Cistrome (http://cistrome.org).
Other data analyses were performed with Prism. Data are presented as
mean ± SD or SEM, as indicated in the figure legends.
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Large-scale transcriptome and epigenome analyses have been widely utilized to discover gene
alterations implicated in cancer development at the genetic level. However, mapping of
signaling dynamics at the protein level is likely to be more insightful and needed to complement
massive genomic data. Stable isotope labeling with amino acids in cell culture (SILAC)-based
proteomic analysis represents one of the most promising comparative quantitative methods
that has been extensively employed in proteomic research. This technology allows for global,
robust and confident identification and quantification of signal perturbations important
for the progress of human diseases, particularly malignancies. The present review summarizes
the latest applications of in vitro and in vivo SILAC-based proteomics in identifying
global proteome/phosphoproteome and genome-wide protein–protein interactions that
contribute to oncogenesis, highlighting the recent advances in dissecting signaling dynamics
in cancer.
KEYWORDS: cancer • phosphoproteome • proteome • proteomics • signaling • SILAC
Cancer is a heterogeneous disease and oncogenic
transformation from a normal cell to a malig-
nant one is a complicated process in humans
[1,2]. To gain a full insight of cancer initiation,
development and progression, a global analysis
of changes in protein properties can generate
exclusive information and complete the massive
data from transcriptome and epigenome analy-
ses [3–5]. Mass spectrometry (MS) has been suc-
cessfully applied to identify and quantify large
numbers of proteins or the entire proteome and
to characterize protein regulation and cellular
signal dynamics, such as posttranslational modi-
fications (PTM) and protein-protein interac-
tions [6,7]. Especially in our attempt to dissect
cancer signaling, MS-based quantitative proteo-
mics has shown wide uses in enabling large-scale
and accurate identification of functional bio-
chemical networks that contribute to oncogene-
sis [4,5]. Recently, SILAC has been shown to be a
relatively simple and straightforward approach
for in vivo metabolic incorporation of stable iso-
topes into proteins for relative quantitation by
MS [8–11]. Here we briefly describe the SILAC-
based experimental approaches and the unique
advantages that enable its wide applications in
cancer research. The main focus of the review is
on the biological and functional findings impli-
cated in cellular processes. We begin by discus-
sing the recent advances of SILAC-based
proteomics in investigating global expression
changes in cancer proteome. We then discuss its
analysis of PTMs and genome-wide protein-
protein interactions that are implicated in onco-
genic signaling dynamics. Another emphasis is
on the emerging role of SILAC-based
approaches in generating mouse models and
decoding the human cancer tissue proteome.
A standard strategy for quantitative
proteomic analysis using SILAC-based
MS
SILAC labeling for quantitative proteomics is
easy to achieve, efficient, and reproducible. Two
main strategies are commonly used, which are
known as double-labeling or triple-labeling
depending on the experimental design. For
example, in a hypothetical testing parental cells
are separately grown in culture media supple-
mented with distinctive stable isotope-labeled
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arginine and lysine amino acids, termed as ‘light’, ‘medium’,
or ‘heavy’ forms (‘light’: L-[12C6,
14N4] arginine (R0) and
L-[12C6,
14N2] lysine (K0); ‘medium’: L-[
13C6] arginine (R6)
and L-[2H4] lysine (K4); ‘heavy’: L-[
13C6,
15N4] arginine (R10)
and L-[13C6,
15N2] lysine (K8)). After several cell divisions,
instead of the ‘normal’ amino acids, stable isotope-labeled amino
acids are successfully incorporated into newly synthesized pro-
teins in the growing cells [12,13]. Subsequently, based on the aims
of studies, different drug treatment or growth factor stimulus at
different time points can be introduced. Total protein lysates are
prepared, and light, medium, and heavy cell populations are
mixed 1:1:1, digested and fractionated to peptides. SILAC
labeled peptides are then processed through liquid chromatogra-
phy tandem MS (LC-MS/MS), and peptides are identified and
quantified using software programs such as MaxQuant. Ulti-
mately, proteomic dynamics are examined for protein identifica-
tion and quantification, posttranslational modifications, and
protein-protein interactions (FIGURE 1). In the case of studying dif-
ferentially regulated phosphoproteins, labeled peptides are subject
to fractionation and enrichment to improve the identification
efficiency prior to subsequent LC-MS/MS analysis. For protein-
protein interaction studies, proteins are immunoprecipitated and
labeled samples are then combined and analyzed by quantitative
proteomics (FIGURE 1).
SILAC-based metabolic incorporation has a number of
advantages over other tagging approaches. Comparing to chem-
ical labeling, SILAC involves no chemical manipulation in cells.
They are cultured in media supplemented with labeled essential
amino acids, which allows the metabolic incorporation into all
proteins as they are being synthesized [6,10,14]. Cells are then
mixed and quantified by MS. The accuracy of quantification is
not affected during the processing. However, in early chemical
labeling, different tags generally have different reaction rates
toward substrate, which rigorously compromise quantification
accuracy [6]. For proteomic analysis using the SILAC method,
the amount of labeled protein needed is much less than the
one required by other chemical methods [9]. Moreover, SILAC
does not involve any radioactive material, differing from early
metabolic labeling with radioactive amino acid for a short
period of time (pulse-chase labeling), which was widely used in
research in early studies [6]. Recently developed chemical label-
ing approaches, isobaric tags for relative and absolute quantifi-
cation (iTRAQ) and tandem mass tags (TMT) have improved
and overcome several disadvantages, including different reaction
rates, incapability of low amounts of peptide identification and
use of radioactivity. However, numerous issues with regards to
the nonperfectly isobaric nature of the iTRAQ reagents, techni-
cal variations resulting from labeling at the peptide level, and
coisolation of peptides causing reporter ion interferences remain
to be addressed [15].
Moreover, ease to implement a variety of cell systems and
robustness of proteome-wide labeling have enabled a rapid and
wide application of SILAC-based proteomics in research [16].
Of note, the increasing applications of SILAC in measuring
dynamic changes, such as PTMs, particularly phosphorylation,
has proven its popularity [16,17]. SILAC can be applied to label
essentially all tryptic peptides and following steps, for example,
subcellular component isolation and fractionation do not com-
promise the output. Additionally, a deep analysis in large-scale
phosphoproteomics studies has become a daily practice in
investigating PTMs due to improvement through enrichment
protocols. However, several limitations have hampered the use
of SILAC. First of all, a conventional SILAC can only be
applied in live cells that incorporate the distinct SILAC amino
acids during protein synthesis. Other issues involve data analy-
sis. For example, when a five-state SILAC is analyzed in a data-
dependent analysis, MS/MS analysis spends five times more
time in fragmenting the same peptide. Potentially, increased
speed in MS technology could overcome this issue. Targeted
analysis of representative peptide may also save time for the
analysis of low abundance peptides.
SILAC-based proteomics is still under fast development. Very
recently, an approach named neutron encoding (NeuCode) was
developed integrating the SILAC and isobaric tagging methods
for multiplexed proteome quantification by high-resolution
MS [18,19]. The application of NeuCode labeling in yeast cells
enabled to record the time-resolved responses of five signaling
mutants in a single 18-plex experiment. This new strategy greatly
expands the scale of proteomic analysis and will be very useful in
comparing deregulated cancer proteomes.
Analysis of global protein expression changes in cancer
Deregulated protein expression represents one of the hallmarks
in cancer. A comprehensive picture of cancer proteome will
therefore advance our understanding in oncogenic signaling
regulation. SILAC-based proteomics is a powerful tool to ana-
lyze distinctive proteomic characteristics in malignant develop-
ment and in response to treatment in a variety forms of cancer,
to dissect cellular signaling components modulated by cancer-
related proteins, to measure secretome proteomic changes in
oncogenic development, and to study micro-RNAs-regulated
proteome.
Elucidation of underlying mechanism during malignant
transformation in various cancers
Owing to its obvious advantages discussed earlier, researchers
have employed SILAC-based proteomics to study the global
changes of protein expression during malignant transformation
using various experimental designs. Several studies have focused
on investigating the proteomic signature in cancer development
through comparing the protein expression changes in different
cell systems, such as between malignant cells and normal tissue
cells, cancer cells with differential aggressiveness, or cancer at
different stages.
Shaw and colleagues combined a quantitative proteomic and
metabolic analysis to study breast cancer progression using a
MCF10A derived cell model that simulates a non-tumor and
three different tumor grades of Ras-driven cancer [20]. In detail,
protein abundance and localization across cell lines were com-
pared to cellular metabolic rates by measuring oxidative
Review Zhang, Xu, Papanastasopoulos, Stebbing & Giamas
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Parental cells
‘Light’ (R0K0)
isotope culture
‘Medium’ (R6K4)
isotope culture
7 cell divisions
Double labeling
R0K0/R6K4 or R0K0/R10K8
Triple labeling
R0K0/R6K4/R10K8
Harvest cells
Mix cell lysates
MW S
Excise bands and
 trypsin digest
LC-MS/MS
Heavy
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Light
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isotope culture
Protein identification and
quantitation (MaxQuant)
Posttranslational modification
Protein-protein interaction
Subject to fractionation
and enrichment
Subject to
immunoprecipitation
Figure 1. A standard strategy for quantitative proteomic analysis using stable isotope labeling with amino acids in cell
culture-based approach.
In general, parental cells are separately grown in culture media supplemented with distinctive stable isotope-labeled arginine and lysine amino
acids, termed as ‘light’ ‘medium’, or ‘heavy’ forms (‘light’: L-[12C6,
14N4] arginine (R0) and L-[
12C6,
14N2] lysine (K0); ‘medium’: L-[
13C6] arginine
(R6) and L-[2H4] lysine (K4); ‘heavy’: L-[
13C6,
15N4] arginine (R10) and L-[
13C6,
15N2] lysine (K8)). After several cell divisions, stable isotope-
labeled amino acids are successfully (completion of labeling >95%) incorporated into synthesized proteins in the growing cells. Depending on
the study design, a double strategy using ‘light’ and ‘heavy’ labeling or a triple strategy using ‘light’, ‘medium’ and ‘heavy’ labeling is commonly
used. Subsequently, total protein lysates are prepared, and light, medium, and heavy cell populations are mixed 1:1:1, digested and fraction-
ated to peptides. SILAC labeled peptides are then processed through LC-MS/MS and peptides are identified followed by accurate quantitation
using quantitation software such as MaxQuant. In the case of posttranslational modifications analysis, labeled peptides are subject to fraction-
ation and enrichment to improve identification before LC-MS/MS. For protein-protein interaction studies, a slightly different strategy is needed.
Proteins are immunoprecipitated, and labelled samples are combined and analyzed by quantitative proteomics.
SILAC-based proteomics for cancer signaling Review
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phosphorylation (OXPHOS), glycolysis, and cellular ATP. Fur-
ther study revealed a decrease of cellular OXPHOS during breast
cancer progression, which is not related to mitochondrial copy
number or electron transport chain protein expression. The
expression levels and subcellular distributions of enzymes related
to lactate and pyruvate metabolism confirmed the observed extra-
cellular acidification profiles. This study integrates metabolic
profiling with global proteomics and offers a useful approach for
investigating biological function of proteins in cancer.
Genomic studies have so far shown a comprehensive complex-
ity of metastatic pancreatic cancer initiated from primary tumors.
However, the proteomic signature and related cellular signaling
remain largely unknown. Kim and colleagues analyzed the total
proteome and tyrosine phosphoproteome of each of the three dis-
tal sites of metastasis (liver, lung, and peritoneum) from a single
patient [21]. Strikingly, their data demonstrated distinctive altera-
tions of overall proteome expression and tyrosine kinase activities
across these metastatic lesions. The substantial heterogeneity
indicated distinct sensitivity of the neoplastic cells to inhibitors
targeting various kinases. Of note, an Axl receptor tyrosine kinase
inhibitor, R428, was capable of inhibiting tumors’ growth
derived from lung and liver metastases much more effectively
than those from the peritoneal metastasis in mice. These findings
highlight the need for personalized therapy of multiple organ
metastases in a single patient.
Grau and colleagues compared the proteomic signature
between a parental T24 bladder cancer cell line and its aggres-
sively metastatic counterpart T24T [22]. In total, there were
289 proteins differentially expressed between these cells, one of
which was Cul3, a protein highly overexpressed in T24T. Fur-
ther analysis demonstrated that depletion of Cul3 inhibited
T24T cells proliferation, migration, and invasion, and up-
regulated the expression of cytoskeleton proteins, such as ezrin,
moesin, filamin, or caveolin. Tumor tissue microarrays (TMAs)
showed that Cul3 abundance correlated with tumor staging,
lymph node metastasis, and disease-specific survival.
A two-step approach with an initial proteomic analysis of
cancer cells at different stages, combined with a validation in
human breast tumors, was designed to acquire global protein
changes and identify novel prognostic markers in breast can-
cer [23]. Using the massive data from 7800 quantified proteins,
a unique signature corresponding to specific stages was pre-
sented and confirmed by MS and TMA analyses. Of note, a
panel of proteins, including IDH2, CRABP2, and SEC14L2,
were shown to be prognostic markers for overall breast
cancer survival.
Chen and colleagues characterized the proteomic profiles of
normal breast epithelial cells and ErbB2/neu-overexpressing
mammary epithelial cells derived from mouse primary mam-
mary tumors [24]. Several upregulated proteins including crea-
tine kinase, retinol-binding protein 1, and thymosin 4 were
associated with the oncogenic phenotype of ErbB2-overexpress-
ing cells. Moreover, a combined use of quantitative proteomics
with siRNA screening was performed to identify potential tar-
gets involved in trastuzumab resistance in ErbB2 amplified
breast cancers [25]. Functional analysis of characterized proteins
from the screening showed that depletion of FAM83A and
MAPK1 improved trastuzumab sensitivity in resistant cells,
proposing potential druggable targets.
Proteomic profiles of the revertant and parental multiple mye-
loma (MM) cells were explored to study the mechanisms impli-
cated in MM reversion [26]. One of the 379 most affected proteins
during the process of reversion was STAT3, whose depletion led
to an inhibition of the malignant phenotype. Liu and others iden-
tified CUB-domain-containing protein 1 (CDCP1) as one differ-
entially expressed transmembrane protein through comparing
proteomic profiles of melanoma cells with high or low metastatic
potentials [27]. CDCP1 upregulation correlated with Src activation
and facilitated tumor metastasis.
Through comparing differentially modulated proteins between
a HepG2 human hepatoma cell line and an immortal hepatic cell
line L02, expression of phosphoglycerate mutase 1 (PGAM1)
was found significantly increased in cancer and was characterized
as a potential therapeutic target in hepatocellular carcinoma
(HCC) [28]. Similarly, Sun and colleagues examined the proteo-
mic profiles between normal (HL-7702) and cancer (HepG2 and
SK-HEP-1) cells [29]. Numerous proteins, including a-
fetoprotein (AFP), intercellular adhesion molecule-1 (ICAM-1),
claudin-1 (CLDN1), and tissue transglutaminase 2 (TGM2),
were documented as tumor markers and validated in patient sam-
ples. Furthermore, proteomic analysis was also conducted in
HCC cell lines–MHCC97L and HCCLM6 with low and high
metastatic abilities to screen for new diagnostic markers and ther-
apeutic targets [30]. Of note, solute carrier family 12 member
2 (SLC12A2) and protein disulfide-isomerase A4 (PDIA4) were
subsequently validated in cells and patient specimen with dispa-
rate metastatic capabilities.
Chen and colleagues examined the whole proteome of
MCF-7 cells cultured on substrates of different rigidity (10 and
100 kPa), and their results showed that the protein abundance of
eight members of chaperonin CCT was increased more than two-
fold in the harder substrate [31]. Further mechanistic data revealed
that CCT can directly interact with AIB1 and CCT-regulated
AIB1 folding affected cell area spreading, growth rate, and cell
cycle. The cooperation between CCT and AIB1 appears to be
important in cells’ response to rigidity, shedding new light into
our understanding of bone metastasis in estrogen receptor a
(ERa)-positive breast cancer.
Investigation of proteomic changes in response to drugs
or other treatment
A number of studies have attempted to decipher the therapy or
drug-induced proteomic changes, aiming to improve our
understanding of the function of drugs and underlying mecha-
nisms for therapy resistances.
Cellular senescence plays an essential role in affecting the
response of cancer cells to treatment [32]. Pasillas and colleagues
employed a quantitative proteomics screen to categorize targets
involved in therapy-induced senescence (TIS) and found that
Bcl2-mediated athanogene 3 (Bag3) was upregulated after
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adriamycin treatment in MCF7 cells [33]. Further analysis
revealed that Bag3 can interact with major vault protein
(MVP). Depletion of either Bag3 or MVP increased apoptosis
in adriamycin-treated cells and reduced ERK1/2 activation,
indicating a cooperative contribution of Bag3 and MVP in
apoptosis resistance in breast cancer.
A profile of proteomic changes in response to epidermal
growth factor receptor (EGFR) inhibition was obtained upon
gefitinib treatment in A431 cancer cells [34]. A number of
400 proteins were shown significant alterations in abundance
in response to gefitinib. Subsequent studies revealed a panel of
proteins that were highly associated with EGFR kinase activity
and changes in their total levels could be useful for prediction
of drug response in cancers.
Global quantification of imatinib-induced protein alterations
was obtained to identify novel targets and biological processes
modulated by imatinib treatment in K562 human chronic mye-
loid leukemia (CML) [35]. Imatinib caused a decreased expression
of the thymidylate synthase, S-adenosylmethionine synthetase,
and glycerol-3-phosphate dehydrogenase, as well as increased
abundance of poly(ADP-ribose) polymerase 1 and hemoglobins,
providing potential biomarkers for CML treatment.
In addition, SILAC-based MS was performed to identify
and quantify the differentially affected proteins after irradia-
tion [36]. There were a total of 123 and 155 significantly altered
proteins identified upon treatment of 2 Gy carbon and x-rays
after 1 h radiation, respectively. Gene Ontology (GO) enrich-
ment analysis demonstrated that the deregulated proteins were
mainly involved in metabolism processes.
Identification of cellular signaling components regulated
by cancer-related proteins
Thus far, a great number of cancer-related proteins (oncogenes
and tumor suppressors) have been identified. However, the sig-
naling components regulated by these proteins need further
investigation. Thus, SILAC-based proteomics provides us a
powerful tool to dissect their associated signaling pathways to
improve our understanding of cancer biology.
To investigate the complex networks that the cell adhesion
molecule CD146 is implicated in epithelial-mesenchymal tran-
sition (EMT) in breast cancer, a whole cell proteomic signature
of MCF-7 cells was analyzed upon CD146 expression [37].
Expression levels of 103 out of 2293 identified proteins were
correlated with CD146 abundance. Further analysis revealed
that ERa was the most significantly repressed transcription fac-
tor during CD146-induced EMT and ERa regulated its effects
on CD146-induced EMT through inhibition of Slug.
Chong and colleagues aimed to screen the oncogenic dual-
specificity phosphatase PRL-3-regulated proteins in acute mye-
loid leukemia (AML) via SILAC-based technique [38]. Their
results showed that 398 proteins were significantly modulated
after PRL-3 overexpression. Of note, Leo1, a component of
RNA polymerase II-associated factor (PAF) complex, was
reported as an important regulator of PRL-3 oncogenic func-
tion in AML and repression of Leo1 inhibited the
PRL-3 oncogenic phenotypes in AML. In addition, in BCR-
ABL-positive acute lymphoblastic leukemia (ALL), Bcl2 was
shown to be one of the direct targets of miR-17~19b and simi-
lar to miR-17~19b overexpression, Bcl2 depletion significantly
prompted apoptosis in BCR-ABL-positive cells [39]. This find-
ing supports an important role of miR-17~92 in regulating
apoptosis, and suggests BCL2 as a potential therapeutic target
in BCR-ABL-positive ALL.
Lu and colleagues utilized two proteomic methods, including
SILAC, to analyze the proteomic perturbations in response to
miR-126 overexpression in the human metastatic breast cancer
cell line MDA-MB-231 [40]. Their data revealed CD97, a pro-
metastatic G-protein-coupled receptor, as a new direct target of
miR-126, highlighting a link between downregulation of
miR-126 and overexpression of CD97 in cancer.
Yan and colleagues studied isodeoxyelephantopin (ESI)-regu-
lated proteins in nasopharyngeal carcinoma (NPC) cells and
identified 124 significantly altered proteins in response to ESI,
which are mainly implicated in the regulating oxidative stress and
inflammation response [41]. Further analysis revealed that ESI led
to G2/M arrest and apoptosis via regulating ROS generation,
and that it increased the expression of anticancer inflammation
factors IL-12a, IFN-a/b through ROS-dependent and indepen-
dent pathways.
Yamada and colleagues investigated nucleolar proteomic
alterations upon p14ARF induction at various time points and
characterized the human Formin-2 (FMN2) protein as a key
player in the p14ARF-involved tumor suppressive pathway [42].
ARF up-regulated FMN2 at both the transcriptional and the
protein level through inhibition of NF-kB and E2F1. Activa-
tion of oncogenes, such as SRC, hypoxia, and DNA damage
can also induce FMN2 expression. Furthermore, FMN2 con-
trols p21 protein levels by preventing its degradation. These
findings together support an important role of FMN2 in regu-
lating the cell-cycle inhibitor p21.
N,N’-Dinitrosopiperazine (DNP) increased NPC 6–10B cell
metastasis in vitro and in vivo, indicating a role of DNP in this
process. Thus, DNP-induced protein expression was examined
to gain insights into the underlying mechanism of DNP-
mediated metastasis in NPC [43]. A total of 371 (172 upregulated
and 199 downregulated proteins) proteins were shown signifi-
cantly modulated after DNP treatment. These proteins are
mainly involved in regulating cellular movement, lipid metabo-
lism, molecular transport, cellular growth and proliferation.
EGFR-regulated molecular networks were investigated upon
EGFR knockdown in head and neck cancer [44]. Twelve signifi-
cantly upregulated (e.g., p21 and maspin) and 24 downregu-
lated (e.g., cdc2 and MTA2) proteins were identified. Further
analysis discovered that these proteins play a role in a variety of
key processes, including cell proliferation, DNA replication,
and apoptosis. Flavin and colleagues combined SILAC-
proteomics with molecular studies and characterized RuvBl2,
AAA+ ATPase, as a transcriptional regulator of human telome-
rase reverse transcriptase (hTERT) through Ets-2 [45]. TMA
analysis further showed that nuclear RuvBl2 abundance
SILAC-based proteomics for cancer signaling Review
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correlated with nuclear expression of hTERT, pEts2 and
advanced nodal disease in colon cancer patients.
A combined approach of quantitative proteomics and tran-
scriptomics was utilized to explore the ERa/b-regulated effects
in T47D breast cancer cells in response to phytoestrogen genis-
tein [46]. Their data revealed an opposite effect on gene and
protein expressions between ERa and ERb, and indicated that
ERb can reduce breast cancer cell survival, motility and meta-
static potential.
Analysis of secretome proteomic changes
SILAC-based quantitative proteomics has also been used for
secretome analysis for cancer biomarker discovery and tractable
alterations in oncogenic development [47–51]. Villarreal and col-
leagues demonstrated that SILAC labeling is a good strategy
that can accurately distinguish proteins from the serum from
those secreted by tumor cells [52]. Of note, numerous identified
secreted proteins were associated with apoptosis in response to
serum starvation, which could be considered as internal cell via-
bility markers in breast cancer cells. To examine the differential
expression pattern of the secretome in cocultured colon cancer
cell line HT29 with normal human colon mucosal epithelial cell
line NCM460, SILAC-based quantitative proteomics was
employed and the results showed that 45 proteins were altered
over twofold in cocultured media, in comparison to monocul-
tured conditions [53]. Interestingly, mimicking different stages of
colon cancer, the secretion levels of acrogranin, IGFBP6, and
vimentin were modulated in parallel with various co-cultured
cell number ratios between NCM460 and HT29 cells. This
study expands the use of SILAC-based proteomics in quantita-
tive secretome profiling that can record secreted protein changes
and their associated biological functions. Barderas and colleagues
characterized the secretome of colorectal cancer (CRC) meta-
static cells by analyzing the conditioned serum-free medium of
KM12SM cells with high or poor metastatic capacities [54]. Bio-
informatics analysis of the deregulated proteins in the secretome
demonstrated a high proportion of proteins involved in cell
adhesion, migration, and invasion. Further functional studies
showed that depletion of NEO1, SERPINI1, and PODXL sig-
nificantly affected cellular adhesion, whereas inhibiting proteins,
such as SOSTDC1 and CTSS, led to a pronounced decrease in
migration and invasion of highly metastatic cells.
Moreover, differentially expressed proteins secreted from neo-
plastic and non-neoplastic gastric epithelial cells were character-
ized [55]. Proprotein convertase subtilisin/kexin type 9 (PCSK9),
lectin mannose binding 2 (LMAN2), and PDGFA-associated
protein 1 (PDAP1) were selected and validated as potential bio-
markers for gastric adenocarcinoma. Similarly, Holmberg and
colleagues studied the secretome of the myofibroblast in gastric
cancer through quantifying protein expression differences
between myofibroblasts derived from gastric cancer and those
from adjacent tissue [56]. Of note, matrix metalloproteinases -1,
-2 and -3 were significantly up-regulated in cancer-derived myo-
fibroblasts, indicating a reprogramming of microenvironment
in cancer.
Analysis of proteomic changes regulated by micro-RNAs
Considering the oncogenic role of miR-21 in MM, a proteomic
profiling was analyzed to identify potential targets of miR-21 and
showed that the protein inhibitor of activated STAT3 (PIAS3)
was a direct target of miR-21 [57]. Significantly, miR-21 facili-
tated the STAT3-dependent cellular pathway through PIAS3
suppression and PIAS3 depletion contributed to the oncogenic
behavior of miR-21. Global protein expression in neuroblastoma
cells was studied upon activation of the miR-17–92 cluster [58].
Further analysis revealed multiple miR-17–92-regulated path-
ways such as TGF-b signaling, cell proliferation, cell adhesion,
and RAS signaling. Of note, the TGF-b pathway was inhibited
upon miR-17–92 activation, which also associated with poor
prognosis in neuroblastoma patients.
Global identification of miR-373-regulated genes showed that
335 proteins, such as TXNIP and RABEP1, were regulated by
miR-373 in MCF7 breast cancer cells and approximately 30 of
them were previously implicated in cancer invasion and metasta-
sis [59]. Similarly, genome-wide characterization of miR-34a
induced changes in CRC demonstrated that 228 proteins
(113 down and 115 up) were altered in response to conditional
miR-34a allele activation [60]. Functional analysis suggests that
miR-34a might suppress key proteins involved in glycolysis,
WNT-signaling, invasion/migration, and lipid metabolism,
whereas it may activate p53 by impeding its acetylation and degra-
dation. Furthermore, potential targets regulated by miR-143 were
identified in MiaPaCa2 pancreatic cancer cells [61]. A total of 93
protein expression levels were decreased by more than twofold in
miR-143 mimic transfected cells in comparison to controls and
luciferase assays confirmed that 10 of them were possible
direct targets.
Analysis of PTM
Posttranslational modifications, such as glycosylation and phos-
phorylation, are important sources of cancer biomarkers, and
key events manifested in cancer development, as well as useful
indicators of the response of cancer cells to treatment [3,62–65].
Thus far SILAC-based proteomic analysis has proven to be a
valuable tool and has been employed to study protein acetyla-
tion, small ubiquitin-like modifier (SUMO)ylation, phosphory-
lation, and the associated signaling dynamics in cancer [66–72].
As deregulated protein kinase activity and resulted aberrant
phosphorylation of target substrates are essential for cancer cells
to sustain their malignant phenotype and have been well stud-
ied, our emphasis is on recent advances in applying SILAC-
based approach in deciphering phosphoproteomics.
Analysis of drug-induced phosphoproteome alterations
SILAC-based phosphoproteomics has been increasingly used to
study the mechanisms of drugs, as well as the response of cancer
cells to treatment, contributing to a better understanding of the
effect of drugs and potential mechanisms of therapy resistance.
Erlotinib and gefitinib are clinically prescribed EGFR inhibi-
tor. To gain better knowledge of their antitumor effect, Weber
and coworkers performed a SILAC-based MS analysis to
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characterize the phosphoproteome of KG1 AML cells and its
regulation upon erlotinib and gefitinib treatment [73]. Thirty-six
site-specific serine, threonine, and tyrosine phosphorylations
showed significant modifications upon 1 h erlotinib or gefitinib
treatment, out of which 34 phosphosites were repressed. Fur-
ther study showed that the Src family kinases and the tyrosine
kinase Btk are direct targets of both erlotinib and gefitinib,
providing detailed mechanisms of the antileukemic activity of
the two inhibitors.
Using a similar technique, Sharma et al. investigated the
global proteomic effect of heat shock protein 90 (Hsp90)
inhibitors, which are increasingly used as chemotherapeutic
agents in cancers [74]. Initial mapping of protein expression
changes revealed that activation of a heat shock response was
associated with induced expression of molecular chaperones
and proteases in HeLa cells. Bioinformatics analysis illustrated
that protein kinases were among the molecules significantly
affected upon inhibitor treatment, and a follow-up phospho-
proteomic analysis was therefore performed. Their results
showed that Hsp90 inhibitors led to more down- than upregu-
lation of the phophoproteome (34% down vs. 6% up), which
is consistent with the expected effect of inhibition of cellular
kinases. This work delineated the proteomic signature in
response to Hsp90 inhibition and demonstrated the mecha-
nisms by which this inhibitor can be used to target cancer cells.
Given that autophagy is an important process that enables
cells, especially cancer cells, to adapt to various stresses and to
maintain energy homeostasis. Bennetzen et al. attempted to
investigate the signaling networks involved in drug-induced
autophagic response [75]. Using SILAC-based MS, the authors
identified the phosphoproteome changes in response to resvera-
trol and spermidine, which are able to induce autophagy.
Numerous proteins, including known autophagic molecules
SIRT1, p62/SQSTM1 and EF2a, were found phosphorylated
upon resveratrol and spermidine treatment. Interestingly, two
distinct kinase motifs (RxxS motifs and SP motifs) were highly
responsive to resveratrol and spermidine. Furthermore, a
computational framework was generated to predict cellular sig-
naling networks modulated by resveratrol and spermidine,
highlighting a crosstalk between distinct networks of PTM and
a functional balance between autophagy and apoptosis.
Salovska et al. investigated the potential mechanisms of radio-
and chemo-sensitizing effect of the ATR kinase inhibitor,
VE-821, in human promyelocytic leukemic cells HL-60
(p53-negative) [76]. The SILAC-based quantitative phosphopro-
teomics identified 9834 phosphorylation sites of proteins, which
are mostly localized in the nucleus and involved in cellular pro-
cesses such as DNA damage response and the cell cycle regulation.
Moreover, sequence motif analysis showed significant changes in
the kinase activities in these processes. Their work provides infor-
mation of the mechanism of this inhibitor and the multiple roles
of ATR in response to DNA damage throughout the cell cycle.
In order to overcome the limited number of groups in one
SILAC experiment, Tzouros et al. introduced a 5-plex SILAC
using different combinations of unlabeled or stable isotopically
labeled Lys, Arg, and Tyr, which allowed recording of phos-
photyrosine signaling perturbations induced by a drug treat-
ment in one single experiment [77]. KPL-4 breast cancer cells
were treated with EGFR inhibitor erlotinib at five different
time points in five differently labeled groups, and subsequently
the affected phosphoproteome was analyzed. 318 unique phos-
phorylation sites belonging to 215 proteins following erlotinib
treatment were identified. This study confirmed the involve-
ment of Tyr453 phosphorylation of FAM59A in the EGFR
cascade. Moreover, it demonstrated a potential remote regula-
tion of ErbB3 phosphorylation (Tyr1289 and Tyr1328) and
ErbB2 phosphorylation (Tyr877) upon EGFR inhibition.
Genistein has been suggested as a potential anticancer
reagent as it can induce G2/M arrest and apoptosis of cancer
cells. Yan and colleagues performed a SILAC quantitative phos-
phoproteomics to study genistein-regulated signaling [78]. With
320 phosphorylation sites on 222 unique phosphopeptides
modulated by genistein, they not only confirmed the known
genistein-regulated effectors, such as ERK1/2 and PI3K, but
also discovered several novel phosphoproteins that are involved
in G2/M arrest or apoptosis, including G-protein-coupled
receptors, MAX and MAG.
In another study, Ge and coworkers investigated the mecha-
nism of this inhibitor through identifying the phosphopro-
teome upon bortezomib treatment, a proteasome inhibitor used
in the treatment of MM [79]. They discovered that 72 phospho-
proteins were significantly changed after bortezomib treatment.
Among those, they suggested that the increase in Ser38 phos-
phorylation on stathmin is a novel mechanism of bortezomib-
induced apoptosis.
Deciphering the signaling components regulated by
important cancer-related proteins
A variety of proteins have been previously suggested as impor-
tant players in cancer, but the mechanisms as well as the associ-
ated signaling components are not fully characterized. SILAC-
based phosphoproteomics is a promising approach to fill in
the gap.
Tissue inhibitor of metalloproteinase 1 (TIMP-1) has been
shown to be involved in drug resistance, but the underlying
mechanisms are largely unknown. To address this, Hekmat
et al. studied the global proteome and phosphoproteome differ-
entially modulated in MCF7 cells with high or low
TIMP-1 protein levels [80]. In TIMP-1 high expressing cells,
topoisomerase 1, 2A and 2B were among the 312 upregulated
proteins with 452 phosphorylation sites, which might offer an
explanation to the resistance to topoisomerase inhibitors. Using
the NetworKIN algorithm, they predicted that CK2a, CDK1,
PLK1 and ATM are potential players that may contribute to
the hyperphosphorylation of the topoisomerases. This study
links TIMP-1 with topoisomerase phosphorylation and the
resistance to topoisomerase inhibitor in breast cancer.
To gain a better understanding of TANK-binding kinase
1 (TBK1)-mediated survival signaling in lung cancer, Kim
and colleagues investigated affected phosphoproteins using
SILAC-based proteomics for cancer signaling Review
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SILAC-based MS following RNAi-mediated TBK1 knock-
down [81]. A total of 385 phosphoproteins were found altered
after TBK1 silencing, one of which was Polo-like kinase 1
(PLK1). Follow-up in vitro study showed that TBK1 could
directly phosphorylate PLK1 and TBK1 depletion reduced
mitotic PLK1 phosphorylation in TBK1-sensitive lung cancer
cells. These findings suggest that TBK1 is a mitosis regulator
in cooperation with PLK1 in lung cancer cell survival.
Glioblastoma is one of the most aggressive human malignan-
cies without highly effective drug treatment available. In order
to decipher the aberrant activated signaling in glioblastoma
progression, Kozuka-Hata et al. explored the phosphoproteomic
differences in glioblastoma initiating cells with or without EGF
stimulation [82]. The analysis showed upon EGF stimulation,
516 phosphorylation sites were significantly upregulated and
275 were downregulated, including those belonging to GAB1,
SHC1, EIF4EBP1, RAF1 and RPS6. Interestingly, several
phosphorylated molecules encoded by novel coding regions on
the human transcripts were identified, revealing new signaling
effectors in the tumorigenic potential of cancer stem-like cells.
Ali and colleague uncovered new signaling pathways controlled
by TGF-b through investigating the TGF-b-regulated phospho-
proteome [83]. They applied SILAC-based phosphoproteomics in
SW480 cells stably expressing Smad4 after 30min TGF-b stimu-
lation. 17 upregulated and 8 downregulated phosphopeptides
were identified, providing new insight into TGF-b-modulated
phosphorylation responses in colon carcinoma cells.
Gu and colleagues performed phosphoproteomic analysis of
FLT3 signaling in human leukemia cells, identifying over
1000 tyrosine phosphorylation sites from about 750 proteins in
both AML (with and without FLT3 mutation) and B cell acute
lymphoblastic leukemia (with and without FLT3 amplification)
cell lines [84]. They further quantified over 400 phosphorylation
sites that responded to FLT3 inhibition in FLT3 driven human
leukemia cell lines using SILAC. Together with the phospho-
proteomic analysis on bone marrow of primary AML patient
samples, they suggested that oncogenic FLT3 regulates proteins
involving diverse cellular processes and affects multiple signal-
ing pathways in human leukemia, providing a valuable resource
for investigating the molecular mechanisms by which FLT3
mutations function in AML.
Larive and colleagues examined the Syk kinase signaling and
identified 41 proteins as signaling effectors [85]. These molecules
are implicated in multiple biological processes such as cell-cell
adhesion, signal transduction, and cell polarization. Functional
analysis revealed that Syk regulates cell-cell adhesion and phos-
phorylation of E-cadherin and a-catenin.Receptor tyrosine
kinase-mediated phosphotyrosine networks were studied upon
EGF or HGF stimulation in A549 lung adenocarcinoma
cells [86]. Their data showed a good overlapping of the signaling
networks in response to EGF or HGF. However, distinctive
effectors which responded to different stimulus were also char-
acterized, such as myosin-X and galectin-1 (in HGF group)
and MAP4K3 (in EGF group). Likewise, phosphoproteome
and transcriptome analyses were conducted to identify tyrosine-
phosphorylated proteins and modulated genes after EGF and
HRG stimulation [87]. Follow-up analysis showed that the dif-
ferentially expressed proteins in response to EGF and HRG are
implicated in ErbB and VEGF signaling.
Recently, our group implemented a SILAC-based phospho-
proteomic analysis to investigate the biological function of
kinase suppressor of Ras 1 (KSR1) in breast cancer [12].
MCF7 cells were labeled with heavy or light isotopes, followed
by overexpression of KSR1 full length or empty vector as the
control, respectively. Among the most significantly modulated
phosphoproteins, deleted in breast cancer 1 (DBC1) phosphor-
ylation was shown decreased upon KSR1 overexpression. Fur-
ther study revealed that KSR1 regulates p53 transcriptional
activation through suppressing phosphorylation of DBC1,
resulting in reduced interaction of DBC1 with situin-1
(SIRT1). This enables the latter to deacetylate p53, which in
turn reduces the transcriptional activity of p53. These findings
shed new light on KSR1-modulated signaling pathways in
breast cancer.
In summary, SILAC-based proteomic analysis is an impor-
tant approach to study functional dynamics, particularly phos-
phorylation. Its powerful capability has enabled global mapping
of cancer signaling pathways, identification of new targets
involved in cancer development, and a better understanding of
underlying mechanism of drug resistance.
Analysis of altered protein-protein interactions
(interactomes & networks)
For the past decades, proteomics-based techniques have enabled
an efficient and sensitive detection of protein-binding partners
and protein interaction networks and have improved our
understanding of how signaling pathways are regulated. For
instance, in two pioneer studies, a large-scale immunoprecipita-
tion followed by MS analyses was performed to characterize
the functional organization of the yeast proteome [88,89]. These
studies have not only generated a systematic view of protein-
protein interaction networks essential for biological functions,
but also support the idea that most of the cellular processes are
carried out by multiprotein complexes. Although these studies
provided highly organized maps with around three times more
interactions in yeast than those described by that time, they
were not able to eliminate the false-positive interactions [90].
The reason for this is that a huge number of the contaminant
proteins, such as proteins that bind nonspecifically to the affin-
ity matrix, were identified through the precipitation assay [91].
Conversely, specific purifications such as the tandem affinity
purification could minimize the unspecific bindings, however,
was losing several low-affinity interactions.
Recently, MS-based quantitative proteomic approaches com-
bined with isotope labeling, such as SILAC, have been used to
overcome the aforementioned drawbacks to study protein-
protein interaction maps. The principle of this application is
the comparison of the ratio of identified proteins between the
experimental group and the negative control group, which are
labeled with a heavy or a light isotope-encoded amino acid,
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respectively. Nonspecific binding proteins are present in similar
amounts and should show a ratio of approximately one, while
the specific binding proteins are enriched in the pull-down
with the bait protein and have a ratio more than one. Conse-
quently, the introduction of a negative control, which provides
a list of nonspecifically bound proteins, allows a distinguishable
separation of the proteins that bind specifically to the protein
of interest from the contaminants [92].
SILAC-based approach has allowed high confidence determi-
nation of specific protein-protein interactions in diverse biologi-
cal processes, including cell adhesion and chromatin formation,
as well as in dissecting cellular signal relay including tyrosine
signaling transduction. For example, SILAC-based proteomics
was applied to determine ILK-interacting proteins by overex-
pressing FLAG-tagged ILK in HEK293 cells in ‘heavy’ medium
and FLAG in cells cultured in ‘light’ medium [93]. This study
not only identified PINCH, previously documented as direct
ILK-binding partner, but also numerous new proteins specifi-
cally enriched in ILK immunoprecipitates. Moreover, using sta-
ble isotope labeling and immunoprecipitation of GFP-tagged
fusion proteins, a new protein phosphatase 1 (PP1) g binding
protein, Repo-Man, was discovered [94]. Repo-Man can form a
complex with PP1 g and is needed for the recruitment of
PP1 to chromatin. Similar approach based on tagged bait pro-
teins was used to map the interactome of human 26S protea-
some [95] and to detect the dynamic components within
TATA-binding protein (TBP) transcription complexes [96].
Moreover, SILAC combined with modification-based affinity
purification was employed to investigate the functional protein-
protein interactions applied to EGF signaling [97]. In this study,
differentially labeled proteins in EGF-stimulated versus unsti-
mulated cells were mixed and purified over the SH2 domain of
the adapter protein Grb2 (GST-SH2 fusion protein) that spe-
cifically binds phosphorylated EGFR and Src homologous and
collagen (Shc) protein. Many signaling components such as
plectin, epiplakin, cytokeratin networks, and histone H3 were
shown to specifically form complexes with the activated EGFR-
Shc. Likewise, SILAC-based proteomics was used to identify
proteins that interact with insulin-regulated glucose transporter
(GLUT4) in an insulin-regulated manner [98]. 36 out of
603 proteins quantified showed a significant change in their
interaction with GLUT4 in response to insulin. Notably, a-
actinin-4 appears to associate with GLUT4, facilitating its rout-
ing to the plasma membrane.
Application of SILAC in dissecting protein interactomes in
cancer signaling
Ecotropic viral integration site 1 (EVI1) has been identified as
an oncogenic zinc finger transcriptional factor in human can-
cers a few decades ago. However, its function and underlying
mechanisms were not clearly studied. Recently, Bard-Chapeau
and colleagues characterized the EVI1-associated proteins
through quantitative SILAC-MS [99]. FLAG-tagged full length
EVI1 was transfected into SKOV3 cells in heavy isotope
labeled medium, while FLAG tag plasmid was transfected into
cells in light medium as a control. EVI1-associated nuclear pro-
teins were pulled down using agarose beads conjugated with
FLAG antibody. 78 EVI1 interacting proteins were confidently
assigned, including transcriptional regulators and molecules
involved in DNA repair and mitosis. Further MS analysis iden-
tified EVI1 phosphorylation sites Ser538 and Ser858 that can
be phosphorylated and dephosphorylated by two EVI1 interac-
tome proteins, casein kinase II, and protein phosphatase-1a.
Moreover, mutations at these phosphorylation sites inhibited
EVI1 DNA binding through its C-terminal zinc finger domain
and increased cancer cell proliferation. Together, comprehen-
sive analysis of the EVI1 interactome has therefore provided an
important resource for improving our understanding of its
function in cancer.
Two recent studies have characterized the interactomes of
the cancer-specific mutants of two well-known tumor suppres-
sor p53 and PTEN. Mutant p53 induces enhanced tumor
metastasis in mice, and human cells overexpressing p53R273H
have aberrant polarity and increased invasiveness [100]. Coffill
and coworkers thus attempted to identify mutant
p53 (p53R273H) specific binding partners that control cancer
cell polarity, migration, or invasion [101]. A triple-labeled
SILAC experiment was employed, in which human nonsmall
cell lung carcinoma cell line H1299 p53-null cells were grown
in media with three different stable isotopes (‘light’, ‘medium’
and ‘heavy’) and then were transfected with vector, wt-p53 or
p53R273H construct, respectively. After immunoprecipitation
and quantification by MS, wt-p53-specific and mutant-
p53-specific interactomes were identified and compared. Inter-
estingly, this study showed that one of the characterized
mutant-p53-specific binding partners- N-argininedibasic con-
vertase (NRD1) can form a complex with mutant p53 and
drive invasion in response to heparin binding-EGF-like growth
factor in a p63-independent manner, highlighting a new mech-
anism of p53-driven invasion and a potential therapeutic
approach to reduce tumor invasion and metastasis.
PTEN is another tumor suppressor that is frequently
mutated in a variety of human cancers. Considering the fact
that more than 20% of PTEN mutations are outside its cata-
lytic domain, Gunaratne and colleagues hypothesized that the
altered cancer suppression activity of PTEN may be due to the
changes of its interacting partner, rather than its catalytic activ-
ity [102]. Thus they compared the interactome of wide-type and
cancer-specific mutant G20E of PTEN by MS-based SILAC in
order to better understand the behavior of PTEN mutant in
cancer progression. As a result, they identified a PTEN wild-
type-specific interactor, NUDTL16L1, as a crucial effect com-
ponent of PTEN-regulated inhibition of cancer cell migration.
The large tumor suppressor 1 (LATS1) is a tumor suppressor
downregulated in human cancers. It regulates cell proliferation,
apoptosis, and stem cell differentiation. Ho and coworkers per-
formed SILAC coimmunoprecipitation analysis to identify
LATS1 interacting proteins, among which they discovered Itch,
a HECT class E3 ubiquitin ligase, as a novel binding partner
and negative regulator of LATS1 stability and tumor
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suppressive function [103]. Similarly, Chuang and coworkers
studied Runt-related protein 3 (RUNX3) binding partners
using SILAC followed by MS. They found b-catenin as one of
the most enriched RUNX3 interactors. They further linked
RUNX3 with rootletin at the centrosome, where it joins a
number of regulatory factors (e.g., cyclin E, BRCA1, and p53)
in regulating cell cycle process in gastric cancer cells [104].
Zhang and colleagues identified the complement component 1,
q subcomponent binding protein (C1QBP) as a PKC interac-
tion partner using SILAC-based coimmunopreciptitation MS.
They discovered that C1QBP can regulate PKC activity and is
involved in breast cancer progression and metastasis in EGF-
dependent manner [105]. Halbach and coworkers explored the
changes in the interactome of Gab2 after imatinib and dasati-
nib treatment in CML. They identified a number of novel
components of the Gab2 signaling complex, such as casein
kinases, stathmins, and PIP1, which may be involved in drug
resistance [106]. In another study, Bai and coworkers identified
14–3–3e interacting protein complexes in hepatocellular carci-
noma (HCC), providing a better understanding of the 14–3–
3e signaling in the progression of HCC [107].
Interactome study using SILAC has also been combined with
other techniques. For instance, Mohammed and colleagues
invented a novel technique named RIME to study the interaction
complex of ERa in DNA binding. They combined the RIME
with MS-based SILAC, and identified a number of estrogen-
specific ERa cofactors (e.g., GREB1) during transcriptional reg-
ulation, revealing their novel roles in breast cancer [108].
In addition to those studies, there are several other reports
on protein interactomes, which are not linked directly to can-
cer, but may subsequently benefit cancer studies. Hilger and
colleagues performed triple-labeling SILAC to identify the
interactomes of four key Wnt signaling components: APC,
Axin-1, DVL2 and CtBP2 after stimulated with the ligand
Wnt3a. This work provided a comprehensive map of the Wnt
signaling pathway, which is important in the development, tis-
sue homeostasis and cancer, and may benefit future studies in
these fields [109]. Myc is a master regulator in multiple cellular
processes. Its oncogenic function in tumor progression has been
well studied. The work of Agrawal and colleagues has presented
a map of the Myc interactome, which would further help us
understand the oncogenic role of this protein [110]. Studies on
the interactomes of receptor tyrosine kinase ErbB family [111],
CDK9 [112] and ILK [93] would also be useful resources for
future investigation of the functions of these proteins in
cancer progression.
Combining SILAC interactiome analysis & genomic studies
in cancer
Despite being applied in studying protein-protein interactions,
SILAC interactome analysis has also been widely used in coop-
eration with genomic studies, such as investigating epigenetic
histone marker interactomes and RNA-protein, DNA-protein
interaction profiles. Vermeulen and colleagues investigated
the interactomes of various histone markers (H3K4me3,
H3K36me3, H3K27me3, H3K9me3 and H4K20me3), which
revealed the interplay between chromatin markers and their
associated protein complexes. They classified transcriptional fac-
tors and cofactors into three groups according to their function:
‘activation’, ‘repression’, and ‘elongation’ [113]. Bartke and cow-
orkers identified the nucleosome-interacting proteins regulated
by DNA and histone methylation using SILAC nucleosome
affinity purifications (SNAP) [114]. Viturawong and colleagues
identified protein interactors at ultraconserved elements
(UCEs) [115]. Scheibe and colleagues performed SILAC quanti-
tative MS-based proteomics to obtain an interactome of telo-
meric repeat-containing RNA (TERRA) [116]. These studies
suggested an expanded area of SILAC-based coimmunoprecipi-
tation analysis in cancer research. Indeed, Ren and coworkers
studied sequence-specific DNA-binding protein maps in can-
cer [117]. CanScript, a cis promoter element controls the cancer-
specific expression of Mesothelin (MSLN), which is highly
overexpressed in almost one third of human malignancies. In
this work, they pulled down associated proteins using Can-
Script wild type and mutant probes from cells labeled with
‘heavy’ and ‘light’ amino acids, respectively. The precipitated
proteins were analyzed by MS to identify the CanScript inter-
actome, in which a number of transcriptional factors (such as
ZNF24, NAB1 and RFX1) were shown to be involved in the
regulation of MSLN expression in cancer. They further sug-
gested that studying nuclear acid-protein interactions is a good
example of combining genomics and proteomics that could
contribute to exploring potential transcriptional regulators of
cancer-specific DNA elements.
Application of a SILAC mouse model in cancer
SILAC mouse has been recently developed as a powerful tool
to identify the proteome from different sources including
plasma and tissue samples in vivo and to quantitatively com-
pare the differentially modulated proteome in various mouse
models, as well as to assess of the drug-drug interaction poten-
tial of therapeutic compounds [118–124]. In general, mice can be
labeled with a diet containing either the natural or heavy
isotope-substituted version of lysine such as the 13C6-lysine and
their development, growth and behavior are normally not
affected. The complete incorporation of labeling allows for the
identification of newly synthesized proteins in all organs. As
one good example, SILAC mouse was used as an in vivo quan-
titation system to characterize the proteomes from platelets,
heart, and erythrocytes from b1 integrin-, b-Parvin- and Kind-
lin-3-deficient mice [118]. Not only were the expression levels of
these aforementioned proteins from numerous organs con-
firmed by SILAC analysis, but also a structural defect of the
red blood cell membrane skeleton in Kindlin-3-deficient eryth-
rocytes was revealed. Furthermore, SILAC mouse-based proteo-
mics screen was deployed to identify modulated proteome of
Dicer-dependent miRNAs in liver of Dicer knockout
mice [125]. Of note, PPAR-a targets and proteins involved in
lipid metabolism were shown among upregulated proteins in
induced Dicer knockout mice, highlighting an integrated
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network involving Dicer, Dicer-dependent miRNAs, and their
target proteins.
Focusing on cancer, tyrosine kinase SRC is overexpressed and
activated in a large number of human malignancies and is associ-
ated with the development of cancer and progression to distant
metastases, such as in CRC [126]. In order to study the SRC onco-
genic signaling in vivo in CRC, SILAC mice with xenograft
tumors expressing different levels of SRC were generated by the
addition of [13C6]-lysine into mouse food [127]. After 30 days of
the heavy lysine diet, an incorporation level greater than 88%
was achieved in xenograft tumors. Subsequent quantitative phos-
phoproteomic analysis of these tumors demonstrated that 61 pro-
teins displayed a significant increase in tyrosine phosphorylation
and/or association with tyrosine phosphorylated proteins after
SRC expression. Some of the identified molecules are involved in
vesicular trafficking and signaling and RNA binding processes.
Interestingly, the authors showed that SRC substrate
TOM1L1 depletion had a minor effect on SRC-induced prolifer-
ation of CRC cells in vitro, but considerably inhibited tumor
growth in nude mice.
Similarly, SILAC mouse coupled to high-resolution MS was
employed to quantify phosphoproteomic changes in skin cancer
development using 12-O-tetradecanoylphor-bol-13-acetate
(TPA) with known carcinogenetic effect. Unlabeled lysates
from non-TPA-treated control skin, TPA-treated skin, lesions
that progressed to the papilloma (Pap) stage, and finally to the
squamous cell carcinoma stage (SCC) were mixed at 1:1 ratio
with SILAC mouse skin lysate (mice fed with isotope labeled
diet) and were subsequently processed for MS analysis. A total
of 3457 proteins and 5249 phosphorylation sites were accu-
rately quantified; Of the 3457 quantified proteins, 483 and
332 were upregulated in papillomas and SCC, respectively, rep-
resenting 10–14% of the proteome. Furthermore, 660 and
720 proteins were downregulated, representing 19–21% of the
proteome. Of the 5249 phosphorylation sites, 825 and
970 were upregulated in Pap and SCC, respectively, while
720 and 1017 were downregulated, indicating that 14–16% of
the phosphoproteome was upregulated, whereas 18–19%
downregulated. Increased levels of pRb1 and pAkt were noted,
along with increased activity of the Erk/MAPK pathway in
SCC. Moreover, the PAK4-PKC/SRC pathway, involved in
cancer invasion, appears to be highly dysregulated in SCC, but
not in papillomas. The authors conclude that papillomas and
carcinomas are distinguished by different proteomic signatures
and highlight the importance of cell adhesion as a key regulator
of cancer progression in SCC [128].
Application of super-SILAC in identifying proteome for
tumor tissue
SILAC coupled with LC-MS/MS has revolutionized proteomics
research through the accurate identification and quantification
of cellular proteome from cell lines with either different molec-
ular characteristics or undergoing ‘treatment’ under different
molecular conditions [129]. However, as SILAC requires whole
proteome labeling, thus far its use has been limited in cell
cultures. It is known that cell cultures do not always reflect the
complexity of biological processes taking place within a specific
tissue, normal or pathologic, as intercellular interactions and
interactions between cells and the dynamic extracellular matrix
are vastly absent within cell cultures. Therefore, it is becoming
clear that successfully applying SILAC in tissues would allow
us to capture a real picture of the on-going molecular events at
the proteomic level [130].
Cells are easily labeled with isotopes, but whole proteomic
labeling in tissues is technically difficult and can only be
achieved in models of whole organism isotope labeling as pre-
viously described, for example, flies, worms and mice [123,131].
The latter approach is clearly not applicable in human tissues,
in which most of the research would be expected to take place.
To overcome the above technical obstacle, researches have
recently used several cell lines with different molecular charac-
teristics, aiming to create a more representative mixture of a
given whole tissue proteome, as opposed to using only one
cell line. Geiger and colleagues described a method to accu-
rately quantify human tumor proteome by combining a mix-
ture of different SILAC-labeled cell lines with human
carcinoma tissue [132]. The cell lines were labeled, and cell
lysates were mixed in equal amounts to create a ‘super-SILAC
sample’. Unlabelled tissue samples of interest were then lysed
and the super-SILAC mix was added to each tissue lysate in a
1:1 fixed weight/weight ratio. Tryptic digestion yielded thou-
sands of labeled peptides functioning as internal standard
quantitative controls for the subsequent LC-MS/MS (FIGURE 2).
In this way, four to six thousand proteins have been previously
identified, and were relatively quantified providing a ratio
between the ‘unlabeled’ (originating from the tissue of interest)
and the ‘labeled’ (originating from the super-SILAC mix)
formats [129,132].
In detail, in this pioneer study, the authors utilized a super-
SILAC mixture from four breast cancer cell lines differing in
origin, stage, and ERa and ErbB2 expression. A normal mam-
mary epithelial cell type was added to expand the tumor sub-
types that can be represented. LC-MS/MS analysis identified
more than 4000 proteins, and the accuracy of quantification
was much higher compared with the results produced from
using a single labeled breast cancer line, as the results distribu-
tion was good and 90% of quantified proteins were within a
fourfold ratio between the tumor and the super-SILAC mix.
More than a hundred protein kinases were identified, including
ErbB2, EGFR, AKT, PAK1/2 and nine members of the
MAPK cascade, all representing pathways central to malig-
nancy. The same approach was used to investigate differential
proteomic signatures between lobular and ductal breast tumor
tissues, using the same super-SILAC mixture as internal stan-
dard; 5175 protein groups were identified and 4336 of them
were quantified. Ductal carcinomas were highly expressing focal
adhesion proteins, as well as glycolytic proteins as compared to
their lobular counterparts. As expected, E-cadherin was more
than 40-fold more highly expressed in the ductal carcinoma,
whereas the lobular tumor had higher levels of Cdc2 and of
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several MCM proteins, which control DNA replication and
cell-cycle progression [132].
Soon, the same group used the super-SILAC proteomic
approach to validate previous results stemming from SILAC
analysis in breast cancer cell lines; unlabeled tissue lysate from
a stage III estrogen receptor negative breast carcinoma was
mixed with the super SILAC lysate, as a standard, and proc-
essed for spectrometric analysis. Downregulation of ANX3,
SEC14L2, several adhesion proteins, and laminins, as well as
the myoepithelial markers, CD109, caldesmon and caveolin
was noted, along with a dramatic decrease in matrix metallo-
proteinases -14. On the contrary, upregulation of IDH2,
CRABP2, FUT8, BLVRB, ANX6 and RBM47, which could
serve as novel biomarkers for breast cancer, was identified.
Interestingly, high levels of IDH2 and CRABP2 and low levels
of SEC14L2 were found to be prognostic markers for overall
breast cancer survival [23]. Liu et al. compared the performance
of label-free quantification (LFQ) and SILAC with shotgun
and directed methods for quantifying breast cancer related
markers in microdissect ERa positive and negative breast can-
cer tissues; whole tissues were used, as well as laser capture
microdissection (LCM) tissues in an effort to minimize the bias
due to the large heterogeneity of cells within each individual
tissue. A SILAC standard mixture was created with mixing the
lysates from several breast cancer lines (ZR-75–1, SK-BR-3,
MDA-MB-231 and MDA-MB-468) representing different
breast cancer subtypes to cover the majority of proteome of
breast cancer epithelial cells. Selected reaction monitoring
(SRM), allowing only for fragment ions of selected peptides to
reach the MS detector was also applied to target proteins
involved in the ‘focal adhesion’ pathway. SILAC quantification
provided better precision than LFQ, although the difference
was smaller after global normalization at protein level, while
LFQ enabled a larger number of peptide and protein quantifi-
cations than SILAC quantification. Five ‘focal adhesion’ pro-
teins were precisely quantified with good quantitative precision
in replicate whole tissue lysate samples and replicate microdis-
sected samples using the SILAC-based SRM assay. The authors
suggested that LCM tissues can be used with label-free proteo-
mic techniques for initial biomarker identification, while
SILAC-based SRM assays can be developed as clinical assays,
once biomarkers are biologically validated [133]. N-glycosylated
secretome was characterized using supernatant from 11 breast can-
cer cell lines representing different stages of progression and five
distinct profiles of glycoprotein dynamics were discovered [134].
Expanding super-SILAC technique in brain tumors, in the
aforementioned pioneer study, a super-SILAC mixture from five
cell lines originating from glioblastomas and astrocytomas was uti-
lized to serve as internal standard. It was then mixed with a lysate
of astrocytoma protoplasmaticum and compared the results to
those with a single labeled astrocytoma cell line, 1321N1. Notably,
in the brain tumor, 5183 proteins were identified and 4318 of
them were quantified, which confirmed the higher accuracy of
super-SILAC in quantifying the proteomes of tumor tissues [132].
Furthermore, Shen and colleagues labeled the glioma-derived cell
line H4, which was used as the internal standard for the investiga-
tion of the differential expression profiling of heat shock proteins
(HSPs) between human glioma tissues (HGTs) and autologous
para-cancerous brain tissues (PBTs). HSP27 expression was found
significantly decreased in HGTs versus PBTs, and its expression
changes associated with cell growth in response to heat shock treat-
ment in glioma H4 cells [135].
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Figure 2. A schematic for quantitative analysis of human cancer tissue proteomes using super-stable isotope labeling with
amino acids in cell culture.
A collection of numerous different cancer cell lines are metabolically labeled by SILAC with lysine and arginine containing heavy isotopes.
Lysates from these labeled cell lines are then combined to generate a super-SILAC mix and used as internal protein standards. Subse-
quently, the super-SILAC lysate is mixed with tumor tissue at a 1:1 ratio and analyzed through high-resolution LC-MS/MS. The proteomic
dynamics including posttranslational medications can be studied to improve our understanding in cancer biology.
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Table 1. A summary of studies using stable isotope labeling with amino acids in cell culture-based
proteomics in dissecting cellular dynamics in various forms of cancer.
Cancer type SILAC applications Ref.
Breast cancer Global proteome [20,23–25,31,33,37,40,46,52,59,132,133,134,140]‡
Phosphoproteome [12,77,80,85,87]
Interactome [103,105,108]
Pancreatic cancer Global proteome [21,61]
Phosphoproteome [21]
Interactome [117]
Bladder cancer Global proteome [22]
Multiple myeloma Global proteome [26,57]
Phosphoproteome [79]
Hepatocellular carcinoma Global proteome [28–30]
Interactome [107]
Epidermoid carcinoma (squamous cell carcinoma) Global proteome [34,128]†, [136]‡
Phosphoproteome [128]†
Leukemia (AML, CML, ALL) Global proteome [35,38,39,138,140]‡
Phosphoproteome [73,76,84]
Interactome [106]
Nasopharyngeal carcinoma Global proteome [41,43]
Osteosarcoma Global proteome [42]
Head and neck cancer Global proteome [44]
Colon cancer Global proteome [45,53]
Phosphoproteome [83]
Colorectal cancer Global proteome [54,60]
Phosphoproteome [75,127]†
Gastric cancer Global proteome [55,56]
Phosphoproteome [78]
Melanoma Global proteome [27,140]‡
Neuroblastoma Global proteome [58]
Lung cancer Global proteome [136,137]‡
Phosphoproteome [81,86]
Interactome [101]
Glioblastoma Global proteome [140]‡
Phosphoproteome [82]
Ovarian cancer Interactome [99]
Malignant glioma Global proteome [135]‡
Interactome [102]
Cervix cancer Global proteome [140]‡
Diffuse large B-cell lymphoma Global proteome [139]‡
†Application of SILAC in mouse models.
‡Application of SILAC in tumor tissues.
AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; SILAC: Stable isotope labeling with amino acids in cell culture.
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In lung cancer, Zhang and colleagues generated a super-SILAC
mixture by combining three common non-small cell lung cancer
(NSCLC) derived cell lines, H460, H520 and HCC827, each
representing one of the three major subtypes large cell carcinoma,
squamous cell carcinoma (SCC) and adenocarcinoma (ADC),
respectively. The super-SILAC cell lysate was added to four pri-
mary tumor-derived xenograft (two-each ADC and SCC) tissue
lysates in an effort to quantitatively compare NSCLC tissue pro-
teomes and identify distinguished proteomic signatures between
the known histological subtypes. Their results showed that a
30-protein signature containing metabolism enzymes, such as
phosphoglycerate dehydrogenase, is highly expressed in SCC.
Furthermore, a comprehensive set of cytokeratins and other com-
ponents of the epithelial barrier are distinctly expressed between
ADC and SCC [136]. Likewise, Schweppe and coworkers per-
formed a super-SILAC based quantitative proteomics to identify
phosphorylation sites in primary tumors from patients with
NSCLC [137]. There were 9019 and 8753 phosphorylation sites
identified in two separate tumors and the differentially modu-
lated phosphoproteome between tumor samples allowed for the
determination of unique signaling dynamics in each tumor. This
in turn potentiates the possibility of patient-specific stratification
based on the downstream phosphorylation events. In AML,
Aasebø and colleagues selected five different cells lines (Molm-
13, NB4, MV4–11, THP-1 and OCI-AML3) to generate a
super-SILAC as internal standard and applied to patient samples
for quantitative shotgun studies [138]. Further analysis confirmed
the high coverage of the AML proteome with high technical
reproducibility and revealed various functional networks related
to disease progression and genetic abnormalities. Moreover,
super-SILAC was also shown to be able to distinguish two histo-
logically indistinguishable subtypes of diffuse large B-cell
lymphoma (DLBCL): activated B-cell-like (ABC) and germinal-
center B-cell-like (GCB) subtypes through their expression
signature [139].
In another study, superior to standard super-SILAC mix
from one histogenic origin, Lund and coworkers combined the
proteins of seven different cancer cell lines, including glioblas-
toma, melanoma, chronic myelogenous leukemia, cervix and
three breast cancer carcinomas, to investigate the underlying
mechanism of varying metastatic capabilities in primary tumors
through quantitative proteomics [140]. Significantly, expression
of myosin-9 and L-lactate dehydrogenase A were shown to cor-
relate with metastatic abilities, whereas expression of elongation
factor tu correlated inversely to metastatic capabilities.
Expert commentary
The development of SILAC coupled with LC-MS/MS has sub-
stantially helped us to decipher cancer proteome (TABLE 1). The
enormous amount of data acquired from proteomics has
allowed deep comparison of altered proteomes in different
stages of cancer progression, mapping of modifications in
response to stimuli and perturbations in a time-course setting,
a systematic view of protein-protein interaction networks, and
the discovery of predictive biomarkers in various cancers.
In vivo SILAC (SILAC-mouse and super-SILAC) has proven to
be a powerful tool to analyze the distinct molecular signatures
during cancer development in various mouse models, to iden-
tify the cancer proteome from different sources from patients
and to record the differential changes unique to premalignant
and malignant tissues. The broader implications of SILAC in
dissecting cancer proteome will greatly improve our understand-
ing in cancer signaling and provide us new therapeutic targets.
Five-year view
In the next 5 years, high throughput SILAC-based proteomics
will aid the rapid identification and quantification of cell pro-
teomes, thus revealing the alterations in developmental and sig-
naling pathways that control cellular decisions in cancer and
other diseases. In depth proteomics together with functional
study and bioinformatics analysis will complement the massive
data from genomic analyses and delineate a complete picture of
biological functions of proteins. Clearly, its application in
decoding altered proteomes in tissues will lead to the develop-
ment of effective biomarkers, provide information related to
cancer classification, and ultimately have a diagnostic and prog-
nostic impact for the patients. Of note, a SILAC-based targeted
proteomics in multiplexed manner will be useful for comparing
the proteome of benign and malignant lesions from patients
and a well-designed SILAC-based proteomics platform for diag-
nostic and prognostic applications will be worth developing
in future.
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Key issues
• Cancer is a heterogeneous disease and oncogenic transformation from a normal cell to a malignant one is a complicated process in humans.
• Cancer proteome analysis provides massive amounts of data and exclusive information about protein expression changes, modifications
and their associated functions to complete the findings from transcriptome and epigenome analyses.
• Mass spectrometry has been successfully employed to identify and quantify the entire proteome and to examine protein regulation and
cellular signal dynamics.
• Stable isotope labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry has been proven to be a simple and
straightforward approach with high-resolution, high-sensitivity and high-accuracy.
• In the past decade, the vast application of SILAC-based proteomics has enabled rapid identification and quantification of cancer
proteomes and significantly improved our knowledge of cancer biology.
• The use of SILAC-mouse and super-SILAC in dissecting cancer proteome further contributes to our understanding of molecular
signatures in the development of cancer.
• Future work will allow the discovery of effective biomarkers of disease that can exponentially increase the quality and efficiency of both
preclinical and clinical research in cancer.
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